Oct 7, 2009 - S. Zenker (Munich, Germany). 09:45. SSP 35.3.1. Combination of ..... Wrong paralysis after BTX - Wait six months? C. Pettke-Rank ( Munich, ...
Wednesday, 7 October 2009 (by 01/07/2009) SSP34 08:00-09:00
Solving the needs for care of the skin in the community. How to help whatever role you play. ISD- Community Dermatology Task Force (ISD-CDTF) Room 44
Chair:
T. J. Ryan (Wiltshire, United Kingdom)
08:00
SSP 34.1
08:10
SSP 34.2
08:25
SSP 34.3
08:40
SSP 34.4
SSP35
Whose job is it, and who will pay for it? T. J. Ryan (Wiltshire, United Kingdom) The migrant populations: an example of the complexity of the need A. Morrone (Rome, Italy) The contribution of the Dermatologist while earning a living in Private practice S. Verma (Vadoroda, India) The contribution of the Allied Health Professional Bornemouth United Kingdom S. Ersser (Bournemouth, United Kingdom)
European Society of Cosmetic and Aesthetic Dermatology (ESCAD) in association with International Academy of Cosmetic Dermatology (IACD)
09:00 – 18:00 Chairs: 09:00
Hall 15.2 H. Zelenkova (Bratislava, Slovakia) L. C. Parish (Philadelphia, USA)
SSP 35.1 SSP 35.2
09:05
SSP 35.2.1
09:10
SSP 35.2.2
09:15
SSP 35.2.3
09:20
SSP 35.2.4
09:25
SSP 35.2.5
09:30
SSP 35.2.6
09:35
SSP 35.2.7
0940
SSP 35.2.8 SSP 35.3
Brief Communications H. Zelenkova (Bratislava, Slovakia) Sci-Bi Cos Derm L. C. Parish (Philadelphia, USA) C. Rowland Payne (London, United Kingdom) H. Zelenkova (Bratislava, Slovakia) Evidence based cosmetic dermatology B. Rzany (Berlin, Germany) Wrinkle fibroblasts disclose specific mechanical behaviour! What are the consequences? P. Humbert (Besancon, France) The stratum corneum toxicity test G. Pierard (Liège, Belgium) Cutaneous manifestations of neurological diseases S. Soueidan (Williamsburg, USA) Biological effects of sub-erythemal doses of UVA A. Rougier (Paris, France) Preclinical diagnosis and early stage treatment of non-melanoma skin cancer in UV-exposed areas D. Kopera (Graz, Austria) Side effects of aroma oils N. Tsankov (Sofia, Bulgaria) G. Pierard (Liège, Belgium) Q&A Lasers & Pigmented Skin J. L. Levy (Paris, France)
SSP 35.3.1 09:45 SSP 35.3.2 09:50 SSP 35.3.3 09:55 SSP 35.3.4 10:00 SSP 35.4
10:05
SSP 35.4.1
10:10
SSP 35.4.2
10:15
SSP 35.4.3 SSP 35.5
10:20
SSP 35.5.1
10:25
SSP 35.5.2
10:30
SSP 35.5.3
10:35
SSP 35.5.4
10:40
SSP 35.5.5
10:45
SSP 35.5.6
10:50
SSP 35.5.7 SSP 35.6
10:55
SSP 35.6.1
11:00
SSP 35.6.2
11:05
SSP 35.6.3
11:10
SSP 35.6.4
11:15
SSP 35.6.5
11:20
SSP 35.6.6
11:25
SSP 35.6.7
R. Sheth (Mumbai, India) S. Zenker (Munich, Germany) Combination of dermaroller & pixellated erbium YAG laser for acne scars in Asian skin J. Sharad (Mumbai, India) How I treat scars and keloids in dark or Asian skin C. Chams (Teheran, Iran) Peels and lasers in Indian skin M. Sachdev (Bangalore, India) Common cosmetic and laser procedures in the Indian subcontinent S. Mutalik (Pune, India) Peels – Current views V. G. Mellado (Granada, Spain) E. Ozunturk (Istambul, Turkey) N. Tsankov (Sofia, Bulgaria) Highlights of a successful chemical peel N. Soueidan (Beirut, Lebanon) Chemical lifting A. Tenenbaum (Lugano, Switzerland) Q&A Fillers – Update P. Jean (Spain) P. Karam (Beirut, Lebanon) M. Kerscher (Hamburg, Germany) Which filler for which indication? M. Landau (Herzlia Pituach, Israel) Lip rejuvenation – anatomical considerations and technique I. Verner (Kiriat Ono, Israel) Silicone in the vermillion border of the lips P. Karam (Beirut, Lebanon) Tear trough filling R. Emerson (Hove, United Kingdom) All fillers, all complications E. Haneke (Freiburg, Germany) Forever softlift L. Polla (Geneva, Switzerland) Q&A Interventional Cos Derm A. Katsambas (Athens, Greece) G. Landi (Cesena, Italy) V. Petronic-Rosic (Chicago, Ilinois) How I treat median nail dystrophies – an experience from more than 100 cases E. Haneke (Freiburg, Germany) Beautiful legs (treatment with IPL, laser, sclerotherapy) S. Langendoen (Rotterdam, Netherlands) Airgent subdermal minimal surgery (SMS): advanced skin rejuvenation technique. S. Zenker (Munich, Germany) Laser for facial rejuvenation K. Nouri (Miami, USA) How and when to treat café au lait spots A. Camps Fresneda (Barcelona, Spain) Rosacea pearls L. Millikan (New Orleans, USA) Body dysmorphic disorder and its relationship to cosmetic surgery
SSP 35.7
11:30
SSP 35.7.1
11:45
SSP 35.7.2 SSP 35.8
11:50
SSP 35.8.1
12:00
SSP 35.8.2
12:10
SSP 35.8.3 SSP 35.9
12:15
SSP 35.9.1
12:30
SSP 35.9.2
12:45
SSP 35.9.3
13:00
SSP 35.9.4 SSP 35.10
13:15
SSP 35.10.1
13:25
SSP 35.10.2
13:35
SSP 35.10.3
13:45
SSP 35.10.4 SSP 35.11
13:50
SSP 35.11.1
14:001
SSP 35.11.2
14:10
SSP 35.11.3
14:20
SSP 35.11.4
A. Bewley (London, United Kingdom) The ESCAD Presidential Address N. Benadetto (Philadelphia, USA) A. Massa (Porto, Portugal) B. Walkoewicz-Cyranska (Warsaw, Poland) Combined methods in aesthetic dermatology H. Zelenková (Bratislava, Slovakia) Q&A Hot Topic I: Botulinum & Lipolysis A. Camps Fresneda (Barcelona, Spain) R. Emerson (London, United Kingdom) Botulinum toxin - 17 years of experience: comparison between Botox, Vistabel, Dysport, Xeomin, Neurobloc D. Grablowitz (Vienna, Austria) Tissue toxic effects of fat dissolution with Lipostabil S. Schuller-Petrovic (Vienna, Austria) Q&A Mini-symposium: High intensity focused ultrasound (HIFU) for non-invasive body sculpting G. Pierard (Liege, Belgium) G. Sattler (Darmstadt, Germay) S. Schuller-Petrovic (Vienna, Austria) High intensity focused ultrasound (HIFU) for non-invasive body sculpting M. Kane (New York, USA) High intensity focused ultrasound (HIFU) for non-invasive body sculpting A. Fatemi (Dusseldorf, Germany) Simulated demonstration M. Kane (New York, USA) A. Fatemi (Dusseldorf, Germany) Q&A Hot Topic II: Cellulite & Fat D. Grablowitz (Vienna, Austria) L. Habema (Bossum, Netherlands) K. Nouri (Miami, USA) What’s new in laser treatment for cellulite and striae? M. Adatto (Geneva, Switzerland) Medical devices for cellulite. What’s new? M. Gold (Nashville; USA) Liposuction and combined procedures in severe lipoedema U. Wollina (Dresden; Germany) Round table discussion State of the Art: Advanced Uses of Fillers M. Adatto (Geneva, Switzerland) P. André (Paris, France) I. Ghersetich(Florence, Italy) What’s new in skin rejuvenation with hyaluronic acid? M. Kerscher (Munich; Germany) Hand rejuvenation A. Benedetto (Philadelphia, USA) Hyaluronidase P. André (Paris, France) Round table discussion M. Lapidoth (Rabin; Israel)
SSP 35.12
14:35
SSP 35.12.1
14:45
SSP 35.12.2
15:55
SSP 35.12.3 SSP 35.13
15:00
SSP 35.13.1
15:15
SSP 35.13.2
15:30
SSP 35.13.3 SSP 35.14
15:40
SSP 35.14.2
15:50
SSP 35.14.3 SSP 35.15
16:00
SSP 35.15.1
16:10
SSP 35.15.2
16:20
SSP 35.15.3 SSP 35.16
16:30
SSP 35.16.1
16:50
SSP 35.16.2 SSP 35.17
17:00
SSP 35.17.1
17:15
SSP 35.17.2
17:30
SSP 35.17.3
17:45
SSP 35.17.4
18:00
SSP 35.18
Keynote Address I: Breast Fillers B. Dreno (Nantes, France) S. Verma (Hyderabad, India) U. Wollina (Dresden; Germany) Macrolane breast filler O. Claude (Paris, France) Brest Lifting by Liposuction L. Habema (Bossum, Netherlands) Q&A Hot Topic III: Needling & Mesotherapy A. Badawi (Cairo, Egypt) E. Haneke (Freiburg, Germany) C. Rowland Payne (London, United Kingdom) Needle sheikhing treatment for vitiligo I. Sheikh (Lahore, Pakistan) Mesotherapy A. Badawi (Cairo, Egypt) Q&A Update on: Melasma L. Marini (Trieste, Italy) L. Millikan (New Orleans, USA) I Verner (Kiriat Ono, Israel) How I treat facial melasma J. L. Levy (Marseilles, France) Round table discussion The ESCAD debate: Sentinel node biopsy in melanoma F. Camacho Martinez (Seville, Spain) M. Neumann (Rotterdam, Netherlands), C. Rowland Payne (London, United Kingdom) C. Voit (Berlin, Germany) The arguments in favor of sentinel node biopsy in melanoma G. Landi (Cesena, Italy) The arguments against sentinel node biopsy in melanoma J. M. Thomas (London, United Kingdom) Debate Keynote Address II: Skin Genomics E. Berardesca (Rome, Italy) P. Humbert (Paris, France) P. Quatrasooz (Belgium) Skin genomic signatures – the route to better cosmetic ingredients J. Tiesman (Cincinnati, USA) Round table discussion What’s New in Cosmetic Dermatology A. Rebora (Rome, Italy) C. Rowland Payne (London, United Kingdom) B. Rzany (Berlin, Germany) What is beauty? What science found out E. Haneke (Freiburg, Germany) Can cosmetics in clinical practice be supported by scientific papers? B. Dreno (Nantes, France) What's new in human stem cells and their applications? C. Zouboulis (Dessau, Germany) Post-inflammatory hyperpigmentation and melasma J. P. Ortonne (Nice, France) Close of ESCAD scientific meeting
C. Rowland Payne (London, United Kingdom)
SSP01
Hyperhidrosis Optimal Results and Emerging Therapies International Hyperhidrosis Society (IHS)
9:00 – 13:30
Hall 14.2
Chair:
D.A. Glaser (St. Louis, USA)
9:00
SSP01.1
9:20
SSP01.2
9:40
SSP01.3
9:55 10:25
SSP01.4 BREAK
10:35
SSP01.5
11:05 11:40
SSP01.6 BREAK
11:50
SSP01.7
12:15
SSP01.8
12:35 12:55
SSP01.9 SSP01.10
SSP02
Defining and Diagnosing Primary and Secondary Hyperhidrosis H. Hamm (Würzburg, Germany) Understanding the Impact of Hyperhidrosis on Patients’ Lives H. Hamm (Würzburg, Germany) Topical Therapies: Emerging Science and Technology (this lecture includes videos) D. M. Pariser (Virginia, USA) Iontophoresis: A Procedure with Promise D. M. Pariser (Virginia, USA) Injections of Botulinum Toxin for Axillary Hyperhidrosis: Evidence-Based Approach (this lecture includes videos) D. M. Pariser (Virginia, USA) Injections of Botulinum Toxin for Non-Axillary Hyperhidrosis: Applying a Proven Treatment to New Areas (this lecture includes videos) D.A. Glaser (St. Louis, USA) Local Surgery for Axillary Hyperhidrosis D.A. Glaser (St. Louis, USA) Endoscopic Thoracic Sympathectomy Surgery: Option of Last Resort? H. Hamm (Würzburg, Germany) Oral Medications: What and When to Use Them D.A. Glaser (St. Louis, USA) Case Studies, Panel Questions, Discussions, Demonstrations
Dermoscopy Update- International Dermoscopy Society (IDS)
9:30 – 11:30
Hall 7
Chairs:
H. P. Soyer (Woolloongabba, Australia) J. Malvehy (Barcelona,Spain)
09:30 SSP02.1
Benign/ melanoma ratio in the dermoscopy era: a worldwide survey. E. Moscarella (Naples,Italy) G: Argenziano (Naples, Italy)
09:40 SSP02.2
A New Algorithm for the Diagnosis of Unpigmented Lesions Predicated on Vessels. H. Kittler (Vienna, Autria)
09:50 SSP02.3
My Best Rules Not To Miss Melanoma. R. Hofmann-Wellenhof (Graz, Austria)
10:00 SSP02.4
Dermoscopy of Familial Melanoma. S. Puig (Barcelona, Spain) Small Melanoma vs. Small Nevus: Do We See the Difference? S. Seidenari (Modena,Italy)
10:10 SSP02.5
10:20 SSP02.6
Stem Cell Theory and Dermoscopy. W. Stolz (München, Germany)
10:30 SSP02.7
Trichoscopy Update. L. Rudnicka (Warsaw, Poland)
10:40 SSP02.8
How many patients should we screen to find one more melanoma? I. Zalaudek (Graz, Austria)
10:50 SSP02.9
Nail Unit Congenital Nevi - An Update L. Thomas (Lyon,France)
11:00
Discussion
SSP02.9
SSP04 11.00 -18.00
How to improve Laser and Light Source Treatments in Dermatology –Theoretical and Practical Progress European Society for Laser Dermatology (ESLD) ICC Lounge
Learning Objectives: Following this meeting the attendee will be able to: 1. Understand the past and present theoretical basis of modern laser dermatology 2. Have knowledge of progressive evolution of laser and polychromatic light treatments presently used in dermatology 3. Choose the appropriate photo-thermal strategies to effectively treat commonly encountered problems in a modern dermatological-surgical practice Description This meeting will help attendees update their knowledge in photo-thermal treatments presently used in modern dermatologic surgery. Their evaluation and management of patients affected by dermatological problems suitable to be treated by lasers and polychromatic light sources will be positively influenced by presentations on treatment strategies using old and new approaches. Knowledge of basic laser and polychromatic light principles as well as their technical evolution will be of great help in taking full advantage of this teaching experience. Practical evaluations and management tips will be discussed by chair persons at the end of each main session. This meeting is addressed to the practicing clinician with specific interests in dermatological laser treatments. 10:30 – 13:40
ESLD Annual Scientific Meeting – Part A-C Open to all EADV Congress participants/ ESLD Members free / ESLD Non-Members € 50.-
A. Vascular Lesions,Warts, Scars 10:30- 11:10 Chairs: M. Adatto (Geneva, Switzerland) A. Troilus (Malmo, Sweden) K. Nouri (Miami, USA) M. Haedersdal (Copenhagen, Denmark) 10:30
SSP04.A1
13:40
SSP04.A2
New exciting treatment of hemangiomas with propranolol and laser A. Troilus (Malmo, Sweden) Laser for treatment of scars K. Nouri (Miami, USA)
10:50
SSP04.A3
11:00
SSP04.A4
Intense pulsed light and paring versus paring alone for recalcitrant hand and foot warts: a randomized clinical trial M. Haedersdal, K. Togsverd-Bo, C. Gluud, P. Winkel, H.K. Larsen, H. Lomholt, M. Cramers, P. Bjerring (Denmark) Long pulsed dye laser for the treatment of leg veins E. Bernstein (USA)
B. Body Shaping and Skin Tightening: efficacy, combined approaches, complications 11:10 – 12:00 Chairs: K. Fritz (Landau, Germany) B. Ascher (France) M. Gold (Nashville, USA) M. Avram (USA) 11:10
SSP04.B1
11:20
SSP04.B2
11:30
SSP04.B3
11:40
SSP04.B4
11:50
SSP04.B5
12:00 – 12:15
Non-invasive fat removal M. Avram (USA) Body Shaping 2009 overview, with a focus on Rollers, RF, US & Lasers B. Ascher (France) Experience with two non invasive systems for volume reduction (Acoustic Wave Therapy & Combined Approach M. Adatto (Geneva, Switzerland) Laser Liposuction M. Gold (Nashville, USA) Body shaping – What new for 2009? M. Lapidoth (Petah Tikva, Israel) Coffee Break
C. Facial and Non-Facial Skin Rejuvenation 12:15 – 13:30 Chairs:
– Ablative, Fractional, Non-Ablative
M. Lapidoth (Petah Tikva, Israel) S. Laningan (Birmingham, United Kingdom) D. Cassuto (Italy)
12:15
SSP04.C1
12:25
SSP04.C2
12:35
SSP04.C3
12:45
SSP04.C4
12:55
SSP04.C5
13:05
SSP04.C6
13:15
SSP04.C7
Fractional resurfacing with different technologies K. Hoffmann (Germany) SPF-R: Sequential Photo-thermal Fractional Rejuvenation combining a short pulse Nd:YAG and Er:YAG lasers L. Marini (Trieste, Italy) Evaluation of micro-focused ultrasound for browlift and improvement of facial skin laxity on the lower face S. Laningan (Birmingham, United Kingdom) Single pass fractionated ultarpulsed co2 laser resurfacing for aging skin- 18 month follow-up M. Tretti Clementoni (Italy) Clinical and histological evaluation of fractional co2 laser D. Cassuto (Italy) Fractional RF- A new concept in fractional photothermolysis S. Halachmi (Tel Aviv ,Israel) Clinical comparison of 200 μm (Fraxel re:store™) and 140 μm (Mosaic HP™) micro necrotic column in 1550 nm fractional rejuvenation. M. Drosner, F. Hajdarević (Germany)
13:30-14:00
Lunch
14:00 – 15:40
News from the Industry supported by companies (limited to Industry Members of ESLD) open to all EADV Congress participants / ESLD Members free / ESLD Non-Members € 50.Industry-What’s new? Chairs: K. Fritz (Landau, Germany) M. Lapidoth (Petah Tikva, Israel) M. Adatto (Geneva, Switzerland)
15:40-18:00
ESLD Annual Scientific Meeting – Part C - E Open to all EADV Congress participants/ ESLD Members free / ESLD Non-Members € 50.-
D. What’s new in photons and electro-optical devices? 15:40- 16:30 Chairs: 15:40
SSP04.D1
16:52
SSP04.D2
16:04
SSP04.D3
16:16
SSP04.D4
16:30 – 16:45
P. Bjerring (Risskov, Denmark) L. Marini (Trieste, Italy) D. Manstein (USA) Fluorescence aided diagnosis of early and latent pre-cancers and skin carcinomas P. Bjerring (Risskov, Denmark) Home used devices- an update D. Manstein (USA) Combination therapy with IPL and a drug delivery method for rejuvenation of the skin T. Omi, S. Kawana (Japan) Laser assisted Vitiligo treatment with cultured melanocyte implantations K. Fritz (Landau, Germany) Coffee Break
E. Free Communications 16:45 -17:50 Chairs: 16:45
SSP04.E1
16:54
SSP04.E2
17:03
SSP04.E3
17:12
SSP04.E4
17:21
SSP04.E5
17:30
SSP04.E6
17:39
SSP04.E7
M. Drosner (Munich, Germany) M. Sachdev (India) CO 2 laser in skin of colour- Mukta Sachdev- India M. Sachdev (India) Treatment of Hyperseborrhea with a 1450nm diode laser: a comparative study B. Pusel (France) Chronic Wounds: Treatment with polarized light(480- 3400nm) J. Begic-Rahic (Bosnia and Herzegovina) Treatment of Pigmented Lesions with Q-Switched Nd:YAG E. Ozunturk (Turkey) Treatment of skin diseases with lasers S. Stangl (Germany) Post acne scarring revision using 1540 fractionated non ablative laser S. F. Ghannam (Kuwait) Co2 laser for rhinophyma J. del Pozo, E. Cuerda, F. Pineyro, R. Fernandez-Torres, L. PérezVarela, E. Fonseca (Spain)
Colorful Facettes of Dermatopathology
SSP05
Joint- Meeting European Society of Dermatopathology (ESDP) /
German Society of Dermatopathology (ADH) 14:00-18:00 Chairs:
14:00
Hall 9 D. Metze (Münster, Germany) C. Tomasini (Torino, Italy) G. Kaya (Geneva, Switzerland)
SSP05.1
14:15
SSP05.2
14:30
SSP05.3
14:45
SSP05.4
15:00
SSP05.5
15:15
SSP05.6
15:30
SSP05.7
15:45
SSP05.8
16:00
SSP05.9
16:15
SSP05.10
16:30
SSP05.11
16:45
SSP05.12
17:00
SSP05.13
17:15
SSP05.14
17:30
SSP05.15
SSP06
13:00
D. Metze (Münster, Germany) C. Tomasini (Torino, Italy) G. Kaya (Geneva, Switzerland) The European Society of Dermatopathology. B. Cribier (Strasbourg, France) G. Kaya (Basel, Switzerland) Certifying Examination in Dermatopathology: some feedback thoughts from a candidate. C. Tomasini (Torino, Italy) Value of molecular techniques in the diagnosis of a cutaneous lymphoma. C. Assaf (Krefeld, Germany) Merkel cell carcinoma and Merkel cell virus. E. Berti (Milan, Italy) Unusual dermatopathologic findings and pitfalls in the spectrum of GVHD G. Borroni (Pavia, Italy) Melanoma and c-KIT (CD117) expression. R. Cerio (London, United Kingdom) Histogenesis of poroma and syringoma. B. Cribier (Strasbourg, France) Molecular targeting of dermatofibrosarcoma protuberans G. Kaya (Geneva, Switzerland) Granulomatous cutaneous lymphomas. W. Kempf (Zurich, Switzerland) The role of electron microscopy in dermatopathology. D. Metze (Münster, Germany) Hyperkeratotic spicules: clinicopathologic spectrum C. Tomasini (Torino, Italy) Combined use of laser-microdissection and gene-expression analysis: a way towards “functional” histology ? J. Wenzel (Bonn, Germany) Cutaneous drug reactions: is a histological diagnosis possible? M. Ziemer (Jena, Germany) Final remarks
Arbeitsgemeinschaft Ästhetische Dermatologie und Kosmetologie in der DDG (ADK e.V.)
9:00 – 14:00 Chair:
Welcome
Hall 9 W.-I. Worret (Munich, Germany) C. Bayerl (Wiesbaden, Germany)
SSP06.1
Wellcome and Introduction W-I Worret (Munich, Germany)
13:10
SSP06.2
13:55 14:00
SSP06.3 SSP06.4
14:50 15:00
SSP06.5 SSP06.6
15:50 16:00
SSP06.7 SSP06.8
16:50 17:00
SSP06.9 SSP06.10
17:50
SSP06.11
SSP07
Swollen and discoloureg after peeling – Aftercare C. Bayerl (Wiesbaden, Germany) Questions and discussion Laser mistakes - What to do? M. Drosner (Munich, Germany) Questions and discussion Wrong paralysis after BTX - Wait six months? C. Pettke-Rank ( Munich, Germany) Questions and discussion Filler reactions - Therapeutic options G. Feller-Heppt (Baden-Baden, Germany) Questions and discussion Scars after surgery – Management W-I Worret (Munich, Germany) Questions and discussion
European Society of Cutaneous Lupus Erythematosus (EuSCLE)
9:00 – 14:00 Hall 10 14:00 14:10
14:40 14:55 15:10 15:25 15:40 15:55 16:10 16:22 16:34 16:46
SSP07.1
Welcome and Introduction A. Kuhn (Münster, Germany) SSP07.2 Key-Note Lecture Role of TREX1 for the pathogenesis of monogenic and complex forms of lupus erythematosus M.A. Lee-Kirsch (Dresden, Germany) Scientific Programme Chair: F. Nyberg (Stocksund , Sweden) SSP07.3 Potential role of HSP70 in cutaneous lupus erythematosus M. Wittmann (United Kingdom) SSP07.4 Analysis of TGF-ß and IL-10 serum levels in patients with cutaneous lupus erythematosus E. Antiga (Prato, Italy) SSP07.6 Requirement of vitamin D supplementation in patients with systemic and discoid lupus erythematosus A. Woźniacka (Lodz, Poland) SSP07.7 Disease manifestations in cutaneous lupus erythematosus: Database analysis of the EUSCLE Core Set Questionnaire from 26 European centers R. Weber (Koblenz, Germany) SSP07.8 “Education” of patients with cutaneous lupus erythematosus T. Gregurek-Novak (Zagreb, Croatia) SSP07.8 Coffee Break Case Reports Chair: F. Nyberg (Stockholm, Sweden) SSP07.9 Bullous skin lesions in a young woman with high suspicion of lymphoma B. Tanczos (Freiburg, Germany) SSP07.10 Lupus in the mucosa E. Aberer (Graz, Austria) SSP07.11 Cutaneous lupus and skin cancer in 260 patients with systemic lupus erythematosus F. Nyberg (Stockholm, Sweden) SSP07.12 Refractory melanin pigmented CDLE lesions in systemic lupus erythematosus M. Worm (Berlin, Germany)
17:00
SSP07.12
EUSCLE Annual Business Report A. Kuhn (Münster, Germany) R. Weber (Germany)
Exciting regional differences in microbial infections and resistance in Europe
SSP08
Arbeitsgemeinschaft für Dermatologische Infektiologie und Tropendermatologie e.V. (ADI-TD) 9:00 – 11:00 Hall 9 Chair:
C. Sunderkötter (Münster, Germany) H. Schöfer (Frankfurt, Germany)
09:00
SSP08.1
09:40
SSP08.2
10:20
SSP08.3
SSP09
Borrrelia, where are they endemic and what do they cause? H. Hofmann (Munich; Germany) MRSA in dermatology M. Mempel (Munich, Germany) Resistance to gonococci A. Stary (Vienna, Austria)
Tropical Dermatology Brazilian Society of Dermatology (BSD)
9:00 – 12:30 Room 42 Chair: Co-Chairs:
P. H. Cunha (Jundiai-Sao Paulo, Brazil) A. Alchorne (Sao Paulo, Brazil) O: Lupi (Rio de Janeiro, Brazil)
09:00
SSP09.1
09:05
SSP09.2
09:25
SSP09.3
09:45
SSP09.4
10:05
SSP09.5
10:25
SSP09.6
10:45
SSP09.7 SSP09.7.1
10:55
SSP09.7.2
11:05
SSP09.7.3
11:15
SSP09.7.4
11:25
SSP09.7.5
11:35
SSP09.7.6
Welcome & Introduction P. H. Cunha (Jundiai-Sao Paulo, Brazil) Viral Hemorrhagic Fevers O. Lupi da Rosa Santos (Brazil) Mucocutaneus Leishmaniasis (MCL) R. N. Ribeiro Sampaio (Brazil) Reactions in Hansen Disease L. da Conceição Margarido (Brazil) Mansonelliasis: Filariasis Without Specific Skin Lesions P. H. Cunha (Jundiai-Sao Paulo, Brazil) Dermatologic Manifestations Caused by Aquatic Animals V. Haddad Junior (Brazil) Tropical Diseases: Cases Reports Mucocutaneous Leishmaniasis A. de Oliveira de Avelar Alchorne (Brazil) Lucio's Phenomenon: A rare and severe leprosy reaction I. M. Carvalho Costa (Brazil) Trichophytic Granuloma: Diagnosis and Treatment B. V. Kadunc (Brazil) Extensive and Long-standing Chromomycosis due Fonsecaea pedrosoi: three cases treated with Voriconazole P.R. Criado (Brazil) Chagasic Paniculitis R. Romiti (Brazil) Chromomycocis on the neck and face
11:45
SSP09.7.7
11:55
SSP09.7.8
12:05
SSP09.7.9
12:15
SSP09.8
SSP10
M. M. de Avelar Alchorne (Brazil) Gnathostomiasis in Brazil C. Pires Amaral Maia (Brazil) An extensive case of mucocutaneous leishmaniasis M. Martins (Brazil) Pheohyphomycose P. H. Cunha (Jundiai-Sao Paulo, Brazil) Questions & answers
“Rose Parade of WDS Cases” Women's Dermatological Society (WDS)
9:00 – 11:00
Room 43
Chairs:
S. Olbricht (Burlington,USA) A. Tosti (Bologna, Italy) U. Blume-Peytavi (Berlin, Germany)
09:00
SSP10.1
09:10
SSP10.2
09:20
SSP10.3
09:30
SSP10.4
09:40
SSP10.5
09:50
SSP10.6
10:00
SSP10.7
10:10
SSP10.8
10:20
SSP10.9
10:30
SSP10.10
10:40
SSP10.11
10:50
SSP10.12
SSP11
The Masqueraders: Benign Pilomatricoma masquerading as malignant lymphoma and Lupus and Psoriasis masquerading as vitiligo and postinflammatory hyperpigmentation. J. B. Downie (USA) Cosmetic Treatments in Patients with Autoimmune Disease J.L. MacGregor (USA) Pemphigus Foliaceus, Pemphigus Erythematosus, Cutaneous Autoimmune Disease M. Tarbox (USA) Atypical Spitz Nevus Mimicking Infantile Hemangioma E. Taylor (USA) Spectrum of late-onset cutaneous lupus in an Irish population C. Fahy (Ireland) Treating Hyperhidrosis D. A. Glaser (St. Louis, USA) Plica neuropathica or 'Plica mechanica'. V. Mendiratta (India) Surgical dermatologic procedures in the pediatric patient in the office setting. S. Sullivan (USA) Skin Needling and Women's Beauty G. Fabbrocini (Italy) Recalcitrant Melasma among Filipinos should not be confused with Exogenous ochronosis E. Handog (Philippines) Complications in Cosmetic Dermatology in Skin of Colour M.B. Sachdev (India) Adult acne in women: what is the role of stress and thyroid disease? T. Vergou (Greece)
International Society of Teledermatology (ISTD)
9:30 – 11:30
Room 44
Chair:
K. McKoy (Burlington, USA) L. Witkamp (Amstelveen, Netherlands)
09:00
SSP11.1
09:15
SSP11.2
International Teledermatology Overview K. McKoy (Burlington, USA) Indications for TeleDermatology
09:30
SSP11.3
09:45
SSP11.4
10:00
SSP11.5
10:15
SSP11.6
10:30
SSP11.7
SSP12
J. van der Heijden (Netherlands) TeleDermatology in the UK H. Saul (Gillingham, United Kingdom) TeleWoundcare/TelePsoriasis R. Hoffmann-Wellendorf (Graz, Austria) Direct TeleDermatology through mobile phones A. Börve (Göteborg, Sweden) TeleDermatology as Best Practice L. Witkamp (Amstelveen, Netherlands) General Assemblee ISTD ALL
Miami Dermatological Society (MDS)
11.30 -13.30 Chair:
Hall 7 P. Romanelli (Miami, USA)
11:30
SSP 12.1
11:50
SSP 12.2
12:10
SSP 12.3
12:30
SSP 12.4
12:50
SSP 12.5
13:10
SSP 12.6
Scalp Dermoscopy A. Tosti (Bologna, Italy) Antioxidants and Depigmenting Agents I. Bogdman Alleman (Zurich, Switzerland) Wound Healing P. Romanelli (Miami, USA) My best cases J. Alonso (Rochester, USA) Is there a rationale for studying Mast Cells in Non-Scarring hair loss disorders ? M. Miteva (Jena, Germany ) Acral Melanoma: Why does it "Sleep under the ridges"? D. Torchia (Florence, Italy)
SSP13 European Society of Dermatology and Psychiatry (ESDAP) 12.30 – 14.30 Hall 4/5 SSP14 12.00-14.00 Chairs:
European Task Force on Atopic Dermatitis (ETFAD)/ EADV Eczema Task Force (ETF) Hall 10 L. De Raeve (Brussels, Belgium) U. Darsow (Munich, Germany)
12:00
SSP14.1
12.15
SSP14.2
12.30
SSP14.3
12.45
SSP14.4
Trichothiodystrophy: pathognomonic? L. De Raeve (Brussels, Belgium) Keratoconus-atopic dermatitis: genetic study of common modifications of epithelial barrier proteins C. Droitcourt (Bordeaux, France) D. Touboul, C. Ged, M. Cario-André, H. de Verneuil, J. Colin, A.Taïeb Interleukin-25 (IL-17E) in atopic dermatitis M. Hvid (Aarhus, Denmark) C. Vestergaard, G. Christensen, K. Kemp, B. Deleuran, M. Deleuran Differences in cerebral processing of histamine-induced itch in atopic
13.00
SSP14.5
13.15
SSP14.6
13.30
SSP14.7
eczema and healthy volunteers F. Pfab (Munich, Germany) M. Valet, J. Huss-Marp, T. Sprenger, G. I. Athanasiadis, H. Behrendt, T. R. Toelle, J. Ring, U. Darsow Treatment of atopic dermatitis with oral alitretinoin M. Grahovac (Munich, Germany) H. Rerinck, T. Ruzicka, A. Wollenberg Difficult doctor-patient interaction predicts organically unexplained symptoms in allergy patients M. Grosber (Munich, Germany) C. Hausteiner, E. Bubel, S. Groben, S. Bornschein,C. Lahmann, T. Zilker, P. Henningsen, D. Huber, B. Eberlein, H. Behrendt, J. Ring, U. Darsow Question & Answers TBA
SSP15
„PDT – An European Experience“ European Society for Photodynamic Therapy (Euro – PDT)
11.00 – 13.30 Chair:
Hall 8 L Braathen (Bern/Tromso, Switzerland/Norway) R.M. Szeimies (Regensburg,Germany) A. Sidoroff (Innsbruck, Austria)
11:00-
SSP15.1
11:10-
SSP15.2
11:30
SSP15.3
11:40
SSP15.4
11:50
SSP15.5
12:00 12:30
Coffee Break SSP15.6
12:40
SSP15.7
12:50-
SSP15.8
13:00
SSP15.9
13:10
SSP15.10
13:20-
SSP15.11
Welcome Address President EURO-PDT L Braathen (Bern/Tromso, Switzerland/Norway) Where PDT stands in 2009 A. Sidoroff (Innsbruck, Austria) Nanostructural hybride materials for photodynamic therapy M. Nowakowska (Kraków, Poland) Enhancing PDT in non-melanoma skin cancer using iron chelating agents S. Campbell (Truro, United Kingdom) Hospital based photodynamic therapy in Germany P. Lehmann (Wuppertal, Germany) Coffee Break Intrandividual, right-left comparison of PDT vs. imiquimod cream for actinic keratoses of the upper extremities E. Sotiriou (Thessaloniki, Greece) In vivo noninvasive evaluation of basal cell carcinoma response to MALPDT by reflectance confocal microscopy M. Venturini (Brescia, Italy) Erbium:YAG laser-stripping of stratum corneum enhances penetration of 5-aminolaevulinic acid in a porcine skin model A. Klein (Regensburg, Germany) Photodynamic therapy – a case of excellence in Portugal C. Brito (Braga, Portugal) Successful treatment of disseminated superficial actinic porokeratosis with 5-aminolaevulinic acid-photodynamic therapy D. Siem (Eindhoven, Netherlands) Final comments and closure of the meeting
SSP16
European Society for Pediatric Dermatology (ESPD)
12:45 – 15:30
Room 42
Chairs:
Z. Szalai (Budapest, Hungary) T. Kakourou (Athens, Greece)
12:45 13:30
SSP16.12 SSP16.1
13:35
SSP16.2
13:50
SSP16.3
14:05
SSP16.4
14:15
SSP16.5
14:25
SSP16.6
SSP16.7
14:35
SSP16.8
14:48
SSP16.9
15:10
SSP16.10
15:25
SSP16.11
SSP17
ESPD Board meeting OPENING Z. Szalai (Budapest, Hungary) Lessons of consultation ambulance: frequent questions for the pediatric plastic surgeon and the pediatric dermatologist Z. Szalai (Budapest, Hungary) External genitalia in newborn: what’s normal? U. Uksal (Turkey) Purpura fulminans due to Meningococcal Septicemia B. Kunz (Hamburg, Germany) E. Harps (Hamburg, Germany) Erythropoetic Protoporphyria - two cases B. Kunz (Hamburg, Germany) Three siblings with lipoid proteinosis (Urbach- Wiethe’s Disease) A.M.T. Karlsson (Stockholm, Sweden) M.A. Hedblad (Stockholm, Sweden) C.F. Wahlgren (Stockholm, Sweden) The prevalence, characteristics and risk factors for eczema in Belgian schoolchildren D. Van Gysel (Aalst ,Belgium) A.P. Oranje (Rotterdam, Netherlands) K.M.C Verhamme (Belgium) E. Doli (Belgium) E. Govaere (Belgium) Patch tests in children with suspected allergic contact dermatitis F. B. de Waard-van der Spek (Rotterdam, Netherlands) A.P. Oranje (Rotterdam, Netherlands) Childhood herpes zoster in the varicella- vaccine era T. Kakourou (Athens, Greece) M. Theodoridou (Athens,Greece) K. Theodoridou(Athens ,Greece) E. Papadogeorgaki (Athens ,Greece) News on Genodermatoses from Lausanne D. Hohl (Lausanne, Switzerland) Closing remarks T. Kakourou (Athens, Greece)
Women-Dermatology-Perspectives European Women's Dermatologic Society (EuWDS)
11:00 - 13:00 11:00
SSP17.1
11:05
SSP17.1.1
11:23
SSP17.1.2
Room 43 Evidence based management of dermatoses in women Chairs: G. Kirtschig (Amsterdam, Netherlands) F. Wojnarowska (Oxford, United Kingdom) Topical steroids in pregnancy F. Wojnarowska (Oxford, United Kingdom) Melanoma in women
11:41
SSP17.1.3
11:59
SSP17.1.4
12:17
SSP17.2
12:22
SSP17.2.1
12:42
SSP17.2.2
SSP18
Ukrainian Association of Dermatologists, Venereologists and Cosmetologists (UADVC)
12:00 -14:00 Chair:
S. Reed (USA) Cicatricial alopecia in the black female W. Bergfeld (Cleveland, USA) Hirsutism U. Blume-Peytavi (Berlin, Germany) Women as Leaders and Managers Chairs: U. Blume-Peytavi (Berlin, Germany) C. de Cuyper (Brügge, Belgium) European Dermatology Forum (EDF) A. Ranki (Hus, Finland) The organisation of Dermatology in China, Africa and India M. Verschoore (Paris, France)
Room 44 V.G. Kolyadenko (Kiev, Ukraine)
12.00
SSP18.1
12.10
SSP18.2
12.20
SSP18.3
12.30
SSP18.4
12.40
SSP18.5
12.50
SSP18.6
13.00
SSP18.7
13.10
SSP18.8
13.20
SSP18.9
13.30
SSP18.10
13.40
SSP18.11
13.50
SSP18.12
Introduction by the UADVC President V.G. Kolyadenko (Kiev, Ukraine) The modern aspects of diagnostic and treatment of the atopic dermatitis L.D. Kaliuzhna (Kiev, Ukraine) Measures against HIV infection transmission in Ukraine V.I. Stepanenko (Kiev, Ukraine) Sexually transmitted infections in an époque of human immunodeficiency virus epidemic in the Ukraine G. I. Mavrov, O.E. Nagorniy (Kharkov, Ukraine) Skin injuries in HIV/ AIDS in dependence with the stage of infection T.V. Protsenko, Ya.A. Goncharova, A.A. Mantula (Donetsk, Ukraine) New method of treatment of epithelial skin tumors V.G. Radionov, D.V. Radionov (Lugansk, Ukraine) Congenital giant dermal nevocellular nevus U.P. Adaskevich (Belarus) P. K. Kohl (Germany) The effectiveness of immunoblotting method of syphilis diagnostics in pregnancy A.M. Ivanov, D.V Zaslavsky, A.V. Samcov, M.V. Serdjutskaya, A.B. Krivoruchko, P.V. Pleshkov (Russia) Some conclusions on treatment of patients with STD in the system of youth-friendly clinic O.G. Hara, O.I. Hara (Ternpoli, Ukraine) Current notion about the role of compensatory systems in the mechanisms of formation and clinical manifestation of eczema A.N. Bilovol (Kharkov, Kiev) Scientific researches of Kiev dermatologists in 19-20 centuries K.V. Kolyadenko (Kiev, Ukraine) Measures for further improvement of atopic dermatitis management P.V. Chernyshov (Kiev, Ukraine)
SSP19
International Skincare Nursing Group/European Skincare Nursing Network (ISNG)
14:00 – 18:00 Chair:
Hall 14.2 P. Kelly (Cape Town, South Africa) K. P. Vineeh (Varanassi, India)
14:00
SSP19.1
14:05
SSP19.2
14:15
SSP19.3
14:45
SSP19.4
15:15
SSP19.5
15:35
SSP19.6
16:05 16:25
SSP19.7
16:30
SSP19.8
17:00
SSP19.9
17:30
SSP19.10
17:50
SSP19.11
SSP20
European Nail Society (ENS)
14:00 – 18:00 Chair:
Chair -Welcome and Introduction P. Kelly (Cape Town, South Africa) Looking back at 10 years of ISNG S. Ersser (Bournemouth, United Kingdom) Venous Eczema S. Aquilina (Malte) Nursing Development and evaluation in patient self management in psoriasis F. Cowdell (Bournemouth, United Kingdom) Feeding the Wound to Heal C. Ward (Malte) Measuring Wounds M. Romanelli (Pisa, Italy) BREAK Chair K: P. Vineeh (Varanassi, India) Difference between irritant contact dermatitis and pressure ulcers D. Beekman (Gent, Belgium) Lymphoedema Framework C. Moffat (Cardiff, United Kingdom) Dissemination of a curriculum framework –an example of ISNG work R. Penzer (United Kingdom) Closing Remarks from the ISNG Chair S. Ersser (Bournemouth, United Kingdom)
Hall 7 A. Tosti (Bologna, Italy)
14:00
SSP20.1
14:05
SSP20.2
14:20 14:20
SSP20.3 SSP20.3.1
14:20
SSP20.3.2
14:20
SSP20.3.3
14:20
SSP20.3.4
14:20
SSP20.3.5
Welcome and Introduction by the ENS President A. Tosti (Bologna, Italy) Top 3 science stories on nails 2008 – 2009 M. Pasch (Netherland) 3 top tips to treat nail disorders Simple onycholysis and chronic paronychia M. Daniel, R. Daniel (USA) Nail fragility M. Iorizzo (Bologna, Italy) One digit onychomycosis N. Lateur (Brussels, Beligium) Nail lichen planus B. M. Piraccini (Bologna, Italy) Nail psoriasis A. Tosti (Bologna, Italy)
14:20
SSP20.3.6
15:00
SSP20.4
15:15
SSP20.5
15:40
SSP20.6
15:40
SSP20.6
16:00
SSP20.7
16:00
SSP20.7
SSP21
Mild lateral nail ingrowing (stage I) E. Haneke (Freiburg, Germany) GENERAL MEETING A. Tosti (Bologna, Italy) N. Lateur (Brussels, Beligium) M. Iorizzo (Bologna, Italy) Update from Melanonychia Study Group N. Di Chiacchio (São Paulo,Brazil) Dermatopathology Potpourri From Around the Globe B. Ruben (USA) Dermatopathology Potpourri From Around the Globe J. André (Brussels, Belgium) E-Nail: Clinical cases D. de Berker (United Kingdom) E-Nail: Surgical cases B. Richert (Liège,Belgium)
Japanese Society for Investigative Dermatology (JSID)
15:00 – 18:00 Chair:
Hall 4/5 Y. Tokura (Kitakyushu; Japan) H. Shimizu (Sapporo, Japan)
15:00
SSP21.1
15:45
SSP21.2
16:30
SSP21.3
17:15
SSP21.4
SSP22 13:00-17:00
“Skin disorders associated with Epstein-Barr virus infection” Y. Tokura (Kitakyushu; Japan) “Atopic dermatitis: Its skin barrier function and filaggrin mutations” H. Shimizu (Sapporo, Japan) “Phototherapy for atopic dermatitis and the underlying mechanisms-induction of apoptosis and regulatory T cells” A. Morita (Nagoya, Japan) “Hair and Skin” R. Paus (Lübeck, Germany)
European Association of Dermato-Oncology (EADO) Hall 6 SSP 22.1
14.00
SSP 22.1.1
14:15
SSP 22.1.2
14:30
SSP 22.1.3
14:45
SSP 22.1.4
15:00
SSP 22.1.5
15:15 SSP 22.2
Part I: New insights in the classification of melanoma J.J. Grob (Marseille, France) H. Pehamberger (Vienna, Austria) Melanoma on naevus or de novo: still an issue at the time of stem cells ? J. Malvehy (Barcelona, Spain) Lentigo maligna , Nodular melanoma: still different entities? J.J. Grob (Marseille, France) Integrating new prognostic and predictive markers in melanoma classification C. Garbe (Tübingen, Germany) Molecular classification of melanoma: is it time? C. Robert (Villejuif, France) Targeting molecular pathways in melanoma: how many and which? F. Meier (Germany) Coffee Break Part II: An update on the management of cutaneous malignancies C. Garbe (Tübingen, Germany)
15.30
SSP 22.2.1
15:42
SSP 22.2.2
15:54
SSP 22.2.3
16:06
SSP 22.2.4
16:18
SSP 22.2.5
16:30
SSP 22.3
R. Kaufmann (Frankfurt, Germany) Targeted treatments for cutaneous T-cell lymphoma M. Bagot (Creteil, France) Treatment of Kaposi sarcoma C. Lebbe (Paris, France) How to manage patients with Merkel cell carcinoma? J. Marsden (Birmingham, United Kingdom) Unresectable or advanced squamous cell carcinomas B. Dreno (Nantes, France) What’s new in the topical treatment of NMSC? E. Stockfleth (Berlin, Germany) EADO Board meeting
SSP23 09:00-13:00
European Immunodermatology Society (EIS) Hall 6
SSP24
European Society of Photodermatology (ESPD Photo)
14:00 – 18:00 14:00
SSP24.1 SSP24.2
14:05
SSP24.2.1
14:30
SSP24.2.2
14:55
SSP24.2.3
15:1515:35
BREAK SSP24.3
15:35
SSP24.3.1
15:55
SSP24.3.2
16:15
SSP24.3.3
16:35
SSP24.3.4
16:50
SSP24.4
Hall 10 Welcome J. Hawk (London, United Kingdom) Session 1 Chairs: J. Hawk (London, United Kingdom) G. Leone (Rome, Italy) Vitamin D Adequacy: What It Is, How To Achieve It, And What If We Don’t? H. Lim (Detroit, USA) Photocarcinogenesis Today: Causes and Prevention Explained. A. Young (London, United Kingdom) Whither Phototherapy in the Age of Biologics? H. Hönigsmann (Vienna, Austria) Session 2 Chairs: M.C. Marguéry (Toulouse, France) P. Thomas (Lille, France) Photocarcinogenesis: The Difference in Transplant Patients. G. Murphy (Dublin, Ireland) Dealing with the Photodermatoses: How Good Are We Now? R. Roelandts (leuven, Belgium) Photoprotection: Towards the Perfect Sunscreen M. Brown (Nottingham, United Kingdom) Photoprotection: Towards the Perfect Sunscreen – Discussion Session Session 3:Short Communications Chairs: J. Krutmann (Düsseldorf, Germany) J. Hawk (London, United Kingdom)
SSP25 German Society of Pediatric Dermatology (GSoPD) 15.30 – 18.00 Room 42 Chairs:
R. Fölster-Holst (Kiel, Germany) H. Traupe (Münster, Germany) U. Blume-Peytavi (Berlin, Germany)
15:30
SSP 25.1
15:35 15:42 15:49 15:57 16:03 16:10
SSP 25.2 SSP 25.2.1 SSP 25.2.2 SSP 25.2.3 SSP 25.2.4 SSP 25.2.5 SSP 25.1
16:32
SSP 25.2
16:54
SSP 25.3
17:16
SSP 25.4
17:38
SSP 25.5
Opening R. Fölster-Holst (Kiel, Germany) Clinical Cases M. Wobser (Würzburg, Germany) N. Garcia Bartels (Berlin, Germany) V. Oji (Münster, Germany) I. Held (Kiel, Germany) K. Foitzik (Hamburg, Germany) Erythroderma in the newborns H. Ott (Aachen, Germany) Dermatoscopic features of nevi in pre-scholar children A. Belloni Fortina (Padova, Italy) Ectodermal dysplasia P. Itin (Basel, Switzerland) New pigmentary disorders R. Happle (Marburg, Germany) Differential diagnosis of bullous skin lesions in infancy C. S. Seitz (Göttingen, Germany)
SSP26 Community Dermatology International (CDI) 13.30 – 15.30 Room 43 SSP27 International Society of Dermatology (ISD) 16.00 – 18.00 Hall 8 Chair:
U. Wollina (Dresden, Germany)
16:00
SSP27.1
16:20
SSP27.2
16:40
SSP27.3
17:00
SSP27.4
17:20
SSP27.5
17:40
SSP27.6
18:00
SSP27.7
Living in extremes S. A. Memish, Z. Memish (Kuwait) Pigmentary Disorders and Climate Change E. Handog (Philippines) Climaderm - German Research Program on Climate Change in Dermatology M. Augustin (Hamburg, Germany) Global Warming and Pollen M. Buslau (Switzerland) Global Warming and Poverty-Related Diseases A. Morrone (Rome, Italy) Pollution, warming and skin disease J. Hercogova (Prague, Czech Republic) Closing Remarks: The Mission of the ISD T. Lotti (Florence, Italy)
SSP28 European Surveillance System on Contact Allergies (ESSCA) 15.30 – 18.00 Room 42 Chair:
W. Uter (Erlangen, Germany) A. Schnuch (Göttingen, Germany) B. Statham (Leeds, United Kingdom)
15.30
SSP28.1
Welcome A. Schnuch (Göttingen, Germany) B. Statham (Leeds, United Kingdom)
15.45
SSP28.2
16.15
SSP28.3
16.45
SSP28.4
17.15
SSP28.5
Overview on results from the Spanish REVAC network 2008 TBA Current state of ESSCA: Contributions, Data Collection 2007/2008 W. Uter (Erlangen, Germany) Expanding research: the scope of allergens and novel epidemiological issues A. Schnuch (Göttingen, Germany) The problem of quantitative exposure information for valid risk assessment A. Schnuch (Göttingen, Germany) W. Uter (Erlangen, Germany)
SSP29
European Society for Micrographic Surgery (ESMS)
16:00 – 18:00 Chair: SSP29.1 SSP29.2 SSP29.3 SSP29.4 SSP29.5 SSP29.6 SSP29.7
Room 43 G. Krekels (Eindhoven, Netherlands) J. Ostertag (Eindhoven, Netherlands)
Mohs micrographic surgery; experiences from Gothenburg. J. Paoli (Göteborg, Sweden) An interim analysis of a prospective randomised scontrolled study on immiquimod as pretreatment of Mohs micrographic surgery for basal cellcarinoma in the face. S. van de Geer (Rotterdam, Netherlands) Surgical excision vs. Mohs' micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomised controlled trial with 5 years follow up. K. Mosterd (Maastricht, Netherlands) Micrographic surgey; an overview of different methods and techniques used in Europe. M Moerhle (Tübingen, Germany) Statitiscal analysis of characteristics of the Mohs Micrographic surgery cases from Eindhoven from the past years. K.G.M.E. Broekhof (Maastricht, Netherlands) How to organize your MOHS CLINIC including the one stop shop mohs. J. Van Roij (Utrecht, Netherlands) Micrograpic surgery; experiences from Wroclaw. A. Bieniek (Wrocław, Poland)
SSP30 European Associates of Mayo Clinic Dermatology (EAMCD) 14.30 – 17.30 Room 44 14:30
SSP 30.1
14:50
SSP 30.2
Skin cancer in immunosuppressed patients: CLL J. Brewer (Rochester, USA) Update on Diagnosis for Autoimmune Mucocutaneous Blistering Disorders
15:10
SSP 30.3
15:30
SSP 30.4
15:50
SSP 30.5
16:10
SSP 30.6
16:30
SSP 30.7
16:50
SSP 30.8
SSP33
M. Camilleri (Rochester, USA) TBA R. Pujol (Barcelona, Spain) The Kindler-Syndrome protein family of 'kindlins': essential for life A. Meves (Düsseldorf, Germany) Psoriasis: Inside Out and Outside In M. Pittelkow (Rochester, USA) Therapeutic interventions for skin disease: old and new M. Davis (Rochester, USA) Genetic research at the Department of Dermatology in Basel, Switzerland Peter Itin (Basel, Switzerland) Darwin and the Evolution of Rosacea F. Powell (Dublin, Ireland)
Joint Meeting European Society for the History of Dermatology and Venereology (ESHDV/ German Working Group for the History of Dermatology and Venereology (AGDV)
09:15–15:00 Outside the ICC in the Berlin Medical Historical Museum of the Chariité Campus Charité Mitte, Charitéplatz 1, 10117 Berlin 09:15
SSP33.1
09:30
SSP33.2
10:00 11:00 12:00
SSP33.3 SSP33.4 SSP33.5 SSP33.6
13:00 15:00
SSP33.7 SSP33.8
Meeting point: Entrance hall of the „Berliner Medizinhistorisches Museum der Charité From Virchows Museum of Pathology to the Berlin Museum of Medical History. An Introduction T. Schnalke (Berlin, Germany) „Tracing life“ a guided tour through the permanent exhibition „Glancing behind the facade“ Alibert Oration: „Brief papers, great advances. A selection in dermatology.“ G. Tilles ESHDV Ordinary General Meeting P. Emmanouil (Athens, Greece) M. Geieges (Zurich, Switzerland) Lunch in the old lecture hall End of the ESHDV Meeting
Thursday, 8 October 2009 COURSES C 1 CONTACT AND OCCUPATIONAL DERMATITIS 08.30-10.00
HALL 15.2
Chair: Co-Chair(s):
W. Aberer (Graz, Austria) M. Bruze (Malmö, Sweden) A. Schnuch (Göttingen, Germany)
Learning Objectives: After this session the attendee will: 1. 2. 3.
Understand the risk factors for allergic contact dermatitis Know the latest news about clinical aspects of allergic and occupational dermatitis and how to prevent them. Learn how to diagnose and manage contact dermatitis.
Description: The course will cover various aspects of allergic contact dermatitis including basic mechanisms, clinical differentials, common and rare allergens as well as measures how to prevent them. Who knows the cause of the Chinese sofa/chair dermatitis, and who would assume that a small molecule drug for psoriasis represents a potent sensitizer? After attending this Course you will know. C 1.1
08:30
C 1.2
08:48
C 1.3
09:06
C 1.4
09:24
C 1.5
09:42
Risk Factors of Allergic Contact Dermatitis A. Schnuch (Göttingen, Germany) Intervention Studies in Hand Eczema T. Agner (Roskilde, Denmark) Update on Dimethyl Fumarate M. Bruze (Malmö, Sweden) Frequently Relevant Drug Contact Allergens A. Gimenez-Arnau (San Cugat del Valles, Spain) Unusual Cases A. Goossens (Leuven, Belgium)
C2 DERMATOPATHOLOGY 08.30-10.00
HALL 14.2
Chair: Co-Chair(s):
B. Cribier (Strassbourg, France) W. Weyers (Freiburg, Germany) R. Cerio (London, United Kingdom)
Learning Objectives: Following this session, the attendee will be able to: 1. 2. 3.
Discuss new concepts on follicular and nail tumors Deal with the diagnosis of CD30+ infiltrates Diagnose deposition disorders
Description: This course is dedicated to various difficult neoplastic and inflammatory skin diseases. The program encompasses a wide range of microscopic entities. New concepts on trichoblastic carcinoma and tumor of the follicular infundibulum will be presented. The importance of clinicopathologic correlation in dermatopathopathology will be illustrated by challenging cases from London. Pitfalls in both deposition disorders and CD30+ infiltrates will be discussed. C 2.1
08:30
C 2.2
08:45
C 2.3
09:00
C 2.4
09:15
C 2.5
09:30
C 2.6
09:15
Tumor of the follicular infundibulum is basal-cell carcinoma W. Weyers (Freiburg, Germany) Unusual nail tumors J. André (Brussels,Belgium) Pitfalls in CD30 proliferations W. Kempf (Zurich, Switzerland) Pitfalls in Deposition disorders F. Rongioletti (Genova Pegli, Italy) Trichoblastic carcinoma B. Cribier (Strassbourg, France) Examples of Informative East London Dermatopathology C. Rino (London, United Kingdom)
C3 DERMATOLOGICAL SURGERY 08.30-10.00
HALL3
Chair: Co-Chair(s):
S. Schuller-Petrovic (Vienna,Austria) F. M. Camacho (Seville, Spain) U. Hohenleutner (Regensburg, Germany)
Learning Objectives: Following this session, the attendee will be able to: 1.
To have an overview on different important topics in dermatologic surgery.
2.
To learn different methods for the treatment of congenital nevi, burns and congelations, superficial skin disorders, subcutaneous atrophies and hypertrophic changes in fat tissue, as well to learn the possibilities of surgical treatments in the face respecting the different regional approaches.
3.
To understand the possibilites, side effects and limits of different surgical methods.
Description: Dermatologic surgery offers a wide spectrum of methods for the treatment of cutaneous and subcutaneous skin changes. On one hand we have to remove nevi, skin tumors, pigmentary changes and to treat vascular disorders and skin injuries like burns and congelations, on the other hand we should be able to perform a wound closure or healing with a good functional and esthetic result. The most important fact is the decision in the choise of the proper treatment method and the right indication. Sometimes there is the question if treatment is really necessary or not, like in congenital nevi, in pigmentary changes, teleangiectasia or in lipoma and lipoatrophies. In any case it is very important to balance between treatment benefit and possible risks of the treatment. C 3.1
08:30
C 3.2
08:48
Reconstruction in skin cancer surgery of the face: subunit by subunit J. Hafner (Zürich, Switzerland) Treatment of burns and congelations J. Koller (Salzburg, Austria)
C 3.3
09:06
C 3.4
09:24
C 3.5
09:42
Ablative Skin Therapy U. Hohenleutner (Regensburg, Germany) Treatment of Congenital Nevi S.Schuller-Petrovic (Vienna, Austria) Liposuction and lipofilling: non esthetic indications F. M. Camacho-Martinez (Seville, Spain)
C4 DERMOSCOPY AND DIGITAL ANALYSIS OF SKIN LESIONS 08.30-10.00
HALL 6
Chair: Co-Chair(s):
W. Stolz (Munich, Germany) P. Rubegni (Siena,Italy) L. Thomas (Lyon, France)
Learning objective: 1. 2. 3.
Analyze important advanced criteria of dermoscopy Knowledge of modern concepts of melanoma development and of strategies for investigating critical patients Benefit from dermoscopy in daily practice
Description: Advanced concepts of dermoscopy will be introduced together with lectures of a combined molecular biologic approach for the understanding of the different types of melanoma. In addition, also the state of the art of image analysis of pigmented skin lesions will be described. At the end quiz cases will be diagnosed together with the audience. C 4.1
08:30
C 4.2
08:40
C 4.3
08:50
C 4.4
09:00
C 4.5
09:10
C 4.6
09:20
C 4.7
09:30
C 4.8
09:40
C5
Special nevi I. Zalaudek (Graz, Austria) Melanoma, from clinical diagnosis to dermoscopy G. Argenziano (Naples, Italy) Malvehy: Integrated approach (clinical,genetic and dermoscopic) for the diagnosis of melanoma S. Puig (Barcelona, Spain) J. Malvehy (Barcelona, Spain) Pigmened Morbus Bowen H. Kittler (Vienna, Austria) Fully regressive melanoma L. Thomas (Lyon, France) Objective follow-up of equivocal pigmented skin lesions P. Rubegni (Siena, Italy) Digital analysis of skin lesions: Fact or Fiction in 2009? W. Stolz (München, Germany) Quiz cases H. Cabo (Buenos Aires, Argentinia)
MEDIAWORKSHOP
08.30-11.45
ICC LOUNGE
Chair: Co-Chair(s):
C. ‘O’Mahony (Chester, United Kingdom) M. Trakatelli (Thessaloniki, Greece) A. Zalewska (Lodz, Poland)
Learning Objectives: 1. Understand how to prepare for media interview 2. Conduct the interview in a relaxed manner 3. Be confident at the important points were successfully conveyed Description: There will be a short period of informal lectures explaining media techniques and preparation. Small groups will then go through actual media interviewing with one or two topics discussed. This will be recorded and played back immediately after the interview, so that instant feedback can reinforce the messages and correct any poor technique. C 5.1
08:30
C 5.2
08:50
C 5.3
09:10
C 5.4
9.45
Welcome and How to present a message C. ‘O’Mahony (Chester, United Kingdom) Body Language on TV K. Fritz (Landau, Germany) EADV Media & PR Committee work M. Trakatelli (Thessaloniki, Greece) Practical part A. Zalewska (Lodz, Poland) C. ‘O’Mahony (Chester, United Kingdom) K. Fritz (Landau, Germany) M. Trakatelli (Thessaloniki, Greece) M. Gniadecka (Herlev, Denmark) G. Chaidemenos (Thessaloniki, Greece)
C6 HAIR DISORDERS 10.15-11.45
HALL 7
Chair: Co-Chair(s):
U. Blume-Peytavi (Berlin, Germany) R. Trüeb (Zurich, Switzerland) A. Messenger (Sheffield, United Kingdom)
Learning objective: 1. manage patients with diffuse hair loss and psychocutaneous disorders of the scalp, 2. diagnose patients with hirsutism and develop therapeutic concepts, 3. identify tropical dermatoses of the scalp. Description: This course will first target the differential diagnosis of diffuse hair loss and provide practical recommendations for diagnostis and therapy. One lecture will be devoted to excessive hair growth, diagnostic work up and non-pharmacologic and pharmacologic therapeutic options. Tropical dermatoses of the scalp present with a broad diagnostic differential spectrum. The attendee will learn to distinguish the most important differential diagnoses. Psychocutaneous disorders of the scalp have enormous impact on patients’ life. A thorough update on management of these patients will be provided. In addition, one lecture will focus on patient experiences of alopecia areata. C 6.1
10:15
C 6.2
10:20
C 6.3
10:38
C 6.4
10:56
Welcome and Introduction U. Blume-Peytavi (Berlin, Germany) Diffuse Hair Loss A. Tosti (Bologna,Italy) Hirsutism U. Blume-Peytavi (Berlin, Germany) Tropical Dermatoses of the Scalp
C 6.5
11:14
C 6.6
11:32
H. Larangeira de Almeida jr. (Brazil) Psychocutaneous Disorders of the Scalp R. Trüeb (Zurich, Switzerland) Patient Experience of Alopecia Areata M. Mowbray (United Kingdom)
C7 ALLERGY AND SPECIFIC IMMUNOTHERAPY 10.15-11.45
HALL 1
Chair: Co-Chair(s):
R. Brehler (Münster, Germany) P. Schmid-Grendelmeier (Zurich, Switzerland) C. A. F. M. Bruijnzeel-Koomen (Utrecht, Netherlands)
Learning Objectives: 1. Quality criteria of SIT preparations must be created 2. The significance of SLIT is documented 3. The impact of SIT in food allergy will be disc Description: The efficacy of SIT depends from allergen preparations. Nowadays high dose immunotherapy is recommend Significant SLIT have been recently published, demonstrating the efficacy of the oral route of Allergen administration. Studies dealing with the efficacy of SIT in food allergic patients will be represented New approach of SIT (recombinant allergens, adjuvants, intralymphatic approach) will be demonstrated. C 7.1
10:15
C 7.2
10:37
C 7.3
10:59
C 7.4
11:21
Quality criteria of SIT preparations R. Brehler (Münster, Germany) The significance of SLIT J. Kleine-Tebbe (Berlin, Germany) SIT in food allergy C. A. F. M. Bruijnzeel-Koomen (Utrecht, Netherlands) New approaches in SIT P. Schmid-Grendelmeier (Zurich, Switzerland)
C8 BACTERIAL AND VIRAL DISEASES OF THE SKIN 10.15-11.45
HALL 3
Chair: Co-Chair(s):
O. Chosidow (Paris, France) R. F. Betts (Rochester, USA) R. Friedman-Birnbaum (Haifa, Israel)
Learning objective: Following this session, the attendee will be able to: 1. diagnose common skin infections 2. appreciate evidence-based information for management 3. give advances in uncommon viral-related skin condition Description: We intend to inform the attendees of the well-established (or not) data and most recent advances in the diagnosis and treatment of skin infections. The topic will cover, erysipela and infectious cellulitis, CA-MRSA infections, genital herpes and Herpes zoster. Management of those infections will include evidence-based information. Uncommon viral-related skin conditions such Merckel carcinoma and Kaposi sarcoma will also be covered. We also hope to be able to answer any questions regarding the session or bacterial/viral skin diseases in general.
C 8.1
10:15
C 8.2
10:30
C 8.3
10:45
C 8.4
11:00
C 8.5
11:15
C 8.6
11:30
Management of erysipela and infectious cellulitis O. Chosidow (Paris, France) Epidemiology and management of CA-MRSA infections in Europe vs USA U. Jappe (Langen, Germany) Viral signature of skin cancers. N. Dupin (Paris, France) Epidemiology of classic Kaposi's Sarcoma and seroprevalence of HHV8 R.Friedman-Birnbaum (Haifa, Israel) Suppressive treatment of genital herpes : what are the evidence ? L. le Cleach (Corbeil-Essonne, France) Epidemiology and management of Herpes zoster R. F. Betts (Rochester, USA)
C9 GENETICS IN DERMATOLOGY 10.15-11.45
HALL 15.2
Chair: Co-Chair(s):
D. Hohl (Lausanne, Switzerland) H. Traupe (Münster, Germany) E. O’Toole (London, United Kingdom)
Learning Objectives: 1. To understand new findings in the molecular basis of genetic skin disease and associated tumors 2. To consider the clinical approach to patients with rare genetic disease and general therapeutic principles 3. To explore the development of novel disease specific treatment options Description: The programme will aim to provide up to date information to promote an understanding of the molecular basis of hereditary skin disease, but this will be particularly oriented towards the clinical setting in which such patients are assessed and managed in general dermatological practice. The current therapeutic trials will be presented with a realistic assessment of their likely applications. C 9.1
10:15
C 9.2
10:38
C 9.3
11:00
C 9.4
11:23
Clinical care for children with genetic skin disease C. Bodemer (Paris, France) What's new in genetic tumor syndromes? D. Hohl (Lausanne, Switzerland) What’s new in ectodermal dysplasias? A. Irvine (Belfast, United Kingdom) What’s new in ichthyoses?: the new consensus classification H. Traupe (Münster, Germany) V. Oji (Münster, Germany)
C10 ALLERGIC AND INTOLERANCE REACTIONS 15.00 – 16.30
HALL 2
Chair: Co-Chairs:
M. Worm (Berlin, Germany) A. Lauerma (Helsinki, Finland) M. Czarnecka-Operacz (Poznań, Poland)
Learning Objectives: 1. Understand allergic and intolerance reactions 2. Plan diagnostic procedures for allergy and intolerance 3. Management of Anaphylaxis
Description: The course attempts to give algorithms for the diagnosis and treatment of allergic cutaneous reactions with the focus of food allergy and anaphylaxis. Cases will be presented in each talk to the audience. This shall improve the skills in diagnostics and therapeutic clinical procedures and will also demonstrate novel developments, e.g. diagnostics which might be relevant in the near future. C 10.1
15:00
C 10.2
15:22
C 10.3
15:44
C 10.4
16:00
Mechanisms of allergy and intolerance-implications for clinics A.Lauerma (Helsinki, Finland) Between provocation test and microarray: current diagnosis of allergic and intolerance reactions P.Schmid-Grendelmeir (Zurich, Switzerland) Food Allergies-myths and facts M.Czarnecka-Operacz (Poznań, Poland) Clinical Management of anaphylaxis M. Worm (Berlin, Germany)
C11 LASERS IN DERMATOLOGY 15.00 – 16.30
HALL 3
Chair: Co-Chairs:
K. Fritz (Landau, Germany) P. Bjerring (Aarhus, Denmarkt) L. Marini (Trieste, Italy)
Learning Objectives: 1. 2. 3.
know the main indications for laser treatments in classic dermatology learn which lasers and wavelenghth are suitable for indications and penetration depth learn how to avoid side effects
Description: This laser session is a 90 min seminar on laser therapy focusing on laser treatment in classic dermatology. The course is supposed to enable dermatologists in private practice and clinics to learn the essentials on the main types of laser treatment, including theoretical background, technical background, lasers available, their differences, prices, the way how to use them, indications, contraindications and the benefit of the laser treatments compared to other therapies C 11.1
15:00
C 11.2
15:11
C 11.3
15:22
C 11.4
15:33
C 11.5
15:44
C 11.5
15:44
C 11.6
15:55
C 11.7
16:06
Laser treatment of scars H.-P. Berlien (Berlin, Germany) Lasers, light sources and PDT for inflammatory acne M. Haedersdal (Copenhagen, Denmark) Fluorescence aided diagnosis of early and latent pre-cancers and skin carcinomas P. Bjerring (Aarhus, Denmark) Common errors in Laser Surgery and how to avoid them L. Marini (Trieste, Italy) Laser assisted Vitiligo treatment including melanocyte Grafting K. Firtz (Landau, Germany) Laser assisted Vitiligo treatment including melanocyte Grafting T. Hunziker (Bern, Switzerland) Laser treatment for difficult vascular leasions M. Lapidoth (Herzelia, Israel) Comparison of short pulsed vs. long pulsed 532nm laser for treatment of Lentigos
16:17
C 11.8
K. Nouri (Miami, USA) The Future of Lasers and Lights M. H. Gold (Nashville, USA)
C12 MYCOLOGY 15.00 – 16.30 HALL 15.2 Chair: Co-Chairs:
G. Ginter-Hanselmayer (Graz, Austria) M. Potocnik (Ljubljana , Slovenia) B. Farkas (Pécs, Hungary)
Learning Objectives: 1. Fungal nail infection: Evaluation of the burden of disease and practical treatment options 2. Clues and pearls to get the diagnosis in unusual features of mycotic skin diseases 3. Insight in the new role of Malassezia furfur in different skin diseases Description: This course is addressed to dermatologists to get insight in the current state of common dermatomycoses like fungal nail infection as well as in concealed mycotic skin disorders like seen in patients with immunosupression. The number of patients suffering from fungal nail infection is steadily on increase, therefore the quality of life in onchyomycosis and stigmatization by the burden of that disease needs to be evaluated. In addition the current treatment options will be outlined step by step for both the experienced as well as the inexperienced dermatologist. Steroid-pretreated mycotic skin infections (tinea incognito) may be seen by dermatologists daily. In view of this matter clinical features of mycotic infections in the immunosuppressed patient as well as of sites usually not common for the eyes of the dermatologists will be presented. Finally some new concepts with Malassezia species will give an interesting insight in the pathogenesis of some skin diseases.
C 12.1
15:00
C 12.2
15:18
C 12.3
15:36
C 12.4
15:54
C 12.5
16:12
Tinea Incognito G.Ginter-Hanselmayer (Graz, Austria) Mycoses in the anogenital region – a permanent challenge M.Potocnik (Ljubljana, Slowenia) Skin Diseases Associated with Malassezia Species: Old Facts and New Concepts B.Farkas (Pécs, Hungary) Onychomycosis: More than Fungal Nail Infection J.C.Szepietowski (Wroclaw, Poland) Treatment of Onychomycosis: Step by Step D.Reinel (Hamburg, Germany)
SYMPOSIA S1 ADVANCES IN THE MANAGMENT OF HIV 08.30-10.00
HALL 1
Chair: Co-Chair(s):
N. Brockmeyer (Bochum, Germany) A. Rieger (Vienna, Austria) M. Alsina Gilbert (Barcelona, Spain)
S 1.1
08:30
S 1.2
08:48
Introduction with details of the HIV epidemiology in Europe N. Brockmeyer (Bochum, Germany) New drugs and treatment
S 1.3
09:06
S 1.4
09:24
S 1.5
09:42
J. Mallolas (Barcelona, Spain) Common side effects in new treatment and strategies IRIS M. Hartmann (Heidelberg, Germany) Pep-Prep saver sex (license to love) A. Rieger (Vienna, Austria) Emerging tumors in HIV infected patients with an emphasis on non AIDS defining cancer especially HPV associated cancer M. Sarcletti (Innsbruck, Austria)
Learning objective: Following this session, the attendee will be able to: 1. Overview of HIV epidemiology in Europe and opportunities of research in Europe 2. Overview of therapies and new therapeutic strategies of HIV infection 3. Diagnosis and management of therapy associated side effects 4. Pathogenesis and therapy of HIV associated tumors Description: The session will give an overview of HIV infection in Europe and will draw attention to opportunities for resesearch in networks. An overview will be given in scientific success with regards to therapy management of HIV infection and HIV associated tumors. At the end of the session they should be able to choose the correct therapeutic regiment for each condition and to inform the HIV-infected patients competently on therapy associated side effects, immune reconstitution syndrome and HIV associated tumors. The session will offer management advice and recent insights on treatment of HIV-infected patients. S2 ADVERSE DRUG REACTIONS 08.30-10.00
ROOFGARDEN
Chair: Co-Chair(s):
H. Hintner (Salzburg, Austria) M. Hertl (Marburg, Germany) C. Paul (Toulouse, France)
Learning Objectives: 1. Diagnosis and therapy of adverse drug reactions in daily practice 2. Therapy of adverse drug reactions in daily practice 3. Side effects of biologics Description: Adverse drug reactions are a frequent and expensive problem in most of the medical disciplines often complicating the course of the disease. It is a wide field and we have chosen to set the symposium in the brackets of the description of an up to date diagnosis and the management of (severe) drug reactions. Focus is laid in addition on side effects of biologics, the common phenomenon of drug induced urticaria and finally on the immunotherapy in drug hypersensitivity. S 2.1
08:30
S 2.2
08:48
S 2.3
09:06
S 2.4
09:24
S 2.5
09:42
How to make diagnosis of drug allergy W. Arberer (Graz, Austria) Adverse reactions to biologics W. Pfützner (Marburg, Germany) Drug – induced urticaria H. Merk (Aachen, Germany) Immunotherapy in drug hypersensitivity state of the art K. Scherer (Basel, Switzerland) Management of severe drug reactions P. Friedmann (Southhampton, United Kingdom)
S3 ATOPIC DERMATITIS 08.30-10.00
HALL 2
Chair: Co-Chair(s):
T. Bieber (Bonn, Germany) J. Ronnevig (Oslo, Norway) G. Girolomoni (Verona, Italy)
Learning Objectives: 1) The genetic and immunologic mechanisms in the pathophysiology of AD 2) Clinical phenotypes of AD 3) Modern management of AD Description: Atopic dermatitis (AD) is the most common inflammatory skin disease and has experienced a tremendous progress in many fields, including genetics, epidemiology, immunology and therapy. This session will supply the newest informations available today and provide the scientific background for a better management of this disease. S 3.1
08:30
S 3.2
08:48
S 3.3
09:06
S 3.4
09:24
S 3.5
09:42
Genetics of Atopic Dermatitis N. Novak (Bonn, Germany) IL-17 in Atopic Dermatitis C. Traidl-Hoffmann (Munich-Germany) Phenotypes of Atopic Dermatitis G. Girolomoni (Verona, Italy) Proactive management of Atopic Dermatitis S. Raitamo (Hus, Finland) Atopic Dermatitis in the Era of Personalized Medicine T. Bieber (Bonn, Germany)
S4 AUTOIMMUNE BULLOUS DISEASE 08.30-10.00
HALL 7
Chair: Co-Chair(s):
P. Joly (Rouen, France) D. Zillikens (Lübeck, Germany) S. Kárpati (Budapest, Hungary)
Learning Objectives: 1. make the diagnosis of the main autoimmune bullous skin disorders, (bullous pemphigoid, , pemphigoid gestationis, pemphigus, dermatitis herpetiformis), 2. understand the pathogenesis of these diseases, 3. manage patients in accordance with recent data from the evidence based medicine Description: Autoimmune bullous disorders are a heterogeneous group of skin disorders characterized by the production of autoantibodies directed against various proteins of the dermal epidermal junction and/or desmosomal junctions. The aim of this session is to present new insights in the pathogenesis and treatment of autoimmune bullous disorders, as well as various uncommon clinical features. S 4.1
08:30
New Options to treat Pemphigus D. Zillikens (Lübeck, Germany)
S 4.2
08:48
S 4.3
09:06
S 4.4
09:24
S 4.5
09:42
New Insights in the Pathogenesis and Diagnosis of Pemphigoid J. Herrero (Spain) Misleading and atypical clinical presentations of autoimmune blistering diseases : common diagnostic pitfalls L. Borradori (Geneva, Switzerland) Management in Patients wiht Dermatitis Herpetiformis S. Karpati (Budapest, Hungary) Alternative Treatments to the Oral Corticosteroids for Patients with Bullos Pemphigoid P. Joly (Rouen, France)
S5 GERIATRIC DERMATOLOGY 08.30-10.0
HALL 4/5
Chair: Co-Chair(s):
K. Scharffetter-Kochanek (Ulm, Germany) J. L. Leveque (Clichy, France) D. Ioannides (Thessaloniki,Greece)
Learning Objectives: 1. To get insight into mechanisms of skin aging 2. To get insight into diagnostics and therapy of aging 3. To appreciate skin aging as a model for organismic aging and to connect it to longevity. Description: Skin aging is due to aging mechanisms on this aging to environmental threats like sun exposure and smoking. The Skin is accessible and undoubtedly shows many mechanisms with the aging of other organs, skin particular those organs which are rich in connective tissues. This session will give you overall insight into mechanisms diagnostics and therapeutic state of the art approaches and will provide perspectives how skin aging and more importantly organismic aging can effectively be tackled in near future by novel strategies. S 5.1
08:30
S 5.2
08:45
S 5.3
09:00
S 5.4
09:15
S 5.5
09:30
S 5.6
09:45
Introduction K. Scharffetter-Kochanek (Ulm, Germany) Endocrine Changes in Skin Aging E. Makrantonak (Dessau, Germany) Characterization of photoaged skin by capicitance imaging J. L. Leveque (Clichy, France) Cosmetics, Photoprotection and Skinaging D. Ioannides (Thessaloniki, Greece) Minimal therapy in Skin aging M. Podda (Darmstadt, Germany) Perspectives-Aging and Longevity K. Scharffetter-Kochanek (Ulm, Germany)
S6 COSMETCEUTICALS IN DERMATOLOGY 15.00 – 16.30
HALL 9
Chair: Co-Chair(s):
T. Agner (Roskilde, Denmark) A. Rougier (Asnières, France) M. H. Gold (Nashville, USA)
Description:
This session will focus on effects and side effects of cosmeceuticals in dermatology. Special emphasis will be on effects of emollients on stratum corneum and skin barrier function in healthy and diseased skin, as well as effects of antioxidants. Contact allergy and contact urtcaria to cosmetics, and recommendations for allergy testing will be discussed. S 6.1
15:00
S 6.2
15:15
S 6.3
15:30
S 6.4
15:45
S 6.5
16:00
S 6.6
16:15
Emollients and Barrier Function in Atopic Dermatitis A. Rougier (Asnières, France) Influence of cosmeceuticals on skin lipids and barrier function J. M. Jungersted (Roskilde, Denmark) Newer antioxidants M. H. Gold (Nashville, USA) Contact allergy and contact urticaria to cosmeceuticals A. Gimenez Arnau (San Cugat del Valles, Spain) Allergic reactions to PPD, and how to test H. Søsted (Hellerup, Denmark) Use of moisturizers in patients with allergic contact dermatitis T. Agner (Roskilde, Denmark)
S8 DERMATOLOGY IN THE LEVANT 08.30-10.00 Chair: Co-Chair(s):
ROOM 42 A. G. Kibbi (Beirut, Libanon) A. Aleisa (Riyadh, Saudi Arabia) M. B. M. El-Domyati (Cairo, Egypt)
S 8.1
08:30
S 8.2
08:43
S 8.3
08:55
S 8.4
09:08
S 8.5
09:20
S 8.6
09:32
S 8.7
09:44
The Clinical and Histological Spectrum of Cutaneous Mycobacterium marinum Infections in Lebanon S. Ghosn (Beirut, Libanon) Skin Aging: Clinicopathological Implications and Expectations M. B. M. El-Domyati (Minya, Egypt) Striae Gravidarum: Risk factors and Prevention with Cocoa Butter Lotion N. Rubeiz (Beirut, Libanon) Henna: The Whole Story. M. Dahdah (Beirut, Libanon) Actinic Lichen Planus: Clinicopathologic Review of Cases at the American University of Beirut. S. Zaynoun (Beirut, Libanon) Botox in Middleast Population A. Aleisa (Riyadh, Saudi Arabia) Q-Switch Pigmented Laser in Dark Skin A. Aleisa (Riyadh, Saudi Arabia)
S9 DERMATOLOGY IN CHINA 10.15-11.45
HALL 8
Chair: Co-Chair(s):
E. Tschachler (Vienna, Austria) X. Zhou (Beijing,China) B Wang (Nanjing, China)
S 9.1
10:15
S 9.2
10:44
New development in the mechanism on pathogenesis and treatment modalities of psoriasis in China M. Zheng (Hangzhou, China) The nonpharmaceutical therapies in the treatment of acne vulgaris in
S 9.3
11:06
S 9.4
11:28
Asian people F. Xiang (Shanghai, China) New dermatoses or new subtype of dermatoses? J. Sun (Nanjing, China) Brief Introduction of Dermatology in China B Wang (Nanjing, China)
S10 SKIN DISEASE AND STI'S IN INDIA 10.15-11.45
ROOM 42
Chair: Co-Chair(s):
V. K. Sharma (New Delhi, India) S. Verma (Vadodara, India) R. Sharma (Aligarh, India)
Learning objectives. 1. To promote international dermatology. Dermatology practice in the Indian Subcontinent is very different from that of the West. 2. To learn about Sexually Transmitted Infections and Leprology along with Dermatology in India as these two fields are practiced along with dermatology in India. 3. To appreciate the difference in priorities of diseases and their treatment in dark skin which is influenced by many non clinical factors. Description: Indian Dermatology marches proudly into international limelight. This is the second time in three years at the EADV congress that an exclusive session has been dedicated to dermatology in India. The first such session in Vienna was organised by Dr. Shyam Verma in Vienna. The raison d’ être of this session is to provide an insight into Indian dermatology which is very different from the Western stereotype and that is what makes it challenging and interesting. The patient population is predominantly Fitzpatrick skin type IV and V and hence many diseases look different and treatment priorities differ too. An attempt is made to showcase the sexually transmitted infections scenario in India too as it is a field practiced by dermatologists. Leprosy is another disease that is looked after by dermatologists and some new investigative modalities will be discussed. And finally, Indians dermatologists are prolific writers, both in the academia as well as in private practice. This session has been thought to be an apt platform to document some dermatologic observations which have never been included in mainstream dermatology literature in spite of their relatively common occurrence. The talks are given by some of the top academic dermatologists heading premiere dermatology departments as well as well known names from the private practice arena. S 10.1
10:15
S 10.2
10:30
S 10.3
10:45
S 10.4
11:00
S 10.5
11:15
Prevalence of Sexually Transmitted Infections in India V. K. Sharma (New Delhi, India) To study the utility & practicality of Ultra Sonography (USG) for measuring thickness of nerves in Leprosy. H. R. Jerajani (Mumbai, India) The role of Private practicing dermatologists in documenting and publishing commonly seen but Undescribed phenomena in dermatologic literature S. B. Verma (Vadodara, India) Reticulate Pigmentary Disorders in India R. Sharma (Aligarh, India) Minigrafting and Narrow band phototherapy in Vitiligo: An Indian experience K. Lahiri (Kolkata, India)
11:30
S 10.6
Cutaneous T cell lymphoma- Recognition of early disease in Indian patients M. Rajagopalan (Chennai, India)
S11 ACNE 10.15-11.45
HALL 2
Chair: Co-Chair(s):
C. C. Zouboulis (Dessau, Germany) V. Bettoli (Ferrara, Italy) A. M. Layton (Harrogate, United Kingdom)
Learning Objectives: Following this session, the attendee will be able to (max 50 words): 1. 2. 3.
Role of new players in acne pathogenesis Background of new therapeutic developments Modern evaluation techniques
Description: The expansion of knowledge on acne pathogenesis and treatment makes it challenging to stay up-to-date in the field, even for experts. Understanding modern aspects of pathogenesis and treatment as well as developing objective and sensitive methods for evaluation will be the milestones for acne in the 21st century. S 11.1
10:15
S 11.2
10:20
S 11.3
10:33
S 11.4
10:46
S 11.5
10:59
S 11.6
11:12
S 11.7
11:25
S 11.8
11:38
Introduction - The magic and mystery of acne A. Layton (Harrogate, United Kingdom) Acne genomics B. C. Melnik (Gütersloh, Germany) Acne lipidomics M. Picardo (Rome, Italy) The acne biofilm K. Honraet (Ghent, Belgium) Future topical treatments for acne V. Bettoli (Ferrara, Italy) Future systemic treatments for acne H. Gollnick (Magdeburg, Germany) Modern imaging in acne assessment N. Kollias (USA) Closing remarks - Acne in the 21th century C. C. Zouboulis (Dessau, Germany)
S12 DERMATOSES OF THE GENITAL AREA 10.15-11.45
ROOFGARDEN
Chair: Co-Chair(s):
M. Pelisse (Paris, France) D. Forsea (Bucharest,Romania) D. Jasaitiene (Kaunas, Lithuania)
Learning objectives: 1. New concepts in the nosology of the main inflammatory and degenerative diseases of vulva 2. New insights in the etio-pathogeny of the vulvar disorders 3. Current strategies of management for the vulvar disorders
Description: The session is dedicated to a field of dermatology which although important and of high impact on patients’ quality of life, remains often less known. Vulvar disorders are frequent, but for various socio-economical, cultural and logistical reasons they are underdiagnosed, less studied and consequently, often discovered only in advanced, invalidating stages. The session addresses a wide spectrum of vulvar pathology, from the acute inflammatory and ulcerative disorders, to the chronic degenerative and neoplastic diseases. The lectures aim to present an updated approach of inflammatory and degenerative disorders of female genital mucosa, based on the newest scientific data regarding the etiology and pathogeny of these disorders; on the new concepts regarding their clinical and pathological classification and nomenclature; on the latest recommendations, evidence-based, regarding the efficient management of these disorders. S 12.1 S 12.2 S 12.2 S 12.3 S 12.4
Diagnostic Value of Bistological Features of Lichen Sclerosus and Atrophicus D. Jasaitiene (Kaunas, Lithuania) New Clinical and Pathological Approach of Vulvar Intraepithelial Neoplasia D. Forsea (Bucharest,Romania) New Clinical and Pathological Approach of Vulvar Intraepithelial Neoplasia A. M. Forsea (Bucharest, Romania) Genital Lichen Planus in Women and Men F. Lewis (Slough, United Kingdom) Acute Ulcer of the Vulva M. Pelisse (Paris, France) N. Dupin (Paris, France)
S 13 DIAGNOSES AND MANAGEMENT OF VASCULITIS 15.00 – 16.30
HALL 6
Chair: Co-Chair(s:)
C. Sunderkötter (Münster, Germany) N. Sepp (Innsbruck, Austria) L. Borradori (Geneva, Switzerland)
Learning objectives: 1. 2. 3. 4.
Differentiate different forms of leukocytoclastic vasculitis according to their clinical relevance Know some causes of vasculitis Recognize the spectrum of dermatologic manifestation of systemic vasculitides Recognize the meaning of livedo
Description: The inflammation of vessel walls can be a primary event or can occur secondary to systemic diseases (secondary vasculitis). The skin is often the first organ where vasculitis becomes apparent. Leukocytoclastic vasculitis (LcV) is the most frequent form of vasculitis in the skin. It presents in different forms and in association with different systemic diseases. A current revision of the classification of vasculitis takes into account the distinct clinical relevance. In immunecomplex mediated vasculitis eg. systemic involvement is likely when IgA, but not IgO or 1gM, is the dominant immunoglobulin in immune complexes. The diagnostic aim is to determine the specific type and systemic involvement of LcV and to identify an underlying cause. Basic work-up should encompass history of drug intake and of preceding or ongoing infections. Livedo is an
intriguing cutaneous sign which can be a symptom of vasculitis, but also of many other conditions, usually associated with a form of identified or unidentified coagulopathy. S 13.1
15:00
S 13.2
15:22
S 13.3
15:44
S 13.4
15:06
Leukocytoclastic Vasculitis. Which Form?How to Proceed? C. Sunderkötter (Münster, Germany) The wide Spectrum of Dermatologic Manifestations of Systemic Vasculitis C. Frances (Paris, France) Vasculitis and Infection N. Sepp (Innsbruck, Austria) Livedo and Purpura: What is your Diagnosis? L. Borradori (Geneva, Switzerland)
S16 PRESIDENTS SYMPOSIUM 08.30-10.00
HALL 10
Chair: Co-Chair(s):
A. Katsambas (Athens, Greece) A. Giannetti (Modena, Italy) F. Powell (Dublin, Ireland)
S 16.1
08.30
S 16.2
08:53
S 16.3
09:16
S 16.4
09:39
The photdynamic therapy in the treatment of Acne Vulgaris F. Xiang (Shanghai, China) Dermatologic Highlights from the new continent J. Ocampo-Candiani (Nuevo León, Mexico) Experience on the management of common skin diseases in a developing country O. Faye (Mali ) TBA M. Ramos-e-Silva (Rio de Janeiro, Brazil)
S17 AN UNDERSTANDING OF SKIN DISEASE FOR THE DERMATOLOGIST (ESDR SYMPOSIUM) 15.00-16.30
HALL 8
Chair: Co-Chair(s:)
E. Healy (Southampton, United Kingdom) S. Karpatí (Budapest, Hungary) C. Mauch (Köln, Germany)
Learning objectives 1. Greater insight into the aetiology / pathogenesis of skin disease 2. Awareness of recent advances in scientific understanding of skin disease 3. Knowledge of processes that impact on disease susceptibility, severity and/or prognosis Description: The session will cover the clinical, aetiological and pathogenetic aspects of these skin disorders (melanoma, immunobullous disorders and non-melanoma skin cancer). In the case of melanoma, the presentation will cover the heterogeneity of this tumour type, and the combination of clinical and genetic staging as a precursor for more personalized therapy for current and future patients. The lecture on blistering skin diseases will describe the antigenic targets of immunobullous disorders in relation to the clinical and histological picture, and the rationale for current therapeutic approaches. The presentation on non-melanoma skin cancer will look at risk factors and susceptibility with a view to understanding the pathogenesis and the reasons why patients develop these tumours. The speakers will provide an up-to-date overview, explaining exciting scientific advances in simple language, so that the delegates will have greater insight into these skin diseases when diagnosing and treating patients in the clinic.
S 17.1
15.00
S 17.2
15.30
S 17.3
16.00
Understanding melanoma C. Mauch (Köln, Germany) Understanding blistering skin diseases S. Karpatí (Budapest, Hungary) Understanding non-melanoma skin cancer E. Healy (Southampton, United Kingdom)
S18 ROSACEA AND OTHER FACIAL DERMATOSES 15.00-16.30 HALL 10 Chair: Co-Chair(s):
F. Powell Dublin, (Dublin, Ireland) L. Scerri (Floriana, Malta) C. Antoniou (Athens, Greece)
Learning Objectives: 1. To recognise and diagnose the different subtypes of Rosacea and other facial dermatoses. 2. Treat effectively Rosacea and other facial dermatoses. 3. Learn about new advances in knowledge in this area. Description: This session will combine clinical features, treatment and recent advances in knowledge relating to Rosacea and Other Facial Dermatoses. The main diagnostic features of the common facial dermatoses will be reviewed and the spectrum of investigations required distinguishing one from the other. The first and second line treatment for these diseases will then be outlined and the clinician guided to the correct choice for each individual patient with the help of short case illustrations. Recent advances in knowledge will be highlighted throughout these presentations. Audience participation will be encouraged at the end of each presentation and during a discussion period at the end of the session. S 18.1
15:00
S 18.2
15:15
S 18.3
15:30
S 18.4
15:45
S 18.5
16:00
S 18.6
16:15
Introduction, The Diagnosis of Rosacea F. Powell Dublin, (Dublin, Ireland) Demodecosis: Diagnosis and Management F. Forton (Brussels, Belgium) Contact Dermatitis of the face J. English (Nottingham, United Kingdom) Seborrhoeic Dermatitis of the face L. Scerri (Floriana, Malta) Melasma: Pathogenesis and treatment C. Antoniou (Athens, Greece) Systemic Disease and the Face L. Gibson (Rochester, USA)
S22 LASERS FOR VASCULAR AND PIGMENTARY DISORDERS 08.30-10.00
HALL 8
Chair: Co-Chair(s):
M. Landthaler (Regensburg, Germany) A. Camps-Fresneda (Barcelona, Spain) A. Troilius (Malmö, Sweden)
S 22.1
08:30
S 22.2
08:42
S 22.3
08:54
Physical basis of laser therapy for vascular and pigmentary disorders W. Bäumler (Regensburg, Germany) Treatment of portwine stains M. Landthaler (Regensburg, Germany) Combined therapy of hemangiomas
S 22.4
09:06
S 22.5
09:18
S 22.6
09:30
S 22.7
09:42
P. Bekhor (Carlton, Australia) Endovenous laser therapy (EVL) S. Schuller-Petrovic (Vienna, Austria) Removal of tattoos A. Troilius (Malmö, Sweden) Melanin pigmented lesions A. Camps-Fresneda (Barcelona, Spain) Rosacea, Morbus Civatte and others S. Lanigan (Birmingham, United Kingdom)
WORKSHOPS W1
ADVANCES IN WOUND HEALING AND WOUND CARE
08.30-10.0
HALL9
Chair: Co-Chair(s):
J. Auböck (Linz, Austria) H. Zelenkova (Svidnik, Slovakia) S. Eming (Cologne, Germany)
Learning Objectives: Following this session, the attendee will be able to: 1. Perform better in managing chronic wounds 2. Have a basic understanding of pathophysiology 3. Have a critical sense for differential diagnoses Description: Condensed overview of chronic wounds - Pathophysiology - Diagnosis- management - Future perspectives W 1.1
08:30
W 1.2
08:52
W 1.3
09:14
W 1.4
09:36
W3
The Chronic Wound - A basic Clinical Approach J. Auböck (Linz, Austria) The Clinical Spectrum of Chronic Ulcers H. Zelenkova (Svidnik, Slovakia) Molecular Mechanisms Linking Inflammation and Repair S. Eming (Cologne, Germany) Future Directions and Perspectives for the Treatment of Chronic Wounds G. Zambruno (Rome, Italy)
MICROGRAPHIC SURGERY- 3D-HISTOLOGICAL GUIDED SURGERY
10.15-11.45
HALL 14.2
Chair: Co-Chair(s):
H. Breuninger (Tübingen, Germany) F. Picoto (Lisboa, Portugal) A. M. Skaria (Vevey, Switzerland)
Learning objectives: 1. Definition of Micrographic Surgery 2. Cost effectiveness vs. Accuracy 3. Results of different methods
Description: The discussion about the need of Micrographic Surgery goes on. The exact definition of Micrographic Surgery is a matter of debate and it rests unclear which methods should be included. A term which could cover all methods with complete histology of the excisional margin of a tumour-specimen might be 3D histology. In the future the most difficult challenge for each health system is to evaluate cost effectiveness against recurrence rate respectively. The use of Confocal Laser Scanning Microscopy is a new tool for 3D-histology. In the workshop the results of the different methods in different health systems are presented and discussed. W 3.1
10:15
W 3.2
10:27
W 3.3
10:40
W 3.4
10:52
W 3.5
11:04
W 3.6
11:16
W 3.7
11:28
W4
A confusing world: what to call histology of three-dimensional tumor margins? H. Breuninger (Tübingen, Germany) "Mohs'Surgery-Indications in The European Practise" F. Picoto (Lisboa, Portugal) Medico-economic evaluation of Mohs' surgery in France P. Saiag (Paris, France) DFSP treated by fixed Mohs J.-F. Sei ( Versailles, France) Managemant of difficult and large tumors by 3D-histology C. Boss (Tübingen, Germany) 1.The frontonasal flap reconstruction in private practise – 2. Evaluation of the recurrence of epidermal tumours treated by Mohs surgery in then years in a private practice. A. M. Skaria (Vevey, Switzerland) Confocal Laser Scanning Microsopy. A new tool for 3D-Histology M. Möhrle (Tübingen, Germany)
DIAGNOSTIC APPROACHES IN STIS AND HIV
10.15-11.45
HALL 4/5
Chair: Co-Chair(s):
D. Freedman (Dublin, Ireland) A. Serwin (Bialystok, Poland) P. Arenberger (Praha,Czech Republic)
Learning Objectives: 1. Be aware of the current controversies in diagnosing STIs. 2. Be updated on definitive diagnosis of newly emerging STIs. 3. Be aware of improved sensitivity and specificity of diagnosis in practice. Description: This session aims to address the current controversies in diagnosis of STIs. How much will the availability of sensitive and specific tests reduce dependence on clinical acumen? Will the availability of these tests make the traditional microscope redundant? Syphilis is today primarily a laboratory diagnosis, which may benefit from the sensitivity and specificity of molecular diagnosis. The clinical diagnosis of dermatological conditions on the genital site is frequently atypical, and the dilemmas posed will be addressed. Precise diagnosis is the keystone of good medical practice. Asymptomatic STI form the majority of infection, so reliance of laboratory diagnosis is absolute. W 4.1
10:15
W 4.2
10:30
With advances in diagnostic technology, do we still need venereologists? J. S. Bingham (London, United Kingdom) The value of molecular methods in diagnosis of syphilis. A. Serwin (Bialystok, Poland)
W 4.3
10:45
W 4.4
11:00
W 4.5
11:15
W 4.6
11:30
W5
Urethritis - value of microscopy H. Moi (Oslo, Norway) Identifying recent HIV infection B. Suligoi (Rome, Italy) Genital dermatology: diagnostic dilemmas P. K. Kohl (Berlin, Germany) LGV diagnosis in practice M. Cusini (Rome, Italy)
DIAGNOSTIC ASPECTS OF CUTANEOUS T-CELL LYMPHOMAS
10.15-11.45
HALL 6
Chair: Co-Chair(s):
W. Sterry (Berlin, Germany) R. Willemze (Leiden, Netherlands) A. Ranki (Hus, Finland)
Learning Objectives: 1. Diagnose CTCL and care for patients with CTCL 2. Distinguish between distinct subtypes of CTCL 3. Follow strategies for workup of CTCL patients Description: Cutaneous T-cell lymphomas (CTCLs) are a group of distinct malignant T-cell neoplasias, arising primarily in the skin. Various subtypes of CTCLs differ in their clinical appearance, but also in their course, and thus require different appraoches in diagnosis and treatment. The workshop will deal with the most frequent and difficult clinical situations in this field, and advise the audience how to optimally care for patients with this type of disease W 5.1
10:15
W 5.2
10:30
W 5.3
10:45
W 5.4
11:00
W 5.5
11:15
W 5.6
11:30
W6
Evaluation of the Biomed II primers in CTCL M. Steinhoff (Berlin, Germany) Differential diagnosis of Sezary syndrome M. Bagot (Paris, France) Evaluation of diagnostic markers in cutaneous CD30+ lymphoproliferations R. Willemze (Leiden, Netherlands) CD8+ CTCL: aggressive and indolent subtypes E. Berti (Italy) Subcutaneous panniculitis-like T cell lymphoma: differential diagnosis and follow up A. Ranki (Hus, Finland) Workup of patients according to European guidelines W. Sterry (Berlin, Germany)
ETIOLOGY AND MANAGEMENT OF PRURITUS IN DERMATOLOGICAL AND NONDERMATOLOGICAL DISEASES
10.15-11.45
HALL 9
Chair: Co-Chair(s):
S. Ständer (Münster, Germany) L. Misery (Brest, France) J. C. Szepietowski (Breslau, Poland)
Learning objectives: 1. Manage a pruritic patient in daily practice 2. Different underlying causes of chronic pruritus 3. New therapies
Description: Chronic pruritus (> 6 weeks duration) is the most frequent and distressing symptom in dermatological patients. It may arise from dermatoses, systemic, neurological or psychiatric / psychosomatic diseases. A systematic approach for the diagnostics and treatment of these patients is therefore necessary. During the past years many international research groups focussed on the development of new clinical algorithms and guidelines. The results were presented for selected pruritic diseases. W 6.1
10:15
W 6.2
10:33
W 6.3
10:51
W 6.4
11:09
W 6.5
11:27
W7
Dermatologic Pruritus: Psoriasis and Pruritus J. C. Szepietowski (Breslau, Poland) Systemic Pruritus: Management of Cholestatic Pruritus U. Beurs (Netherlands) Neurologic Pruritus: Update on Brachioradial Pruritus S. Ständer (Münster, Germany) Psychogenic Pruritus:Validation of new diagnosis criteria L. Misery (Brest, France) New systematic: Pruritus in pregnancy: diagnostic and therapy C. Ambros-Rudolph (Graz, Austria)
HOW TO ORGANIZE A DERMATOLOGICAL OFFICE
10.15-11.45
HALL 10
Chair: Co-Chair(s):
M. Gniadecka (Herlev, Denmark) J. Olafsson (Reykjavik, Iceland) V. Steinkraus (Hamburg, Germany)
Description: The purpose of the session is to assist and inspire dermatologists working in the private office. Various models of organization of private office in different countries in Europe will be presented. The organizations that are helpful to practicing dermatologists will be described. We aim to open free discussion forum between the audience and the speakers. We hope to be able together to point out the challenges and to give the solutions for practicing dermatologists in Europe. W 7.1
10:15
W 7.2
10:28
W 7.3
10:41
W 7.4
10:54
W 7.5
11:07
W 7.6
11:20
W 7.7
11:33
EADV Task Force: Managing private practice M. Gniadecka (Herlev, Denmark) How to organize a private practice in Greece R. Dimitris (Athens, Greece) How to organize a private practice in Romania M. Leventer (Buchatrest, Romania) How to organize a private practice in Germany V. Steinkraus (Hamburg, Germany) Management in private practice R. Ostendorf (Mönchengladbach, Germany) European organisations and programmes assisting private practising dermatologist J. P. Gabbud (Muri, Switzerland) Task recognision and strategy development: skin cancer treatment in private practice in Europe G. Reuter (Strassbourg, France)
W9
INHERITED DISEASE IN PEADIATRIC DISEASE
15.00 – 16.30
HALL 7
Chair: Co-Chair(s):
C. Blanchet-Bardon (Paris, France) P. Itin (Basel, Switzerland) H. Hamm (Würzburg, Germany)
Learning Objectives: 1. imagine the broad spectrum of extracutaneous features in relevant groups of syndromic genodermatoses 2. understand the significant role of the dermatologist in establishing the definite diagnosis of inherited diseases 3. comprehend the importance of interdisciplinary cooperation for the best possible management of individuals affected by inherited multiorgan disease Description: Following an introduction on principles and concepts in syndromic genodermatoses, the significance of both skin lesions and extracutaneous signs for the correct classification and management of inherited multiorgan diseases is discussed exemplarily in four phenotypical subsets of potentially genetic origin: cornification disorder, abnormality in pigmentation, cutaneous inflammation, and blister formation. Current knowledge on new developments in diagnosis, work-up and handling of these multi-faceted conditions will be provided. W 9.1 W 9.2 W 9.3 W 9.4 W 9.5 W10
Genodermatoses for practitioners – principles and concepts P. Itin (Basel, Switzerland) Syndromic ichthyoses – what’s new? A. Valquist (Uppsala, Sweden) Pigmented lesions as cutaneous markers of inherited diseases H. Hamm (Würzburg, Germany) Differential diagnosis of inherited autoinflammatory sydromes A. Torrelo (Madrid, Spain) Epidermolysis bullosa: problems beyond blisters C. Moss (Birmingham, United Kingdom) IS THERE A PLACE FOR ALTERNATIVE MEDICINE IN DERMATOLOGY?
15.00 – 16.30
ICC LOUNGE
Chair: Co-Chair(s):
J. Serup (Copenhagen, Denmark) M. Augustin (Hamburg, Germany) R. Graham-Brown (Leivester, United Kingdom)
Learning Objectives: 1. Have a better understanding of what alternative medicine techniques are being used for skin disorders in Europe 2. Have a better understanding of how commonly alternative medicine is being used for skin disorders in Europe 3. Have an opportunity to judge the merits of the case for alternative medicine for skin disorders
Description: This workshop will open with an overview of what alternative medicine techniques are being used by patients with skin disorders in three European countries and data will be presented that indicates how common such practices are. There will then be an open debate between two experienced dermatologists on the motion: “This house believes that it is legitimate and desirable for alternative medicine to be available to patients with skin disease”. This will be based on their experience of the practice and legislative framework in place in Germany. W 10.1 W 10.2 W 10.2.1 W 10.2.2 W 10.2.3 W 10.3 W 10.3.1 W 10.3.2 W 10.3.3 W 10.4 W11
Welcome and Introduction 15:00 R. Graham-Brown (Leivester, United Kingdom) How is it where we work? M. Augustin (Hamburg, Germany) How is it where we work?- The United Kingdom 15:05 J. Schofield (United Kingdom) How is it where we work?- Denmark 15:17 J. Serup (Copenhagen, Denmark) How is it where we work?- Switzerland 15:29 P. Itin (Basel, Switzerland) Debate: “This house believes that it is legitimate and desirable for alternative medicine to be available to patients with skin disease” The case for 15:41 M. Augustin (Hamburg, Germany) The case against 15:56 R. Happle (Marburg, Germany) 16:11 Discussion and voting Closing remarks 16:26 J. Serup (Copenhagen, Denmark)
NEUROINFLAMMATIONS
15.00 – 16.30 Chair: Co-Chair(s):
ROOM 42 M. Steinhoff (Münster, Germany) J. Ansel (Little Rock, USA) C. Pincelli (Modena, Italy)
Learning Objectives: 1. Understand the Mechanisms of Neuroinflammation 2. Get to know the important Pathways of Neuroinflammation 3. Learn the link of Neurobiology to Clinical Neuroinflammation Description: This session wants to give on up-to date review on the impact of the neuro-immune network in neurobiology as well as clinical neuromedicine and neuro-dermatology. It is well known that cutaneous nerves play an essential role in regulating skin barrier function, hair follicle biology and immune responses during inflammation (e.g. atopic dermatitis, urticaria, psoriasis). The underlying mechanisms how nerves talk to skin cells axe poorly understood. The aim of this seminar is therefore to learn about the mediators, receptors, pathways and clinical impact of the peripheral and central nervous system for the regulation or deregulation of the skin under physiological and pathophysiological conditions. We wilI learn what is known about the communication network of the nervous system with the immune system and endocrine system affecting inflammatory responses, the epidermis, inicrovasculature, hair dysfunction etc. Therapeutic capabilities of inflammatory skin diseases in which nerves are involved will be presented.
W 11.6
09:15
W 11.5
09:20
W 11.4
09:34
W 11.1
09:48
W 11.2
10:02
W 11.3
10:16
W21
Clinical Impact on Neuroinflammation M. Steinhoff (Münster, Germany) Growth Factors in Neuroinflammations C. Pincelli (Modena, Italy) Mediators of Neuroinflammation J. Ansel (Little Rock, USA) Neuroinflammation:Hair &. Skin R. Paus (Lübeck, Germany) Neurobiology of Mast Cells M. Maurer (Berlin, Germany) Vascular Aspects of Neuroinflammation Brain (United Kingdom)
TOPICAL ANTI-INFLAMMATORY THERAPIES
15.00 – 16.30
HALL 4/5
Chair: Co-Chair(s):
M. J. Cork (Sheffield, United Kingdom) S. Reitamo (Helsinki, Finland) A. Rubins (Riga, Latvia)
FOCUS SESSIONS F1 BEHCET'S DISEASE 13.15-14.15
ICC LOUNGE
M.A. Gürer (Ankara, Turkey) contributions also from M. Onder (Ankara, Turkey); E. Alpsoy (Antalya, Turkey) Learning Objectives 1. Diagnose cutaneous manifestations of Behcet’s Disease 2. Understand the pathogenesis of Behcet’s Disease 3. Select the optimal management strategy and discuss the therapeutic modalities for Behcet’s Disease Description: Behçet’s Disease is characterized by recurrent oro-genital ulcerations and skin eruptions, ocular, articular, gastro-intestinal, neurological, and vascular involvements. It occurs endemically in the Mediterranean countries, The Middle East and Far East. The highest prevalence is reported in Turkey with familial occurrences. It may be seen in Europe as well. Most patients in Germany are of Turkish origin. The etiopathogenesis of Behcet’s Disease is very complicated. Genetic, environmental, bacterial, viral and immunologic factors have been proposed. It is probably mediated by a combination of these factors. Activation of circulating T and B lymphocytes occurs and these cells infiltrate into the affected regions followed by a neutrophil chemotaxis. This session will cover the clinical, laboratory findings and pathogenesis. In addition the current treatment modalities will be discussed as well. F2 MASTOCYTOSIS 13.15-14.15 HALL 6 M. Maurer (Berlin, Germany) Learning objectives: The participants of this focus session will 1. learn how to diagnose mastocytosis (and distinguish its sub forms) 2. receive practical advice on how to deal with patients' fears and expectations
3.
get up to date information on the management of cutaneous mastocytosis including novel therapeutic options.
Description: Mastocytosis is a group of disorders defined by an abnormal accumulation of tissue mast cells in one or more organs. Mastocytoses are traditionally divided into cutaneous and systemic forms. This session will focus on cutaneous mastocytosis. In all forms of cutaneous mastocytosis, by definition, the skin is the only organ affected by mast cell infiltrates. There are three main forms and various sub forms of cutaneous mastocytosis and this session will provide hands on guidance on how to diagnose all of these cutaneous mastocytosis forms and sub forms. The prognosis of cutaneous mastocytosis is good, and in childhood onset spontaneous regression is frequent. However, many patients diagnosed with cutaneous mastocytosis are afraid of disease progression and expect causal and curative treatment. This session will give practical advice on now to address and deal with these fears and expectations. Finally, we will discuss the management of cutaneous mastocytosis and present novel therapeutic options. F3 RADIOTHERAPY OF SKIN DISEASES 13.15-14.15
HALL9
R. G. Panizzon (Lausanne, Switzerland) Learning objectives: 1. Basic knowledge of radiotherapy of skin diseases 2. Select patients properly for this treatment modality 3. Present treatment schedules, outcome, and effects to the patients Description: In addition to surgical techniques and medical therapy, X-ray treatment remains an excellent alternative to treat skin diseases, precancerous lesions or skin cancers, especially in elderly patients. Advantages of superficial X-ray treatment will be discussed : basic patients' selection, dose schedules, safety and side effects will be developed. After this lecture, the attendees will be able to go through the treatment procedure. F4 HPV IN THE MALE 13.15-14.15
HALL 10
M. Skerlev (Zagreb, Croatia) F5 APOPTOSIS AND SKIN: PHYSIOLOGY AND PATHOPHYSIOLOGY 13.15-14.15 ROOM 42 M. Leverkus (Magdeburg, Germany) Learning objectives: 1. How is apoptosis in the skin regulated? 2. The Relevance of Apoptosis for Inflammatory Diseases of the Skin Apoptosis and Skin Cancer: 3. Targeting the Apoptotic Machinery for the Treatment of Skin Cancer Description: Programmed cell death or apoptosis is a highly regulated cellular process with relevance during embryogenesis, autoimmunity, inflammatory diseases and for the development of cancer. The session first summarizes the current knowledge how cell death in the skin is initiated and how this process is regulated at the molecular level. We will then discuss the relevance of apoptosis during the regulation of inflammatory diseases of the skin. Lastly we will identify cellular targets of
the apoptosis machinery that are dysregulated during carcinogenesis of malignant melanoma or squamous cell carcinoma. We will present current possibilities of interference with the apoptotic machinery of the tumor cell that might be useful to develop novel therapeutic options for skin cancer. In summary the session gives a broad overview about the role of apoptosis during physiology and pathophysiology of the skin and is relevant to the dermatologist interested in these fields of skin diseases. F6 STIS IN PREGNANCY 13.15-14.15 HALL 8 E. Foley (Southampton, United Kingdom) Learning objectives: 1. Know the prevalence of sexually transmitted infections in pregnancy and the risk to the neonate 2. Understand how to test for and monitor patients with STIs during pregnancy. 3. Be able to develop clear management strategies to treat infections in pregnancy and reduce the risk to the neonate. Description: Sexually transmitted infections in pregnancy are a major of concern not only to the mother but also to the health care professionals responsible her care, as they can lead to severe outcomes in the neonate which to a large extent are preventable. In addition, many infections can be asymptomatic in the mother so can only be detected by specific screening tests during the pregnancy. This workshop will include the common STIs that can complicate a pregnancy including HIV, Herpes simplex virus, Gonorrhoea and chlamydia. During this session, clinical scenarios will be used to develop clear management strategies to deal with each infection incorporating the latest research and evidence. F7 SENTINEL LYMPH NODE BIOPSY 13.15-14.15 ROOFGARDEN J. Koller (Vienna, Austria)
DERMATOLOGY FORUM DF4 BIOLOGICS IN PSORIASIS 15.00 – 16.30 ROOFGARDEN J. C. Prinz (Munich, Germany) W. Gulliver (St. John's, Canada) Learning Objectives 1. assess particular indication for biologics in psoriasis 2. consider the role of infections in adverse events 3. judge on perspectives associated with treatment Description: The aim of the workshop is to address particular aspects that may arise during treatment of psoriasis with biologics in clinical practice. As such the presentations should provide information related to therapeutic decisions, prevention of potential adverse events, dealing with unforeseen incidents and consider long-term perspectives for psoriasis patients associated with treatments based on biological products.
DF 4.1
15:00
DF 4.2
15:22
DF 4.3
15:45
DF 4.4
16:08
Treatment of psoriasis: particular indications for the different biologics H. Bachelet (Paris, France) Long term prognosis in patients and how they are affected by biologics and conventional therapy W. Gulliver (St. John's, Canada) Severe adverse events of Biologics: The role of infection in lupus-like syndrome, demyelination and Jörg C. Prinz (Munich, Germany) Biologics and tuberculosis: interpretation of test results, prevention of exacerbation G. Girolomoni (Verona, Italy)
TEST YOURSELF TY1 WHAT’S YOUR CLINICAL DIAGNOSIS? K. Rappersberger (Vienna, Austria) L. Dubertret (Paris, France)
PLENARIES 12.00-13.00
HALL 1
Chairs E. Christophers (Kiel, Germany) M. Black (London, United Kingdom) TBA P1 A HEALTH CARE PERSPECTIVE OF EUROPEAN DERMATOLOGY H. Golnick (Magdeburg, Germany) P2 GENETICS IN DERMATOLOGY J. Uitto (Philadelphia; USA) P3 MOUSE MODELS OF HUMAN DISEASES H. Shimizu (Sapporo, Japan)
FREE COMMUNICATIONS FC 1 MELANOMA &. NON-MELANOMA SKIN CANCER 08:30 – 10:00 ROOM 43 TABLE (TIMES, SPEAKER NAMES, TITLES) FC 2 LASER THERAPY 10.15 – 11.45 ROOM 43 TABLE (TIMES, SPEAKER NAMES, TITLES) FC 3 SKIN AND SYSTEMIC DISEASE 15.00 – 16.30 HALL 14.2 TABLE (TIMES, SPEAKER NAMES, TITLES) FC 4 INFECTIOUS DISEASES 15.00 – 16.30 ROOM 43 TABLE (TIMES, SPEAKER NAMES, TITLES)
SATELLITE SYMPOSIA SAT 1 JANSSEN-CILAG 13.15 – 14.45 HALL 1 TABLE (TIMES, SPEAKER NAMES, TITLES) SAT 2 GALDERMA 13.15 – 14.45 TABLE
HALL 2
SAT 3 LEO PHARMA 13.15 – 14.45 HALL 3 TABLE SAT 4 L’OREAL 13.15 – 14.45 HALL 15.2 TABLE SAT 5 INTENDIS 13.15 – 14.45 HALL 14.2 TABLE SAT 6 PIERRE FABRE 13.15 – 14.45 HALL 7 TABLE SAT 7 IBSA 13.15 – 14.45 TABLE
HALL 4/5
SAT 8 SCHERING PLOUGH 17.00 – 18.30 HALL 3 TABLE ( SAT 9 WYETH 17.00 – 18.30 HALL 15.2 TABLE SAT 10 BEIERSDORF 17.00 – 18.30 HALL 14.2 SAT 11 VICHY 17.00 – 18.30 HALL 7
MEET THE EXPERTS MT1 IPC 17.00 – 18.30
HALL 9
Friday, 9 October 2009 COURSES C13 OBJECTIVE ASSESSMENT TECHNIQUES OF DERMATOLOGIC DISEASES 9.15 – 10.45
HALL 14.2
Chair: Co-Chair(s):
J. Fluhr (Jena, Germany) E. Berardesca (Roma, Italy) G. Jemec (Roskilde, Denmark)
Learning Objectives:
1. How do use biophysical instruments for disease activity quantification? 2. How to use biophysical methods in the dermatology practice? 3. What are the limits of new instruments? Description: This workshop is intended to provide basic understanding of biophysical measurements on the skin and their implementation in distinct dermatological diseases. Over the last 3 decades multiple biophysical measurement tools have been developed (formerly called skin bioengineering) to assess and quantify different physiological parameters of healthy and diseased skin. The workshop provides the necessary background for technical understanding of clinical measurements e.g. transepidermal water loss, stratum corneumn hydration, analysis with ultrasound, image analysis, clinical photography, surface pH, inflammatory signs and surface properties. In atopic dermatitis, suspicious moles psoriasis and other inflammatory diseases scores including biophysical measurements have been introduced. C 13.1
09:15
C 13.2
09:28
C 13.3
09:41
C 13.4
09:54
C 13.5
10:07
C 13.6
10:20
C 13.7
10:33
Scoring Psoriasis: What is essential – what is new E. Berardesca (Roma, Italy) Melanocytic lesions: ABCD rules and beyond G. Pellacani (Modena, Italy) Objective assessement of atopic dermatitis J. Fluhr (Jena, Germany) Ultrasound in Dermatology : Practical use and new indications E. Holm (Denmark) Practical aspects of assessing hair disorders U. Blume-Peytavi (Berlin, Germany) Assessment of acne activity: Lesion count only? G. Jemec (Roskilde, Denmark) Clinical photography: General rules and new approaches H. Gollnick (Magdeburg, Germany)
C14 PHLEBOLOGY 9.15 – 10.45 Chair: Co-Chair(s):
HALL 2 M. Jünger (Greifswald, Germany) M. Neumann (Rotterdam, Netherlands) M de la Brassinne (Liège, Belgium)
Learning Objectives The course will impart knowledge about
1. modern methods of active therapy for the treatment of varicose veins 2. particularly crossectomy and exhairesis 3. in comparison to minimal invasive endoluminal Laser therapy. Description: Varicose veins, particular varicosis of long and short incompetent saphenous veins, lead to damage of the skin, chronic venous insufficiency. Therefore venous reflux should be excluded. During recent years new intraluminal thermoablative methods have been developed and stand side by side to classical methods like crossectomy and exhairesis or sclerotherapy. During the course clinical indication, diagnostic proof of venous disturbances, performance of modern surgical approaches and of minimal invasive endoluminal therapeutical methods are presented and discussed. Appropriate methods to improve venous hemodynamics in patients with severe stage of the disease, venous ulcers, will be assessed. The risk and chance of vein surgery to lymphatic drainage is thought about. Methods of primary and secondary prevention will be presented. C 14.1
09:15
C 14.2
09:26
C 14.3
09:37
C 14.4
09:48
C 14.5
09:59
C 14.6
10:10
C 14.7
10:21
Modern diagnostics to develop the individual treatment concept M. Stücker (Bochum, Germany) Measures to reduce the risk of surgery M. Neumann (Rotterdam, Netherlands) Modern surgical treatment (crossectomy, stripping, miniphlebectomy) D. Stenger (Saarlouis, Germany) A. A. Ramelet (Lausanne, Switzerland) Evidence of clinical benefit by vein surgery with regard to ulcer healing M. Romanelli (Pisa, Italy) Efficacy and invasiveness of thermoablative endoluminal treatment M. Jünger (Greifswald, Germany) Lymphoedema development after surgical treatment of varicous veins J. Daroczy (Budapest, Hungary) Prophylactic measures (sports, compression therapy, diet - body weight). M. Flour (Leuven, Belgium)
C15 PAEDIATRIC DERMATOLOGY 9.15 – 10.45 Chair: Co-Chair(s):
HALL 1 A. Taieb (Bordeaux, France) C. Gelmetti (Milan, Italy) R. Fölster-Holst (Kiel, Germany)
Learning Objectives Update in pediatric dermatology for the topics covered: 1. Hemangiomas, Pediculosis, 2. Traditional and engineered tissues for a healthier skin 3. Localised hyperpigmentation/hypertrichosis. Description: The session will highlight new treatment options for hemangiomas and pediculosis capitis, review Becker’s nevus and its differential diagnosis, and present innovative clothing technology for less irritancy; an interactive clinical case session will be included. C 15.1
09:15
C 15.2
09:30
Propranolol in Infantile Hemangiomas- an update C. Léauté-Labrèze (Bordeaux, France) Old and New Tissues for our Skin C. Gelmetti (Milan, Italy)
C 15.3
09:45
C 15.4
10:00
C 15.5
10:15
Becker’s Nevus Syndrome Prof R. Happle (Marburg, Germany) Pediculosis capitis- an update R. Fölster-Holst (Kiel, Germany) Clinical Cases of the Chairs
C16 SEXUALLY TRANSMITTED INFECTIONS 9.15 – 10.45 Chair: Co-Chair(s):
HALL 3 A. Stary (Vienna, Austria) G. Gross (Rostock, Germany) A. Poder (Tartu, Estonia)
Learning Objectives 4. Get informed about the immunology of syphilis 5. The epidemiology of STIs in Europe 6. practical aspects on STIs Description: The course will inform participants about the recent trends of STIs in Europe. Data on trends of the epidemiology of sexually transmitted infections including LGV will be summarized. Participants will be updated on the practical aspect of HPV vaccine and the prevention of HPVassociated neoplasia. The difference of the situation in Europe will be highlightened. Furthermore, the course will offer ithe participants on the most recent attitudes and knowledge of STIs. C 16.1
09:15
C 16.2
09:33
C 16.3
09:51
C 16.4
10:09
C 16.5
10:27
Recent STI trends in Europe A. Põder (Tartu, Estonia) Immunology of Syphilis: New Aspects G. Stary (Vienna, Austria) Evidence-based guidelines for prophylactic vaccination against HPVassociated neoplasia G. Gross (Rostock, Germany) LGV: is the epidemic over? M. Cusini (Italy) STIs in the 21st Century - new knowledge, new attitudes D. Freedman (Dublin, Ireland)
C17 SKIN RESURFACING AND REJUVENATION 11.00 – 12.30 Chair: Co-Chair(s):
HALL 3 G. Sattler (Darmstadt, Germany) D. Roseeuw (Brussels, Belgium) D. Manstein (Boston, USA)
C 17.1
11:00
C 17.2
11:05
C 17.3
11:17
C 17.4
11:29
C 17.5
11:41
Introduction: fundamental explanations of old skin, rejuvenation, differences according to location M.H. Gold (Nashville, USA) Different Fractional Laser Lreatments M. Adatto (Geneva, Switzerland) Fractional Laser Ablative and Non-Ablative C. Dierickx (Ghent, Brussels) Rejuvenation with Home Devices – Do They Work M.H. Gold (Nashville, USA) A Structural Approach to 3-Dimensional Rejuvenation S. Sadick (New York, USA)
C 17.6
11:53
C 17.7
12:06
C 17.8
12:18
Fillers - the total facial approach G. Wahl (Berlin, Germany) Rejuvenation with botulinum toxin B. Rzany (Berlin, Germany) Rejuvenation with combined treatments G. Sattler (Darmstadt, Germany)
C18 PHOTOBIOLOGY 11.00 – 12.30 Chair: Co-Chair(s):
HALL 14.2 T. Schwarz (Kiel, Germany) P. G. Calzavara-Pinton (Brescia, Italy) G.M. Murphy (Dublin, Ireland)
Learning Objectives 1. understand biologic effects of UV radiation 2. understand the pathologic effects of UV radiation 3. understand the physical principles of UV radiation Description: UV radiation is one of the, if not the most important environmental factor affecting humans. Besides its positive and indispensable effects, including vitamin D synthesis, UV radiation in particular the UVB range can cause both acute and chronic damage to the skin. The skin in turn reacts to UV exposure with certain protection mechanisms including DNA repair. A detailed knowledge about the physiologic and pathologic effects of UV radiation will contribute to a better understanding how to prevent UV damage and help to improve strategies to use UV radiation as a therapeutic tool. C 18.1
11:00
C 18.2
11:15
C 18.3
11:30
C 18.4
11:45
C 18.5
12:00
C 18.6
12:15
The basic principles of photobiology H. Hönigsmann (Vienna, Austria) Pigmentation B. Ortel (Chicago, USA) DNA damage and repair M. Berneburg (Tübingen, Germany) Photoimmunology S. Beissert (Münster, Germany) UV and photosensitivity G.M. Murphy (Dublin, Ireland) Photoaging and skin cancer P. G. Calzavara-Pinton (Brescia, Italy)
C19 CUTANEOUS ONCOLOGY 11.00 – 12.30 Chair: Co-Chair(s):
HALL 2 D. Schadendorf (Heidelberg, Germany) P. Saiag (Paris, France) T. Estrach (Barcelona, Spain)
Learning Objectives 1. To get an overview over the current diagnostic and therapeutic modalities in melanoma, epithelial skin cancers,and cutaneous lymphomas. 2. To achieve insight into the developments of skin tumors. 3. To learn about strategies which will in future change the treatment in cutaneous oncology.
Description : The current practice of treatment of skin cancers shall be discussed for melanoma, epithelial skin cancers, and cutaneous lymphoma. The present therapeutic options will be critically reviewed for these tumors. Furthermore,potential future developments for topical therapyof epithelial cancers and targeted therapy will be analyzed. C 19.1
11:00
C 19.2
11:15
C 19.3
11:30
C 19.4
11:45
C 19.5
12:00
C 19.6
12:15
Update on Cutaneous Lymphoma T. Estrach (Barcelona, Spain) What is the real evidence for Moh´s Surgeryin skin cancer in 2009? P. Saiag (Paris, France) Adjuvant Therapy in Melanoma – Anything new? A. Hauschild (Kiel, Germany) Is there a place for topical treatment of melanoma? A. Stratigos (Athens, Greece) Role of Dermatoscopy in follow-up? M. Binder (Vienna, Austria) Molecular Advances – Consequences for the practice? D. Schadendorf (Heidelberg, Germany)
C20 BOTULINUM TOXIN: USE AND MISUSE (3H) 15.00 – 18.00
HALL 1
Chair: Co-Chair(s):
C. Bayerl (Wiesbaden,Germany) P.M. Levy (Geneva, Switzerland) A. Tosca (Heraklion,Greece)
Learning Objectives 1. understand the role of botulinum toxin in pain 2. enlarge his knowledge in cosmetic indications 3. learn the best options for hyperhidrosis treatment Description: The course focuses on three topics: - new indication for botulinum toxin in the treatment of pain. - a more sophiscticated insight in specialized botulinum toxin application in face and neck - hyperhidrosis treatment indications on different body sides, axilla, hands and feet including problems like focal hypderhidrosis and refractory sweating areas after minimally invasive surgery with discussion about the safety concerns of botulinum toxin preparations. C 20.1
15:00
C 20.2
15:30
C 20.3
16:00
C 20.4
16:30
C 20.5
17:00
C 20.6
17:30
Botulinumtoxin against pain in skin diseases A. Tosca (Heraklion,Greece) Cosmetic BTX-A-update M. Landau (Israel) Lower Face and Neck: Cosmetic Use of and complications P.M. Levy (Geneva, Switzerland) Hyperhidrosis of the axilla, hands and palms - indication for treatment and dosis M. Heckmann (Starnberg, Germany) To cut or to inject - that is the question in hyperhidrosis F. Bechara (Bochum, Germany) Any hazards in botulinum toxin ? C. Bayerl (Wiesbaden,Germany)
SYMPOSIA S7 CPD SESSION 9.15 – 10.45 Chair: Co-Chair(s):
HALL 10 J.-P. Gabbud (Muri, Switzerland) I. M. Bergbrant (Gothenburg, Sweden) H. J. Rauch (Vienna, Austria) Learning Objectives: Following this session, the attendee will be able to: 1. Know about newest trends in European CME-CPD 2. Know how it works with daily practice 3. Know how we can save D/V Description: The question is: is Dermatovenereolgy an endangered species? "Lifelong Learning" or Continuing Professional Development (CPD) encompasses and goes beyond Continuing Medical Education (CME) It has become compulsory in more and more countries in Europe and worldwide. It is the patient's right to ask for Quality Assurance and Quality Improvement. CME-CPD costs money. How does CME-CPD affect private practice? Is it useful or harmful to free entrepreneurship? S 7.1
09:15
S 7.2
09:30
S 7.3
09:45
S 7.4
10:00
S 7.5
10:15
S 7.6
10:30
Do we really need a regulated CME-CPD H. J. Rauch (Vienna, Austria) How does CME-CPD function in private practice in different European countries ? M. Gniadecka (Herlev, Denmark) How do we measure the quality of Dermatology care? I. M. Bergbrant (Gothenburg, Sweden) Is Dermatovenereology an endangered species? J.-P. Gabbud (Muri, Switzerland) Can private practice afford the cost of CME-CPD? J. Olafsson (Reykjavik, Island) How to keep up with safety standards in a dermatologic practice J. Snauwaert (Brasschaat, Belgium)
S14 DISEASES OF ORAL MUCOSA 11.00 – 12.30
HALL 15.2
Chair: Co-Chair(s):
G. Laskaris (Athens, Greece) D. Parent (Brussels, Belgium) S. Menni (Milan, Italy)
Learning Objectives: Following this session, the attendee will be able to: 1. To understand the link between skin and oral disease 2. To become familiar with mucosal disease diagnosis 3. To become familiar with treatment of mucosal disease
Description: Proper diagnosis and management. Diagnosis and treatment of oral mucosal disease is of particular Oral Medicine is a rapidly developing specialty that bridges dentistry with Medicine. Over 1000 diseases have been documented to manifest and develop in the oral cavity and they require that importance to the specialty of Dermatology, since a number of skin diseases manifest in the oral cavity. Thus, it is essential for the dermatologist to be familiar with oral mucosal disease and to maintain an open channel of communication with the Oral Medicine specialist. With this view in mind, this session will highlight selected topics in oral pathology that will be presented by skilled and knowledgeable Oral Medicine specialists. Latest developments in diagnosis, pathogenesis and treatment of oral disease will be discussed. Particular emphasis will be accorded on treatment modalities and current diagnostic tests available. S 14.1
11:00
S 14.2
11:18
S 14.3
11:36
S 14.4
11:54
S 14.5
12:12
Uncommon diseases of the tongue in children S. Menni (Milan, Italy) Desquamative gingivitis as a manifestation of chronic mucocutaneous disease E. Gagari (TBA) Early lesions of oral squamous cell carcinoma S. Porter (London, United Kingdom) Oral leukoplakia, clinical and laboratory markers of malignant transformation S. Fedele (London, United Kingdom) HPV and oral diseases D. Parent (Brussels, Belgium)
S15 DISORDERS OF THE HAIR FOLLICLES AND SCALP 15.00 -16.30 HALL 6 Chair: Co-Chair(s):
R. Paus (Lübeck, Germany) A. Tosti (Bologna, Italy) D. Sotiriadis (Thessaloniki, Greece)
S19 MANAGEMENT OF PRECANCEROUS SKIN LESIONS 9.15 – 10.45 HALL 4/5 Chair: Co-Chair(s):
E. B. Bröcker (Würzburg,Germany) N. Basset-Seguin (Paris, France) K. Peris (L'Aquila, Italy)
Learning objectives: 1) Understanding the molecular steps of cancerogenesis in the skin 2) Insight to the biology of early melanoma and early cutaneous lymphoma 3) Practical consequences in the means of therapy Description: Cancergenesis is a multistep process. The research of the last years gave insight to the relevant genetic changes as well as to environmental factors leading to clinically visible precursors of skin neoplasms. Petra Boukamp will summarize her basic research on the molecular pathogenesis of non melanoma skin cancer. Eva Bröcker will focus on melanocytic precursor lesions in the view of clinical and histological appearance, and genetic changes known so far. Viral skin cancerogenesis as well as UV-induction of epithelial skin cancer will be
discussed by Nicole Basset-Seguin in the view of clinical diagnosis and management. Antonio Cozzio will provide informations on histological and molecular differential diagnosis of early cutaneous lymphoma, and Ketty Perris will inform on modern nonsurgical treatment option for precancerous skin lesions. S 19.1
09:15
S 19.2
09:17
S 19.3
09:42
S 19.4
09:57
S 19.5
10:12
S 19.6
10:27
S 19.7
10:42
Introduction E. B. Bröcker (Würzburg,Germany) Molecular Pathogenesis of Nonmelanoma Skin Cancer E. B. Boukamp (Heidelberg, Germany) Precursors of melanoma: pathogenesis and management E. B. Bröcker (Würzburg,Germany) Precursors of Epidermoid Lymphoma: pathogenesis and management N. Basset-Seguin (Paris, France) Precursors of cutaneous lymphoma: pathogenesis and management A. Cozzio (Zurich, Switzerland) Photodynamic and pharmacologic therapy of precancerous skin lesions K. Peris (L'Aquila, Italy) Cloncluding Remarks N. Basset-Seguin (Paris, France)
S20 HUMAN PAPILLOMAVIRUSES 11.00 – 12.30 HALL 6 Chair: R. Kirnbauer (Vienna, Austria) Co-Chair(s): R. Maw (Belfast, Northern Ireland) E. Nicolaidou (Athens, Greece) Learning Objectives: Basic and clinical aspects of HPV diseases Treatment in the immunocompetent and immunocompromised patient HPV-associated anogenital diseases in HIV-positive men Rational for prophylactic HPV vaccination and appropriate target groups Epidemiology and role of HPV in skin cancer
1. 2. 3. 4. 5.
Description: Genital HPV is the most common sexually transmitted infection. Persistent infection with high-risk types may lead to ano-genital dysplasia and, if left untreated, invasive cancer. About 25% of cancers caused by HPV arise in men, and the burden of HPV-associated oropharyngeal cancers are second only to cervical cancer in developed countries. Persistent HPV-infection in HIVpositive MSM is common and these patients have a significantly increased risk for the development of anal intraepithelial neoplasia and carcinoma. There is evidence that HPV are responsible for an increased risk of cutaneous squamous-cell carcinomas, as measured by the presence of HPV DNA in eyebrow hairs and serological responses. Introduction of an HPV vaccine into the population by a free school-based vaccination program of 12 - 18 year old girls, and to women up to 26 years in Australia has resulted in rapid decline in genital warts diagnoses within a few years. S 20.1
11:00
S 20.2
11:18
Facts and fiction about HPV infection E. Nicolaidou (Athens, Greece) HPV-associated anogenital diseases in HIV-positive men A. Kreuter (Bochum, Germany)
S 20.3
11:36
S 20.4
11:54
S 20.5
12:12
Prophylactic HPV vaccines R. Kirnbauer (Vienna, Austria) Current and future treatment options for genital warts R. Maw (Belfast, Northern Ireland) Cutaneous HPV infection and skin cancer J. N. Bouwes Bavinck (Leiden, Netherlands)
S21 HYPERPIGMENTARY DISORDERS 9.15 – 10.45 HALL 6 Chair: J. P. Ortonne (Nice, France) Co-Chair(s): C. L. Goh (Singapore) M. Amer (Zamalek, Egypt) Learning Objectives: 1. Understand the mechanisms of hypermelanoses 2. Develop a strategy to diagnose hypermelanoses 3. Discuss the treatment strategy Description: This symposium will review current knowledge of melasma. A wide range of therapeutic options are now available for hypermelanoses and will be discussed. S 21.1
09:15
S 21.2
09:28
S 21.3
09:41
S 21.4
09:54
S 21.5
10:07
S 21.6
10:20
S 21.7
10:23
Lasers and light devices in the treatment of melasma C. L. Goh (Singapore) Hypopigmentating agents and pre and post-translational regulation of tyrosinase K. C Park (Seoul, Korea) New combination approach for the treatment of melasma T. Passeron (Nice, France) Lentigo maligna and imiquimod A. Alomar (Barcelona, Spain) Combined depigmentation treatment T. Lotti (Florence, Italy) Melasma treatment options M. Amer (Zamalek, Egypt) In vivo reflectance confocal microscopy for pigmentary disorders J. P. Ortonne (Nice, France)
S23 LUPUS ERYTHEMATOSUS 9.15 – 10.45 HALL 8 Chair: A. Kuhn (Münster, Germany) Co-Chair(s): S. Krüger-Krasagakis (Herakleon,Greece) F. Nyberg (Stocksund, Sweden) Learning Objectives 1. address the pathogenesis of various disease subtypes 2. recognize the cutaneous manifestations of opus 3. understand new therapeutic options Description This symposium will focus on different clinical aspects of opus erythernatosus. which will be presented by dermatologists and rheumatologists, In the past years research an the pathogenic mechanisms of this heterogeneous autoimmune disease has become an increasingly dynamic field and significant advances have been made in understanding of the specific cellular and
molecular events leading to inflammation and tissue damage Moreover, the clinical expression of cutaneous lesions in lupus erythematosus shows great variety and uncommon manifestations of the disease will also be discussed, Various environmental factors have been shown to influence the clinical expression of lupus erythematosus and a striking relationship has emerged between sunlight exposure and the various subtypes of the disease, there will be an update on new therapeutic options for lupus erythematosus including the use of biologics and other novel approaches S 23.1
09:15
S 23.2
09:37
S 23.3
09:59
S 23.4
10:22
New Aspects of SCLE F. Nyberg (Stocksund, Sweden) Lupus Erythematosus Tumidus A. Kuhn (Münster, Germany) Vasculitis in Lupus Erythematosus S. Krüger-Krasagakis (Herakleon,Greece) New Treatment Options in Lupus Erythematosus U. Müller-Ladner (Bad Nauheim, Germany)
S24 MANAGEMENT OF CUTANEOUS LYMPHOMA 11.00 -12.30 HALL 7 Chair: Co-Chair(s):
R. Stadler (Minden, Germany) M. Bagot (Créteil, France) M. H. Vermeer (Leiden, Netherlands)
Learning Objectives : Following this session, the attendee will be able to: 1. Cutaneous B-cell lymphoma – understanding and therapy 2. Spectrum of cutaneous T-cell lymphoma 3. Advances in therapy Description: Cutaneous T-cell lymphoma and B-cell lymphoma represent a group of Non-Hodgkin lymphomas showing a growing incidence, especially in the western world. Meanwhile, in the WHO classification cutaneous lymphomas are accepted as a unique entity with distinct biological behaviour. B-cell lymphomas are divided into three main entities, follicular B-cell lymphoma, marginal zone B-cell lymphoma and primary cutaneous large B-cell lymphoma. The Dutch lymphoma group headed by Rein Willemze, and others characterized B-cell lymphoma by clinical pathologic and genetic features. Among cutaneous T-cell lymphoma new entities were characterized as subcutaneous panniculitis-like T-cell lymphoma with different biological behaviour. Chromosomal genetic and transcriptional aberrations characterized cutaneous T-cell lymphoma as well as epigenetic changes. By gene expression profiling a number of relevant genes are overexpressed, many Th2-specific transcription factors, like GATA-3 and JUNB. For diagnostic tests in CTCL new molecular markers were identified, e.g. T-plastin, and killer cell immunoglobulin-like receptors (KIR) in Sézary cells. S 24.1
11:00
S 24.2
11:15
S 24.3
11:30
S 24.4
11:45
S 24.5
12:00
Update on pathogenesis and therapy of cutaneous B-cell lymphoma R. Willemze (Leiden, Netherlands) Update on pathogenesis and therapy of cutaneous B-cell lymphoma N. J. Senff (Leiden, Netherlands) Early stages of cutaneous T-cell lymphoma and their variants A. Ranki (Hus, Finland) New aspects on Sézary syndrome M. Bagot (Créteil, France) Advanced and aggressive cutaneous T-cell lymphoma
S 24.6
12:15
M. H. Vermeer (Leiden, Netherlands) New compounds fort he treatment of cutaneous T-cell lymphoma R. Stadler (Minden, Germany)
S25 NAIL DISEASES 15.00 – 16.30 HALL 4/5 Chair: Co-Chair(s):
E. Haneke (Freiburg, Germany) R. Baran (Cannes, France) B. Richert (Liège, Belgium)
Learning Objectives : 1. Make the diagnosis and differential diagnosis of nail psoriasis and trachyonychia 2. Be able to advise patients with ingrown nails as to which treatment might be the best for him and for which paediatric nail condition surgery is an option, and 3. Improve his diagnostic and surgical skills in the management of nail melanoma. Description: Psoriasis is the most frequent dermatosis causing nail alterations. It may mimic a great number of other nail conditions; hence its clinical features, differential diagnosis and course must be known by every dermatologist. Trachyonychia is a relatively common sign of a variety of different nail disorders. When it affects most nails it is the hall mark of twenty nail dystrophy. The course and potential treatment of this often enigmatic condition have to be known by dermatologists to either avoid overtreatment or undue neglect. Ingrown toenails are frequent and most physicians treat them surgically. However, there are very efficacious conservative alternatives. Nail melanomas remain a challenge both concerning their diagnosis as well as their treatment. Progress in ungual melanoma diagnosis and surgery will be outlined. S 25.1
15:00
S 25.2
15:12
S 25.2
15:24
S 25.3
15:36
S 25.4
15:48
S 25.5
16:00
S 25.6
16:12
Nail psoriasis and its differential diagnoses R. F. Baran (Cannes, France) The many causes of trachyonychia B. M. Piraccini (Italy) The many causes of trachyonychia A. Tosti (Italy) Conservative treatment of ingrown nails H. Arai (Japan) Nail surgery in children B. Richert (Liège, Belgium) Diagnosis of nail melanoma – what is new? N. DiChiacchio (Brazil) Surgery of nail melanoma E. Haneke (Freiburg, Germany)
S26 NON-INFECTIOUS DERMATOSES WITH SEVERE SYSTEMIC INVOLVEMENT 11.00 – 12.30 HALL8 Chair: Co-Chair(s):
L. French (Zurich, Switzerland) J. Peyrí (Barcelona, Spain) P. Wolkenstein (Créteil, France)
Learning Objectives 1. To know the cutaneous signs of the selected life threatening diseases. 2. To recognize indicators of systemic involvement in the selected life threatening diseases. 3. To be familiar with the management of life-threatening diseases with skin signs.
Description: The aim of this Symposium is to provide dermatologists with a practical update on the skin manifestations of a selected number of life threatening diseases. Participants will learn about the clinical forms and indicators of systemic involvement in cutaneous lupus; the diagnosis and treatment of dermatomyositis and overlap syndromes; skin manifestations of neurofibromatosis and tuberous sclerosis including the required workup; the spectrum of skin manifestations in sarcoidosis; as well as specific and nonspecific skin lesions associated with hematooncological diseases. S 26.1
11:00
S 26.2
11:15
S 26.3
11:30
S 26.4
11:45
S 26.5
12:00
Lupus erythematosus: clinical forms and indicators of systemic involvement A. Kuhn (Münster, Germany) Dermatomyositis and overlap syndromes; diagnosis and evidence basedtreatment R. Trueb (Zurich, Switzerland) Neurofibromatosis and tuberous sclerosis P. Wolkenstein (Créteil, France) Cutaneous sarcoidosis and systemic involvement J. Marcoval (Barcelona, Spain) Dermatoses associated with hematooncological disease L. French (Zurich, Switzerland)
S27 PREVENTION AND DIAGNOSIS OF SKIN CANCER 15.00 -16.30 HALL 15.2 Chair: Co-Chair(s):
E. W. Breitbart (Buxtehude, Germany) A. Stratigos (Athens, Greece) S. Seidenari (Modena, Italy)
Learning Objectives: 1. ignificance of early detection methods (for cancer) 2. Requirements on screening programs as part of early detection methods 3. Necessary requirements for the implementation of a national standardised cancer screening Description: In the symposium "Prevention and Diagnosis of Skin cancer" different requirements for judging the significance of early detection methods as well as judging screening as a tool for early cancer detection will be discussed. For this, known screening programs such as mammography screening, cervical screening but also skin cancer screening will be used as examples. Further, we will differentiate between the range of different cancer screening methods and discuss how different screening programs impact on program evaluation. Given that evaluations provide essential information on the effectiveness of such programs and are the basis for political decision making, the symposium concludes with a discussion of different approaches to the evaluation of screening programs. S 27.1
15:00
S 27.2
15:10
S 27.3
15:30
S 27.4
15:50
Introduction T. A. Luger (Münster, Germany) Necessary prerequisites for (skin) cancer screening A. Katalinic (Lübeck, Germany) Skin cancer screening in Germany E. W. Breitbart (Buxtehude, Germany) The need for national and international (skin-) cancer screening trials A Geller (USA)
16:10
S 27.5
Diagnosis of skin cancer A. Stratigos (Athens, Greece)
S28 NOVEL DRUGS – NEW ADVERSE SKIN REACTIONS 15.00 -16.30 ICC LOUNGE Chair: Co-Chair(s):
H. Merck (Aachen, Germany) S. Segaert (Leuven, Belgium) C. Robert (Villejuif, France)
Description: Skin is a special target organ for adverse drug reactions. Those reactions may be related to the dosage or they are unrelated such as allergic reactions. Multiple side effects are associated with drugs used in oncology. The range of different side effects to new biological agents also include most severe reactions related to a “cytokine storm”. Calcineurin antagonists can be used topically and may reduce side-effects of glucocorticoids, on the other hand the spectrum of their effects also lead to a “black box warning”. The talks of this symposium will present the spectrum of these reactions to new drugs and will give advices for an appropriate risk/ benefit evaluation. S 28.1
15:00
S 28.2
15:18
S 28.3
15:36
S 28.4
15:54
S 28.5
16:12
Introduction H. Merck (Aachen, Germany) Cutaneous side effects of oncology drugs C. Robert (Villejuif, France) Skin toxicity of EGFR-inhibitors S. Segaert (Leuven, Belgium) Topical calcineurin antagonists P. Friedmann (Southampton, United Kingdom) Cutaneous side effects of biological agents H. Ott (Aachen, Germany)
S30 PSORIASIS 15.00 -16.30 HALL 3 Chair: Co-Chair(s):
P. van de Kerkhof (Nijmegen, Netherlands) L. Dubertret (Paris, France) J. N. Barker (London, United Kingdom)
Learning Objectives: 1. To appreciate the heterogeneity of psoriasis in terms of clinical presentation and response to treatments. 2. To understand new approaches to optimize usage of treatments in psoriasis 3. To learn long-term course of psoriasis by using patient registries. Description: The management of individual patients with psoriasis. Psoriasis is a heterogeneous disease. Every patient has his/her own psoriasis. This implies inter-individual differences with respect to the course of psoriasis and extent of lesions. It also implies the inter-individual differences with respect to burden of disease. Important differences can be seen between patients with respect to the response to treatment. A spectrum of treatments is needed in order to provide an optimal individualized treatment. Although several guidelines have become available, a consistent, stepwise approach in individual patients is regarded as “beyond reality”. During this symposium, the heterogeneity of psoriasis will be in the lead: with respect to phenotypes and with respect to treatment responses.
S 30.1
15:00
S 30.2
15:05
S 30.3
15:20
S 30.4
15:35
S 30.5
15:50
S 30.6
16:05
S 30.7
16:20
Introduction P. van de Kerkhof (Nijmegen, Netherlands) Psoriasis: six different clinical phenotypes L. Dubertret (Paris, France) Optimizing methotrexate usage in psoriasis J. N. Barker (London, United Kingdom) Utilization of European Guidelines (EDF)
W. Sterry (Berlin, Germany) Four years patient registry data in psoriasis E. de Jong (Netherlands) How to adjust the therapeutic strategy to specific clinical situations? U. Mrowietz (Kiel, Germany) Closure L. Dubertret (Paris, France)
S31 RARE DISEASES IN EUROPE – UNDERESTIMATED AND OVERLOOKED? 15.00 -16.30 HALL 10 Chair: Co-Chair(s):
L. Bruckner-Tuderman (Freiburg, Germany) G. Zambruno (Rome, Italy) A. Vahlquist (Uppsala, Sweden)
Learning Objectives: Following this session, the attendee will be able to 1. know the definition, number and variety of rare disease 2. retrieve information about rare diseases in the net 3. understand diagnostics & patients' perspectives Description: This workshop will present the current status of European activities in the field of genodermatoses. Information networks, research and clinical networks and patient organisations' perspectives will be introduced. The changing spectrum of genodermatoses in Europe as a result of increased mobility and its effects on diagnostics and care of affected individuals will be discussed. Finally, recent de-velopments on the field of biological therapies will be presented. S 31.1
15:00
S 31.2
15:15
S 31.3
15:30
S 31.4
15:45
S 31.5
16:00
S 31.6
16:15
Introduction - Setting the Stage L. Bruckner-Tuderman (Freiburg, Germany) Genodermatosis Networks in Europe G. Zambruno (Rome, Italy) Orphanet - Information Provider without Borders K. Rommel (Hannover, Germany) Priorities from Patients' Perspectives TBA The Changing Spectrum of Autosomal Recessive Diseases in Europe A. Vahlquist (Uppsala, Sweden) Perspectives for Biological Therapies for Genodermatoses J.S. Kern (Freiburg, Germany)
S42 WHAT HISTORY OF DERMATOVENEREOLOGY CAN TEACH TODAY’S DERMATOVENEREOLOGIST 9.15 – 10.45
ICC LOUNGE
Chair: Co-Chair(s):
K. Holubar (Vienna, Austria) D. Wallach (Paris, France) P. Emmanouil (Athens, Greece)
Learning Objectives Attendees should be briefed on memorable details of dermato-history in Europe and beyond, “il n´y a pas d´histoire inactuelle” (Louis-Jules Gernet) Description In contrast to the historical frame of the spring sessions which are devoted to the national profile of dermatology in the new countries of the European Union or of smaller nations, the topic of the main annual conference is not restricted by a singular theme but is open to the respective authors´ view of important personalities, developments or literary oeuvres. S 42.1
09:15
S 42.2
09:28
S 42.3
09:40
S 42.4
09:53
S 42.5
10:05
S 42.6
10:18
S 42.7
10:31
Analysis of 130 departments of dermatology in Germany between 1900 and 2000 A. Scholz (Dresden, Germany) Dermatology Autobiography L. Parish (Philadelphia, USA) "Jaques Louis Reverdin (1842-1929): From the Epidermal Graft to the Study of Lepidoptera". J. Martel (Paris, France) The Legacy of Olavide in the United States N. Curcio (Nashville, USA) Felix Pinkus (1868-1947) -Dermatopathologist and Artist N. Haas (Berlin, Germany) Eduard Lipp (1831-1891) – Pioneer of the German Society of Dermatology W. Aberer (Graz, Austria) Life of Professor Marian Grzybowski R. Bialynicki-Birula (Breslau/Wroclaw, Poland)
S44 DIAGNOSTICS AND THERAPY OF LEG ULCERS 15.00 -16.30
HALL 7
Chair: Co-Chair(s):
A. Gorkiewicz-Petkow (Warsaw, Poland) M. Stücker (Würzburg, Germany) T. Karlsmark (Copenhagen, Denmark)
Learning Objectives 1. Diagnostic of Mixed Type Ulcers, Evaluation of Inflammation in Leg Ulcer and Modern Approach to Treatment 2. Evaluation of Healing Process ( TIME concept), Possibilities and Limitations of Bio Active Dressings 3. Influence of Systemic Therapies and Nutrition on Healing Process. Description Treatment of chronic leg ulcers is not only medical but economic and social problem. The approach to this problem varies in different countries concerning health care organisation and financial possibilities .During this session some clinical aspects of leg ulcers will be discussed including often missed i n diagnosis mixed ulcers, modern approach to microbiology and
inflammation , evaluation of healing process and influence of compression therapy. Some data of systemic therapies including prostoglandins, pentoxifilline, oedema protective agents as well as possibilities of new local treatments with bio-active dressings will be discussed. S 44.1
15:00
S 44.2
15:05
S 44.3
15:20
S 44.4
15:35
S 44.5
15:50
S 44.6
16:05
Introduction A. Gorkiewicz-Petkow (Warsaw, Poland) Diagnostic of venous leg ulcers and the problem of mixed ulcers M. Stücker (Würzburg, Germany) Microbiology in chronic wound. How and when to treat the chronic infection. T. Karlsmark (Copenhagen, Denmark) Bio active dressings in hard to heal ulcers M. Romanelli (Pisa, Italy) Systemic Therapy of leg ulcers A. Ramelet (Lausanne, Switzerland) TIME concept of chronic wound healing in venous leg ulcer treatment. A. Gorkiewicz-Petkow (Warsaw, Poland) L. Petkov (Warsaw, Poland)
WORKSHOPS W2 CONTROVERSIES IN SUN PROTECTION OF THE SKIN 09.15 – 10.45 ROOM 43 Chair: Co-Chair(s):
J. Krutmann (Düsseldorf, Germany) H. Hönigsmann (Vienna, Austria) H. Lim (Detroit, USA)
Learning Objectives 1. know the new EC regulations for sunscreens, DNA repair 2. get insight on Vit D production and sunscreen use 3. and IR protection 4. learn about consumer compliance Description: This workshop is dealing with new developments and controversies in sun protection. New EC regulation must be made available to the consumers.The significance of DNA repair enzymes in sunscreens will be dicussed. Is there a role for IR protection? What compliance can be expected from consumers? W 2.1
09:15
W 2.2
09:33
W 2.3
09:51
W 2.4
10:09
W 2.5
10:27
Introduction: New EC Regulations for sunscreens H. Hönigsmann (Vienna, Austria) Do we need more than filters: The role of sunscreens with DNA repair activity. P. Wolf (Graz, Austria) Photoprotection and vitamin D H. Lim (Detroit, USA) IRA-Photoprotection: Do we need it? J. Krutmann (Düsseldorf, Germany) Sunscreens - Issues of compliance Z. D. Draelos (High Point, USA)
W8 MOLECULAR-TARGETED THERAPY OF MALIGNANT MELANOMA 11.00 – 12.30 Hall9 Chair: Co-Chair(s):
G. Stingl (Vienna, Austria) B. Dreno (Nantes, France) A. Enk (Heidelberg, Germany)
W12 NEW APPROACHES TO THE TREATMENT OF INFLAMMATORY SKIN DISEASES 09.15 – 10.45 HALL 15.2 Chair: Co-Chair(s):
J. C. Simon (Leipzig, Germany) S. Beissert (Münster, Germany) H. Lui (Vancouver, Canada)
Learning objectives: Following this session the attendee will be able to 1. 2. 3.
learn about new systemic treatments for inflammatory skin disorders differentiate the mechanisms of action of new treatment regimens learn the modern management of patient’s with inflammatory skin diseases
Description: Patients with chronic inflammatory skin disorders often require rotational or combinational usage of different therapy regimens to avoid emerging adverse effects. In this workshop experts in the field will demonstrate and evaluate a number of new immunosuppressive treatments that have been recently developed. The beneficial effects of these new immunosuppressants have been demonstrated in clinical trials. These drugs were designed to target keratinocytes, T cells, endothelial cells or main inflammatory signaling pathways and to inhibit their activation. Especially the knowledge of this specific mechanism of action will enable the practicing dermatologist to select the optimal treatment for each patient and thereby to achieve a better patient tailored therapy. W 12.1 W 12.2
09:15 09:33
W 12.3
09:51
W 12.4
10:09
W 12.5
10:27
Alitretinoin - a new therapeutic option to treat hand eczema "Ustekinumab the "new kid on the block" for the treatment of psoriasis" T. Ruzicka (Munich, Germany) "Digital ulceration in systemic sclerosis - Treatment with Bosentan" J. Barker (London, United Kingdom) "The IL-1 antagonist Anakinra for treating inflammatory dermatoses?" S. Beissert (Münster, Germany) "Glucocorticoids - the sharpening of an old spear ?" J. C. Simon (Leipzig, Germany)
W13 NEW DEVELOPMENTS IN SYSTEMIC IMMUNOTHERAPY FOR SKIN DISEASES 09.15 – 10.45 HALL 7 Chair: Co-Chair(s):
S. Grabbe (Mainz, Germany) L. Kemény (Szeged, Hungary) S. Pavel (Leiderdorp, Netherlands)
W14 NON-SURGICAL TREATMENTS OF NON MELANOMA SKIN CANCER 09.15 – 10.45 HALL 9 Chair: Co-Chair(s):
G. Schuler (Erlangen, Germany) B. Giannotti (Firenze, Italy) C. A. Morton (Stirling, United Kingdom)
Learning Objectives: Following this session, the attendee will be able to 1. Improve the knowledge of the rationale of the non surgical treatment of NonMelanoma Skin Cancer (NMSC) in order to have a better approach to its management 2. Become familiar with old and new methods of treatment 3. Select the most appropriate treatment in individual cases Description: The different techniques of non surgical treatment of NMSC will be examined, in particular the new immunological approaches, in order to tailor the treatment for individual patients also taking into account the condition of the subject and/or the location of the tumor. Finally, suggestions on how to improve primary prevention of actic keratosis and basal/squamous cell carcinoma may result from the analysis of epidemiological data. W 14.1
09:15
W 14.2
09:20
W 14.3
09:34
W 14.4
09:48
W 14.5
10:02
W 14.6
10:16
W 14.7
10:30
Welcome and introduction B. Giannotti (Firenze, Italy) Trends in non-melanoma skin cancer therapy : an overview G. Schuler (Erlangen, Germany) Cryotherapy : still a treatment for today's patients R. Suhonen (Mikkeli, Finland) Photodynamic therapy - for which indications? C. A. Morton (Stirling, United Kingdom) Secondary prevention of cancer with non-surgical field therapies O. Larkö (Gothenburg, Sweden) Immunological treatments : place in practice? R. Strohal (Gothenburg, Sweden) Is there a place for radiotherapy in NMSC? R. Panizzon (Lausanne, Switzerland)
W15 PATCH TESTING UPDATES 09.15 – 10.45 ROOM 42 Chair: Co-Chair(s):
A. Barbaud (Nancy, France) W. Uter (Eerlangen, Germany) K. Andersen (Odense, Denmark)
Learning Objectives 1. learn about false pos. and neg. PT reactions in CDAR 2. peculiarities of protein contact dermatitis 3. update on important allergens in children and elderly Description: This session shall update knowledge on skin testing in eczema. We will especially focus on the interpretation of patch tests with false-posi-tive, negative or irritant results. We will discuss the value of protein prick tests in determining the responsible allergen when patch tests are negative in protein contact dermatitis. As different allergens can be in volved according to the age of the
patient, we will focus on special as-pects when testing children and elderly (with chronic leg ulcer). W 15.1
09:15
W 15.2
09:33
W 15.3
09:51
W 15.4
10:09
W 15.5
10:27
Protein contact dermatitis K. Andersen (Odense, Denmark) Irritability and patch test reactivity W. Uter (Eerlangen, Germany) Quality control in patch testing B. Statham (United Kingdom) Patch testing in children D. J. Gawkrodger (Sheffield, United Kingdom) contact allergy in patients with chronic leg ulcers A. Barbaud (Nancy, France)
W16 NEW RETINOIDS IN DERMATOLOGY 11.00 – 12.30 ROOFGARDEN Chair: Co-Chair(s):
T. Ruzicka (Munich, Germany) J. H. Saurat (Geneva, Switzerland) P. Steijlen (Maastricht, Netherlands)
Learning Objectives 1. The participant should learn the basic mechanisms of action of retinoids relevant for skindiseases. 2. The use of retinoids – both topical and systemic – in common skin diseases will be dealt with. 3. Important new developments in the field of retinoids should be learned Description: Retinoids are classical systemic drugs, which have been in use in dermatology for more than 30 years. However, new exciting developments are ongoing in the field of retinoids. The basic mechanisms of action relevant for skin disease will be presented. Important novel developments concerning topical use of retinoids shall be dealt with. Chronic hand eczema has been a very common and difficult to treat disease in dermatologist’s practice. Here, the new systemic alitretinoin represents a very promising agent. Finally, retinoids represent the best treatment option for disorders of keratinisation, as will be shown in the session. W 16.1
11:00
W 16.2
11:22
W 16.3
11:44
W 16.4
12:06
Retinoids-How do they work in skin disease? B. Homey (Düsseldorf, Germany) What's new on topical retinoids J. H. Saurat (Geneva, Switzerland) Alitretinoin-a quantum leap in hand eczema T. Ruzicka (Munich, Germany) Application of retinoids in disorders of keratinization P. Steijlen (Maastricht, Netherlands)
W17 SKIN AND ENDOCRINE DISORDERS 11.00 – 12.30 ICC LOUNGE Chair: Co-Chair(s):
M. Böhm (Münster, Germany) T. Lotti (Florence, Italy) J. Schmidt (Vienna, Austria)
Learning Objectives 1. Understand the role of skin as a complex endocrine organ
2. 3.
Recognize skin as an important mirror of endocrine disorders Learn about novel concepts using hormone-like agents for the treatment of skin diseases
Description: The skin as the largest organ of the human body is a well-known target for the action of hormones. In addition, the skin holds the capacity to generate autonomously multiple hormones which previously were thought to be generated only in specialized endocrine glands. These skinderived hormones play a crucial role in maintaining the cutaneous homeostasis. In the present workshop, the dermatologist should learn to appreciate the skin as a complex endocrine organ and to recognize it as a unique mirror of a variety of endocrine disorders. The workshop will also provide insight into cutting-edge translational research on endocrine dermatology, i. e. preclinical studies on how to exploit hormone-like agents for the future therapy of skin diseases. W 17.1
11:00
W 17.2
11:15
W 17.3
11:30
W 17.4
11:45
W 17.5
12:00
W 17.6
12:15
Introduction into „Endocrine dermatology M. Böhm (Münster, Germany) Endocrine abnormalities in pigmentary skin disorders T. Lotti (Florence, Italy) What is new in vitamin D and skin? J. Reichert (Homburg/Saar, Germany) Hyperandrogenism and skin C. C. Zouboulis (Dessau, Germany) Estrogens in dermatology – an update J. Schmidt (Vienna, Austria) MSH peptides: from bench to bedside M. Böhm (Münster, Germany)
W18 THE SKIN IN SYSTEM DISEASES 11.00 – 12.30 ROOM 42 Chair: M. Röcken (Tübingen, Germany) Co-Chair(s): S. Aractingi (Paris, France) B. Volc-Platzer (Vienna, Austria) Learning Objectives 1. Recognize severe systemic diseases 2. Perform/ organize first diagnostic procedures 3. Initiate adequate first diagnostic steps Description: The skin is the primary site where many severe system diseases present for the first time. This includes hematologic leukemias or clotting disorders, systemic infections, metabolic or endocrine disorders, sarcoidosis, autoimmune diseases, systemic tumors or their novel therapies. The skin is either primarily involved or the primary site of visible disease manifestation. Thus the dermatologist is at the forefront of diagnosing severe system diseases, of differential diagnosis and of taking the first diagnostic and therapeutic steps. Based on selected diseases the workshop will be clinically oriented, provide the attendees with clear diagnostic ‘to do lists” and give insight into the first therapeutic steps. The workshop will also indicate important secondary procedures that should be managed by the dermatologist. W 18.1
11:00
W 18.2
11:22
W 18.3
11:44
Emergencies presenting as primary skin disease M. Röcken (Tübingen, Germany) Cutaneous side reactions to chemotherapy S. Aractingi (Paris, France) Skin - the major site of paraneoplastic diseases B. Volc-Platzer (Vienna, Austria)
W 18.4
12:06
The metabolic syndrome: diagnosing system diseases from the skin T. Biedermann(Tübingen, Germany)
W19 MANAGEMENT OF SKIN TUMOURS IN IMMUNE COMPROMISED PATIENTS 11.00 – 12.30 HALL 10 Chair: Co-Chair(s):
E. Stockfleth (Berlin, Germany) A. Peserico (Padova, Italy) S. Euvrard (Lyon, France)
Learning Objectives 1. Skin Cancer in Organ Transplant Patients 2. Change of Immunosuppressive Treatment 3. Prophylaxis and New Treatment Options for Skin Cancer Description: Skin cancers are the most frequent malignancies in organ transplant recipients (OTR) with 95% being nonmelanoma skin cancers (NMSC), especially squamous (SCC) and basal cell carcinomas. Most OTR with a first SCC subsequently develop multiple NMSC within 5 years, highlighting the concept of “field cancerization”, and are also at high risk for noncutaneous cancers. In order to reduce the tumor burden in these patients, their management requires an interdisciplinary approach including revision of immunosuppression, new dermatological treatments and adequate education about photoprotection in specialized dermatology clinics for OTR. W 19.1
11:00
W 19.2
11:13
W 19.3
11:26
W 19.4
11:39
W 19.5
11:52
W 19.6
12:05
W 19.7
12:18
Immunosuppression and inflammation: Two sides of the coin in skin cancer G. Hofbauer (Zurich, Switzerland) Cutaneous lymphomas in organ transplant recipients Deniz Seckin (Ankara, Turkey) The role of human papillomavirus in the development of squamous cell carcinoma J. N. Bouwes Bavnick (Leiden,.Netherlands) Merkel cell carcinoma and other rare skin tumors J. Kanitakis (Lyon, France) Nevi and melanoma in organ transplant patients M. Alaibac (Padova, Italy) Revision of immunosuppression for post-transplant skin cancer S. Euvrard (Lyon, France) Prophylaxis and management of skin cancers in organ transplant recipients C. Ulrich (Berlin, Germany)
W20 SYSTEMIC DRUG THERAPY (Newest Strategies for Old and New Compounds) 11.00 – 12.30 HALL 4/5 Chair: Co-Chair(s):
B. Bonnekoh (Magdeburg, Germany) G. Chaidemenos (Thessaloniki, Greece) A. Figueiredo (Coimbra, Portugal)
W 20.1
11:00
W 20.2
11:05
Greetings and Introductory Remarks B. Bonnekoh (Magdeburg, Germany) Methotrexate in Dermatology
W 20.3
11:20
W 20.4
11:35
W 20.5
12:50
W 20.6
13:05
W 20.7
13:20
L. Dubertret (Paris, France) Topoproteome Analysis under Infliximab Treatment of Psoriasis B. Bonnekoh (Magdeburg, Germany) Biologic survival in Psoriasis patients G. Chaidemenos (Thessaloniki, Greece) Responder Prediction to Biologics J. C. Simon (Leipzig, Germany) Off-label use of Biologics in Dermatology J. Wohlrab (Halle, Germany) General Discussion
W22 TOPICAL ANTIMICROBIAL THERAPIES 15.00 – 16.30 HALL 9 Chair: Co-Chair(s):
R. L. Gallo (San Diego, USA) R. Gläser (Kiel, Germany) J. Lipozencic (Zagreb, Croatia)
Learning Objectives 1. Describe the function and regulation of endogenous antimicrobial peptides 2. Understand the applications of topical antibiotic therapy 3. Understand the benefits and limitations of a topical antibiotic approach Description: This workshop will discuss the latest advances in antimicrobial therapy of the skin. Topics will include an overview of the endogenous antimicrobial peptides produced by normal skin, and induced after injury or infection. Since control of antimicrobial peptide expression is critical to normal defense, a discussion of new advances in regulating expression will be given with emphasis on Vitamin D. When natural antimicrobial synthesis is not sufficient, a pharmacologic approach is necessary. A review of topical antimicrobial substances will be provided, and the indications and limitations of this approach discussed. W 22.1
15:00
W 22.2
15:15
W 22.3
15:30
W 22.4
15:45
W 22.5
16:00
W 22.6
16:15
Clinical Implications of natural Antimicrobial Peptides R. L. Gallo (San Diego, USA) Antimicrobial implications of Vitamin D J. Schaber (Munich, Germany) Antimicrobial substances in the clinical practice R. Gläser (Kiel, Germany) Where are the limits of local therapy? C. Sunderkötter (Münster, Germany) Topical Antibiotics in Dermatology and Venereology J. Lipozencic (Zagreb, Croatia) Is there an indication for topical antibiotic therapy E. Aberer (Graz, Austria)
W23 PHOTOPHERESIS AND IMMUNOABSORPTION 15.00 – 16.30 HALL 8 Chair: Co-Chair(s):
R. Knobler (Vienna, Austria) M. Sticherling (Münster, Germany) M. Schiller (Erlangen, Germany)
Learning Objectives: 1. Understand Photopheresis(ECP) and its Indications
2. 3.
Be updated on qualitiy management in ECP Understand the technology and use of Immunapheresis
Description: The aim of this session is to provide an update on photopheresis, its current and posibble future indications within and outside the field of dermatology . Similarly the session will discuss the principle and uses and applications ot the technology of immunapheresis. Both technologies offer challenges and opportunities for the dermatologist who with a better understanding of both will be better equiped to optimize their use. W 23.1
15:00
W 23.2
15:22
W 23.3
15:44
W 23.4
16:06
Photopheresis(ECP): Past Present and Future R. Knobler (Vienna, Austria) Quality Management in Photopheresis M. Schiller (Erlangen, Germany) Immunapheresis in Dermatological Indications M. Sticherling (Münster, Germany) Immunapheresis in Non-dermatological Indications M. Rech (Erlangen, Germany)
FOCUS SESSIONS F8 TUMOR SURGERY OF THE FACE 13.00 – 14.00 ICC LOUNGE R. Rompel (Kassel, Germany) Learning Objectives 1. Principles of Tumor Surgery 2. Guidelines for functional and aesthetic reconstruction 3. flops and grafts for the plastic-reconstructive dermatosurgery Description: Focus Session with practice-relevant guidelines of tumor surgery of the face, including types of tumors, differential diagnosis, clinical view and recognition, individual surgical strategies. Principles of tumor excision with focus on micrographic surgery. All kinds of plastic reconstructive dermatologic surgery. Presentation is made by detailed intra-operative pictures and videos. F9 PROCTOLOGY 13.00 – 14.00 HALL 10 W. Hartschuh (Heidelberg, Germany) F10 ANDROLOGY 13.00 – 14.00 HALL 8 G. Haidl (Bonn, Germany) Learning Objectives 1. Summarize the diagnosis and treatment options of male fertility 2. Understand the impact of genital tract Inflammation on male fertility 3. Define late-onset hypogonadism and name indications for treatment
Description: The field andrology covers -a o. - disturbances of male reproductive functions including erectile dysfunction and problems with the aging male. In the symposium an overview of mole fertility disorders including the link between sexually transmitted diseases, further genital tract inflammations and male infertility will be addressed as well as disorders of the male endocrine system, in particular diagnosis and treatment of the so-called late-onset hypogonadism. The most recent developments like new WNO reference values of semen parameters, the predictive value of specific sperm function tests for the outcome of assisted reproduction treatment or the association between testosterone deficiency and metabolic syndrome will be discussed as well. Inflammatory diseases of the genital tract and disturbances at the male sexual hormones are frequently met by the clinical dermato-venereologist and emphasize the role of andrology as an integral pan within the broad range of dermatological disciplines. F11 GENETIC TESTING IN MELANOMA 13.00 – 14.00 ROOM 43 S. Puig (Barcelona, Spain) Learning Objectives 1. Identify candidates to receive genetic counselling/assessment in familial melanoma 2. Decide the better approach to each situation (assessment, genetic testing or others) informing patients about risks and benefits 3. Evaluate results of genetic testing and to inform adequately about risk, primary and secondary prevention Description: In this focus session the participants will improve their knowledge about melanoma genetics and melanoma susceptibility in a practical setting. Risk factors for melanoma will be discussed and categorized according to those known genes as CDKN2A or CDK4 in familial melanoma and MC1R in red hair people, or mostly unknown genetic factors as the number of nevi. The participants will learn how to draw a pedigree of familial melanoma, obtain all the essential information for the estimation of risk to develop melanoma or other related cancers. The participants will also be able to estimate in an individual patient the risk to be a carrier of a mutation in a known melanoma gene. According to this knowledge, the participants will be able to give accurate information about the indication of offering a genetic testing in melanoma, evaluate the results and discuss them with the patient. F12 HOW TO EVALUATE CLINICAL STUDIES 13.00 – 14.00 HALL 9 T. L. Diepgen (Heidelberg, Germany) F13 CUTANEOUS PORPHYRIAS 13.00 – 14.00 ROOM 42 M. Lecha (Barcelona, Spain) Learning Objectives 4. Learn about variability of genetic mutation and clinical disease 5. Learn about factors modifying clinical Expressions of these diseases 6. Learn about rationale of transplantation as treatment approach Description: Genetic mutations causing Porphyria are very numerous and the clinical picture resulting shows very variable severity. Studies performed have established the mutations related to serve clinical
disease. Identifying patients at risk of severe diseases is extremely useful to prevent, as far as possible, the deleterious evolution of these cases during their lives. Or on the other hand we should have considered other factors that may influence the evolution of patients with Porphyria. In the most severe cases of Porphyria new treatment approaches have been considered. We will refer especially to transplantation, bone-marrow or liver transplantation or both combined. This treatment approach can be life saving in severe cases of Congenital Erythropoietic Porphyria. The published reports have shown that this treatment approach has to be considered in the treatment of severe cases. F14 OFF-LABEL PRESCRIPTION 13.00 – 14.00 HALL 6 U. Mrowietz (Kiel, Germany) Learning objectives: 1. How off-label use is defined 2. When off-label use is necessary 3. How to do off-label therapy Description: Off-label use characterizes the use of a registered drug outside of the labelled indication, dose, or duration. Close to off-label use is compassionate use which describes the use of not (yet) registered drugs for treatment in humans. Off-label use is mainly necessary in diseases where no drugs or therapeutic procedures are registered for and in children. There is a huge diversity of legal perspectives among different countries even in the European Union where the European Medicines Agency (EMEA) only has advisory status but no legal power. The EMEA can provide recommendations which have to be transferred into national law in each of the European countries. The Focus-Session aims to familiarize the participants with general aspects of off-label use in dermatology by giving examples and practical advice on how to document therapy. F15 MELANOMA 13.00 – 14.00 HALL 4/5 A. Hauschild (Kiel, Germany) Learning Objectives 1. Melanoma epidemiology 2. Surgical and systemic treatment of high-risk melanoma 3. Melanoma follow-up strategies 4. Description: Current epidemiology trends for incidence and mortality will be discussed, It appears that particularly older individuals are still presenting with high-risk melanonias. It became apparent that the ulceration of the primary tumor is a very strong prognostic factor. The sentinel node biopsy is an accepted standard procedure for the staging of melanoma patients, although it has not demonstrated survival benefits. The discussion on adjuvant interferon a treatment is still controversial. Meta-analyses consistently reported on small benefits for disease-free and overall survival. Treatment of advanced metastatic melanoma is extremely difficult since melanoma appears as widely chemo-resistant. There is an international consensus for treating those patients preferentially within controlled clinical trials. The follow-up recommendations for melanoma patients are risk-adapted. Careful clinical examinations and lymph node sonography are standards of care for patients with an intermediate or high risk of relapse. The session covers all above mentioned aspects of melanoma.
DERMATOLOGY FORUM DF5 LASERS AND NON-LASERS IN HAIR REMOVAL 15.00 – 16.30 ROOFGARDEN C. Dierickx (Ghent, Belgium) M. Adatto (Geneva, Switzerland) DF 5.1
15:00
DF 5.2
15:20
DF 5.3
15:35
DF 5.4
15:55
DF 5.5
16:15
Laser Hair Removal: State of the art 2009 C. Dierickx (Ghent, Belgium) Laser Hair Removal complications M. Adatto (Geneva, Switzerland) Laser Hair Removal for dark skin E. F. Battle (Washington, USA) Hair transplantation and Laser Hair stimulation M. Avram (New York, USA) Home Devices & Future Technologies M. Lapidoth (Herzelia, Israel)
DF6 ADVANCED COSMETIC PROCEDURES 15.00 – 16.30 HALL 14.2 C. R. Payne (London, United Kingdom) M. Lapidoth (Herzelia, Israel)
TEST YOURSELF ´ TY 2 WHAT’S YOUR HISTOLOGICAL DIAGNOSIS? 15.00 – 16.30 HALL 2 H. Kutzner (Friedrichshafen, Germany) B. Zelger (Innsbruck, Austria)
PLENARY 11.00-12.0
HALL1
Chairs
A. Ranki (Hus, Finland) J. N. Barker (London, United Kingdom)
P7 GUIDELINES: SENSE OR NONSENSE? USEFUL OR USELESS? (EDF- Lecture) L. R. Braathen (Switzerland) AAD/EADV LECTURE- HIDRADENITIS SUPPURTIVA 11.00 – 12.30 ROOM 43 Chairs:
M. E. Maloney (Worcester, USA) A. Katsambas (Athens, Greece)
1. Emerging Science and Technology D. M. Pariser (Norfolk, USA) 2. Newer Concepts in Rosacea W. D. James (Philadelphia, USA)
3. New Concepts on Acne Vulgaris H. Gollnick (Magdeburg, Germany) 4. Hidradenitis Suppurtiva G. Jemec (Roskilde, Denmark) Skin Cancer Screening (Sponsored in part by Almirall) 11:00 – 12:30 ROOM 43 11:00 11:10 11:30 11:50 12:10
Introduction T. A. Luger (Münster, Germany) I. Skin cancer screening in Germany: Health political decision E. Breitbart (Buxtehude, Germany) II. Skin cancer screening in Germany:Practicale experience M. Reusch (Hamburg, Germany) Incidence of skin cancer M. Binder (Vienna, Austria) Euromelanoma-day:Recent activities A. Stratigos (Athens, Greece)
PHLEBOLOGY ULTRASOUND COURSE Chair:
T. Nijsten (Rotterdam, Netherlands) A. Sommer (Maastricht, Netherlands) TBA
FREE COMMUNICATIONS FC 5 CLINICAL RESEARCH AND THERAPY 09:15 – 10:45 ROOFGARDEN FC 6 PSORIASIS 09:15 – 10:45
ROOM 44
FC 7 AUTOIMMUNE DISEASES 11:00 – 12:30 ROOM 44 FC 8 PHOTDERMATOLOGY AND PIGMENTARY DISORDERS 15:00 – 16:30 ROOM 44
SATELLITE SYMPOSIA SAT 12 ABBOTT 13.00 – 14.30 HALL 1 SAT 13 ASTELLAS 13.00 – 14.30 HALL 2 SAT 14 GALDERMA 13.00 – 14.30 HALL 3 SAT 15 BASILEA
13.00 – 14.30
HALL 15.2
SAT 16 SANOFI-PASTEUR 13.00 – 14.30 ROOFGARDEN SAT 17 GENERAL TOPICS 13.00 – 14.30 HALL 14.2 SAT 18 MERZ 13.00 – 14.30 HALL 7 SAT 19 INNEOV 17.00 – 18.30 HALL 14.2 SAT20 LIPOSONIX 15.00 -16.30 HALL 7
Saturday, 10 October 2009 WORKSHOPS W24 URTICARIA AND ANGIOEDEMA 8.30 – 10.00 Chair: Co-Chairs:
HALL 2 A. Kapp (Hannover, Germany) G. S. Tiplica (Bucharest, Romania) C. E. Grattan (London, United Kingdom)
Learning Objectives: 1. understand the actual European guidelines for diagnosis and management of urticaria 2. understand the different subtypes of physical urticaria 3. understand current pathophysiological concepts 4. use the new management guideline updates in daily practice Description: The session will focus on the Update of the European guidelines regarding classification, diagnosis and management of different urticaria subtypes. Newest available data addressing pathophysiology will be presented in addition to expert opinion on the impact on daily practice. W 24.1
08:30
W 24.2
08:48
W 24.3
09:06
W 24.4
09:24
W 24.5
09:42
Physical urticaria subtypes: what's new? M. Maurer (Berlin, Germany) Is an extensive laboratory evaluation essential in the diagnosis and management of chronic Urticaria? G. S. Tiplica (Bucharest, Romania) Update of the urticaria management guideline: Impact on daily practice? B. Wedi (Hannover, Germany) Antiinflammatory activity of H1-antihistamines in urticaria G.A. Vena (Bari, Italy) 'Is there a place for the biologicals in the management of chronic urticaria?' C. E. Grattan (London, United Kingdom)
W25 UTILIZING THE INTERNET IN DERMATOLOGY
8.30 – 10.00
HALL 9
Chair: Co-Chairs:
R. Suhonen (Mikkeli, Finland) M. Schmitt-Egenolf (Umea, Sweden) M. Le Maitre (Caen, France)
Learning Objectives: Following this session, the attendee will be able to: 7. 8. 9.
To benefit the medical databases in daily patient work to understand the global potential of internet-based teledermatology realize the utility of personal website in office dermatology
Description: Pubmed is the main database dermatologists use in internet, but there are other resources that could be as useful as Pubmed. NCBI, Google, CME providers, dermatologic atlas, databases, and a few less known but useful websites for dermatologists that want to give a different flavour to their practice. Medical data in internet can be free (out of charge) – but is it reliable? The new systemic therapies e.g. for psoriasis necessitate the strict follow-up. Internet offers the tools for profession based pharmacosurveillance at Europe level. Personal website can be a useful way to interact with patients – but only with a good domain, professional standard of content and regular updating. W 25.1
08:30
W 25.2
08:48
W 25.3
09:06
W 25.4
09:24
W 25.5
09:42
How to get free (out of charge) medical data on the web? M. Le Maitre (Caen, France) Profession based pharmacosurveillance for systemic psoriasis treatment in Europe M. Schmitt-Egenolf (Umea, Sweden) Is there anything else beyond Pubmed? P. F. Penas (Spain) Internet and teledermatology G. Jemec (Roskilde, Denmark) Personal website and office dermatology R. Suhonen (Mikkeli, Finland)
W26 WHAT CLINICIANS SHOULD KNOW ABOUT DERMATOPATHOLOGY 10.15 – 11.45 HALL 3 Chair: Co-Chairs:
D. Metze (Münster, Germany) J. Kanitakis (Lyon, France) R. Anadolu-Brasie (Ankara, Turkey)
Learning objectives 1. The role of pathology in Dermatology 2. Appropriate diagnostic biopsy 3. Interpretation of a histologic report Description: Knowledge of dermatohistology is essential for understanding the clinical features, pathophysiology and therapy of skin diseases. Many difficult and complex dermatological conditions can only be diagnosed by pathologic examination. In addition, histopathology is crucial for planning surgical procedures. The diagnostic process starts and ends with the clinician. The clinician decides when a biopsy is mandatory. He is responsible for properly obtaining and transport of the specimen, and for providing the dermatopathologist with sufficient clinical information. The final diagnosis is always made by integration of the clinical aspect and the
histological findings. Therefore, the clinician must be able to interpret the histology report and should be aware of current diagnostic techniques, limits and pitfalls in dermatopathology. W 26.1
10:15
W 26.2
10:30
W 26.3
10:45
W 26.4
11:00
W 26.5 W 26.6
11:15 11:30
Diagnostic biopsy –why, where and how ? J. Kanitakis (Lyon, France) New techniques in Dermatopatholgy H. Kutzner (Friedrichshafen, Germany) Pitfalls in Dermatopathology and Clinical Dermatology D. Metze (Münster, Germany) How to interpret a histological report B. Cribier (Strassbourg, France) The Importance of Clinicopathologic Correlation Colorful Vignettes of Clinico-pathological Correlation : A Tribute. R. Anadolu-Brasie (Ankara, Turkey)
W27 WHAT’S NEW IN FOOD ALLERGIES 10.15 – 11.45 ROOFGRADEN Chair: G. Klein (Linz, Austria) Co-Chairs: C. Bindslev-Jensen (Odense, Denmark) R. Treudler (Leipzig, Germany) W 27.1
10:15
W 27.2
10:33
W 27.3
10:51
W 27.4
11:09
W 27.5
11:27
Food allergy in atopic dermatitis TBA Food allergy in urticaria / anaphylaxis T. Zuberbier (Berlin, Germany) "New" allergens - "New" cross reactions W. Aberer (Graz, Austria) Pseudo allergens G. Klein (Linz, Austria) Diagnostic procedures C. Bindslev-Jensen (Odense, Denmark)
W28 SOFT TISSUE AUGMENTATION 10.15 – 11.45 ICC LOUNGE Chair: P. André (Paris, France) Co-Chairs: I. Ghersetich (Folrence, Italy) M. Kerscher (Hamburg, Germany) Learning Objectives: 1. 2. 3.
To have a good knowledge of filling agents To start to inject according to demands of patients To be aware of potential drawbacks and complications
Description: All different types of filling techniques will be present. Peri-ocular and peri-buccal treatments will be described in details New techniques for volumizing the face will be described up to date on lipostructure will be discussed complications and managements will be explained W 28.1
10:15
W 28.2
10:30
W 28.3
10:45
What’s New on the Fillers Market ? I. Ghersetich (Folrence, Italy) Rejuvenation of the Péri-Ocular Area with Fillers M. Kerscher (Hamburg, Germany) Rejuvenation of the Mouth with Fillers - My Technique
W 28.4
11:00
W 28.5
11:15
W 28.6
11:30
C. R. Payne (London, Germany) How to Restore Volumes of the Face with Fillers ? P. André (Paris, France) What’s New in Lipostructure of the Face ? G. Sattler (Darmstadt, Germany) All about Complications : Clinical, Histological Aspects and Management. E. Haneke (Freiburg, Germany)
W29 THE MANAGEMENT OF HYPERHIDROSIS 10.15 – 11.45 HALL 6 Chair: A. Campanati (Ancona, Italy) Co-Chairs: S. Gregoriou (Athens, Greece) R. Popescu (Ilfov,Romania) Learning Objectives: 1. to achieve clinical informations on F. I. H. 2. to achieve therapeutic news on F.I.H. 3. to improve knowledge on F.I.H. course Description: Focal idiopathic hyperhidrosis -FIH represent a very disabling condition with great impact on patients' quality of life.The etiopathogenesis of FIH still remains uncompletely clear. The authors report their experiencess in the clinical and therapeutic management of hyperhidrotic patients, focusing on the use both of non - invasive and minimally - invasive treatments. W 29.1
10:15
W 29.2
10:30
W 29.3
10:45
W 29.4
11:00
W 29.5
11:15
W 29.6
11:30
Topical approach to hyperhidrosis G. Micali (Catania, Italy) Use of Botulinum toxin type A in focal idiopathic hyperhidrosis N. Skroza (Rome, Italy) Treatment of dermatological disorders with concomitant hyperhidrosis with botulinum toxin A S. Gregoriou (Athens, Greece) Use of anesthetic agents in hyperhidrosis treatment J. Vadoud (Brussels, Germany) Botulinum toxin type A in focal hyperhidrosis: factors predicting therapeutic respose A. Campanati (Ancona, Italy) Minimally Invasive Surgery for Axillary Hyperhidrosis U. Wollina (Dresden, Germany)
W30 HOW TO ASSESS QUALITY OF LIFE 8.30 – 10.00 HALL 6 Chair: A. Finley (Cardiff, United Kingdom) Co-Chairs: S. Davidsson (Reykjavik, Iceland) C. M. Popescu (Bucharest, Romania) Learning Objectives 1. Understand why measurement of QoL is impor 2. Know how to use QoL measures in dermatology 3. Know how to interpret scores from QoL measu Description: This workshop will explain why quality of life measurement is important in reaching clincial dermatology as well as in clincial trials, health serivce research and in order to demonstrate the
effectivness of clincial serivces. There are many methods now described to measure quality of life in dermatology including disease specific, dermatology specific and general health quality of life measures. These will be described and guidance given how to decide which quality of life measures to use, how to use them, and how to interpret their scores. W 30.1
08:30
W 30.2
08:35
W 30.3
08:51
W 30.4
09:07
W 30.5
09:23
W 30.6
09:39
W 30.7
09:55
Introduction S. Davidsson (Reykjavik, Iceland) Why quality of life measurement is important in dermatology A. Y. Finlay (Cardiff, United Kingdom) Health related quality of life assessment in dermatology, interpretation of Skindex-29 scores C A C Prinsen (Amsterdam, Netherlands) How to measure quality of life in clinical and health service research M. Augustin (Hamburg, Germany) How to measure quality of life in routine practice D. Abeni (Rome, Italy) Specific quality of life issues in young adults with skin disease M K A Basra (Cardiff, United Kingdom) Summary C M Popescu (Bucharest, Romania) A. Y. Finlay (Cardiff, United Kingdom)
W31 SCABIES AND OTHER ECTOPARASITIC ENFESTATIONS 13.00 – 14.30 HALL 15.2 Chair: K. J. Mumcuoglu (Jerusalem,Israel) Co-Chairs: G. Leigheb (Novara, Italy) M. Zaoura Petranyi (Limassol, Cyprus) Learning Objectives: 1. Insights in the biology of ectoparasites such as scabi 2. Clinical outcome of contact with non-parasitic arthropo 3. Use of fly larvae (maggots) for the treatment of chron Description: Arthropods such as insects, mites and ticks have an enormous impact on human and animal health. In addition to their direct damage with their mouthparts and toxins they are also vectors of diseases such as malaria, endemic and epidemic typhus, filariasis and Lyme diseases. In this workshop the clinical aspects, diagnosis and treatment of ectoparasitic infestations such as scabies, pediculosis and trombiculosis, as well as the clinical outcome of a contact with nonparasitic insects such as butterfly larvae (lepidopterism) and adult beetles (paederism) will be discussed. Maggot debridement therapy, the use of fly maggots for the treatment of chronic wounds e.g., in diabetic patients will be also discussed. W 31.1
08:30
W 31.2
08:35
W 31.3
08:51
W 31.4
09:07
W 31.5
09:23
Diagnosis and treatment of special forms of scabies M. Zaoura Petranyi (Limassol, Cyprus) Clinical aspects in diagnosis of ectoparasitic diseases H. Lapeere (Ghent, Brussels) Misdiagnosed entomodermatosis: paederismus, trombidiasis and lepidopterism# G. Leigheb (Novara, Italy) Epidemiology and recent treatment modalities in pediculosis A. Izri (Bobigny, France) Head lice and their treatment with oral ivermectine O. Chosidow (Paris, France)
W 31.6
09:39
The use of maggots for the treatment of intractable wounds K. Y. Mumcuoglu (Jerusalem, Israel)
SYMPOSIA S29 NOVEL THERAPEUTIC OPTIONS FOR SKIN DISEASES 13.00 – 14.30 Hall 3 Chair: Co-Chairs:
H. Gollnick (Magdeburg, Germany) A. Alomar (Barcelona, Spain) C. Griffiths (Manchester, United Kingdom)
S32 RARE NEOPLASMS OF THE SKIN 8.30 – 10.00 ROOFGARDEN Chair: Co-Chairs:
J. C. Becker (Würzburg, Germany) E. Calonje (London, United Kingdom) N. Stavrianeas (Chaidari-Athens, Greece)
Learning Objectives 1. Pathogenesis and Clinic of Rare Cutaneous Malignancies 2. Epidemiology and Trends in Changes in Incidence 3. Therapetic Approaches Description: Recent advances in the understanding of the carcinogenesis particularly of some of the rare skin cancers allowed the development of new means for diagnosis and therapy of these tumors. Within the symposium a comprehensive overview of latest developments for several of the rare skin neoplasm will be discussed. S 32.1
08:30
S 32.2
08:52
S 32.3
09:24 09:46
S 32.4
Dermatofibrosarcoma Protuberans S. Ugurel Würzburg, Germany) Sweat Gland Tumors E. Calonje (London, United Kingdom) Rare Cutaneous Lymphomas W. Kempf (Zurich; Switzerland) Merkel Cell Carcinoma J. C. Becker (Würzburg, Germany)
S33 SCLERODERMA 8.30 – 10.00 ICC LOUNGE Chair: T. Krieg (Köln, Germany) Co-Chairs: S. Majewski (Warsaw, Poland) S. Ullman (Copenhagen, Denmark) Learning objectives: 1. How to diagnose different subsets of SSc 2. Early detection of organ complications 3. Management of scleroderma patients Description: The term "Scleroderma" ist descriptive and summarizes a number of different clinical entities characterized by hardening of skin. This Symposium will concentrate mainly on the systemic form and will summarize new developments in the understanding of the pathophysiology and the clinical criteria for classifying the disease into subsets. The epidemiology of these subsets will be
discussed and a major emphasis of the symposium in the early recognition and management of organ complications, which often determine the life expectation and quality of life of many patients with scleroderma. Although there has been a considerable progress in dealing with these organ manifestations due to the development of several new drugs there is still limited success in treating the progress of fibrosis. The symposium will therefore also review the latest developments in using anti-inflammatory and antifibrotic approach to reduce disease progression. S 33.1
10:15
S 33.2
10:30
S 33.3
10:45
S 33.4
10:55
S 33.5
11:10
S 33.6
11:25
S 33.7
11:40
Introduction:Diagnostic Criteria and Classification T. Krieg (Köln, Germany) Pathogenic Concepts and Therapeutic Principles S. Majewski (Warsaw, Poland) Epidemiology of Systemic Sclerosis P. Moinzadeh (Cologne, Germany) Organ Manifestations in Systemic Sclerosis and their Management S. Ullman (Copenhagen, Denmark) Significance of ECHO Screening in Patients with Systemic Sclerosis S. Ullman (Copenhagen, Denmark) Is there a Role for anti-inflammatory and antifibriotic Therapy in Scleroderma? A. Kreuter (Bochum; Germany) Discussion
S34 MANAGEMENT OF SKIN DISEASES IN PREGNANCY 10.15 – 11.45 HALL 7 Chair: F. Wojnarowska (Oxford, United Kingdom) Co-Chairs: C. Ambros-Rudolph (Graz, Austria) G. Kirtschig (Amsterdam, Netherlands) Learning objectives: 1. 2. 3.
recognise and manage the physiological changes of pregnancy recognise and manage dermatoses that may affect pregnancy and delivery be aware of information available to pregnant women
Description: The theme of this symposium is identifying dermatological conditions in the pregnant woman including normal changes, common and rare co-incidental disease, and to identify any potential risk to mother and foetus of the dermatological conditions and their treatment. There will be an emphasis on management of the pregnant woman, addressing her concerns and involving her in the decision making. The objectives will be to recognise physiological and coincidental common dermatoses including infections, quantify their risk to the mother and baby, and to be aware of the potential problems associated with the use of treatments. S 34.1
10:15
S 34.2
10:27
S 34.3
10:39
S 34.4
10:51
S 34.5
11:03
Interactive quiz: diagnosis and treatment? C. Ambros-Rudolph (Graz, Austria) Physiological skin changes: is treatment needed if available? S. Vaughan-Jones (Surrey, United Kingdom) Co-incidental skin diseases in pregnancy: risk and treatment. R. R. Müllegger (Vienna, Austria) Vulval diseases in pregnancy: management and implications for delivery G. Kirtschig (Amsterdam, Netherlands) The mother with EB: what are the problems? D. Murrell (Australia)
S 34.6
11:15
S 34.7
11:28
Internet information for dermatology problems in pregnancy F. Wojnarowska (Oxford, United Kingdom) Interactive quiz answers C. Ambros-Rudolph (Graz, Austria)
S35 SKIN INFECTIONS WITH SYSTEMIC INVOLVEMENT 8.30 – 10.00 HALL 7 Chair: E. Aberer (Graz, Austria) Co-Chairs: H. Schöfer (Frankfurt, Germany) N. Tsankov (Sofia, Bulgaria) Description: In this symposium the variety of clinical symptoms in systemic infectious diseases is presented. Staphylococcal and streptococcal infections are characterized by their recurrence, their potency of severe clinical symptoms caused by toxins and the problem of increasing resistance to antibiotics. Most viral infections present with a cutaneous eruption that in the greater majority of cases is self-healing. Only in rare instances is the eruption accompanied by constitutional symptoms, and even more rarely, irreversible damage may occur or death may ensue. Systemic fungal infections are mostly seen in immunosuppressed individuals. The early clinical diagnosis of typical skin lesions is crucial for treatment in time. Sexually transmitted infections can be the cause of chronic systemic disease with following complications. A systemic infection of Lyme borreliosis is already present in “localised erythema migrans”. However, whether persistence of borrelia is always associated with a clinical disease remains to be determined. S 35.1
08:30
S 35.2
08:45
S 35.3
09:00
S 35.4
09:15
S 35.5
09:30
S 35.6
09:45
Methicillin-resistant Staphylococcus aureus (MRSA) in the skin and in systemic infection M. Mempel (Germany) Toxin mediated systemic reactions in staphylococcal and streptococcal infections N. Tsankov (Sofia, Bulgaria) Life-threatening cutaneous viral diseases A Rebora (Genova, Italy) Aspergillus to Zygomycetes: Causes, Risk Factors, Prevention, and Treatment of Invasive Fungal Infections M. Rüping (Germany) Systemic involvement in sexually transmitted infections H. Schöfer (Frankfurt, Germany) Systemic infection in Lyme borreliosis E. Aberer (Graz, Austria)
S36 DERMATOMYOSITIS AND RELATED DISORDERS 8.30 – 10.00 HALL 4/5 Chair: Co-Chairs:
M. Meurer (Dresden, Germany) A. Rebora (Paris, Italy) C. Frances (Paris, France)
Learning Objectives: 1. 2. 3. #
differentiate clinical features of dermatomyositis from related disorders define tools for diagnosis and autoimmune evaluation of dermatomyositis design evidence-based treatment modalities
Description Dermatomyositis is a disease of presumed autoimmune pathogenesis demonstrating bimodal age distribution with increased malignancy association in the adult patient group. The symposium focuses on cutaneous and Systemic clinical features of dermatomyositis, drug induced dermatomyositis and dermatomyositis and related disorders. It will enable the attendees to differentiate between classical dermatomyositis and other idiopathic myopathies. In this context, the relevance of diseases and subgroup-specific auto- antibodies will be discussed. An update overview of present treatment modalities for the large array of clinical manifestations in dermatomyositis will conclude the symposium. S 36.1
08:30
S 36.2
08:45
S 36.3
09:00
S 36.4
09:15
S 36.5
09:30
S 36.6
09:45
Dermatomyositis: An Update M. Lecha (Barcelona, Spain) Drug-induced Dermatomyositis C. Frances (Paris, France) Eosinophilic Fasceitis and Related Disorders M. Meurer (Dresden, Germany) The Serological Diagnosis of Dermatomyositis A. Parodi (Genova, Italy) Skin Manifestations of Monoclonal Gammopathy D. Lipsker (Strassbourg, France) New Treatment Strategies for Dermatomyositis B. Volc-Platzer (Vienna, Austria)
S37 STRESS AND SKIN 10.15 – 11.45 HALL 9 Chair: J. Lambert (Ghent, Belgium) Co-Chairs: R. Granstein (New York, USA) U. Gieler (Gießen, Germany) Learning Objectives 1. position molecular nervous interactions 2. link stress to clinical entities of skin and hair 3. understand novel therapeutic approaches Description: There is a growing interest and evidence with regard to the molecular basis of the interaction between brain, nerves and skin. In this session involvement of the endocrine, and immune system on various skin conditions will be explained and novel therapies presented. S 37.1
10:15
S 37.2
10:30
S 37.3
10:45
S 37.4
11:00
S 37.5
11:15
S 37.6
11:30
Stress and Cutaneous Immunity R. Granstein (New York, USA) Atopic Dermatitis and Stress - Basic Research and Management U. Gieler (Gießen, Germany) Stress and Psoriasis C. E. M. Griffiths (Manchester, United Kingdom) Influence of Stress on the Human Hair Follicle, Clinical Perspectives V. Meuleman (Brugge, Belgium) Altered brain-adrenal axis function-role in stress-induced exacerbation of inflammatory skin disease A. Buske-Kirschbaum (Dresden, Germany) Are educational programmes an added value for chronic skin disease patients ? J. Lambert (Ghent, Belgium)
S38 TELEDERMATOLOGY 13.00 – 14.30 HALL 6 Chair: P. Elsner (Jena, Germany) Co-Chairs: P. Soyer (Graz, Austria) S. Chimenti (Roma, Italy) Learning Objectives: 1. describe the scope of teledermatology 2. know current teledermatology applications 3. use teledermatology for CME Description: Teledermatology utilizes modern telecommunication technology to exchange expert medical information. It holds great potential for revolutionizing the delivery of dermatologic services. In this Symposium, leading experts from Europe and the US will review the state of the art of teledermatology projects, show specific applications and discuss quality assurance and standardization issues. In addition, the potential of teledermatology in continuing medical education will be demonstrated. S 38.1
13:00
S 38.2
13:15
S 38.3
13:30
S 38.4
13:45
S 38.5
14:00
S 38.6
14:15
Overview of International Teledermatology K. McKoy (Burlington, USA) TeleDermatology Consultations in The Netherlands J. van der Heijden (Amsterdam, Netherlands) Specific Applications in Teledermatology: Apropos Telewoundcare and Telepsoriasis R. Hoffmann-Wellenhof (graz, Austria) Networks in Dermatology- Innovations in Medical Record Keeping and Communication J. Tittelbach (Jena, Germany) Standardization in Teledermatology M. Binder (Vienna, Austria) CME Teleteaching: The Dermocrates Initiative G. Burg (Zurich, Switzerland)
S39 TROPICAL DERMATOLOGY 13.00 – 14.30 HALL 9 Chair: H. Grossmann (Moshi, Tanzania) Co-Chairs: A. Morrone (Rome, Italy) A. H. El-Zurghany (Tripoli, Libya) Learning Objectives: 1. Understand the Key Determine Is a Pathogenesis of Skin Disease 2. Appreciate Magnitude and Dimension of Skin Problems 3. Realize Nature and Enormity of Challenges ahead Description: The symposium will highlight the magnitude and heavy burden of skin disease in tropical belt countries and will give examples on how the skin diseases differ in various parts due to socioeconomic, cultural, ecologic, climatologic or genetic influences. Operational constraints which are faced in source-limited setting and which are leading to dermatological health and service inequities will be pointed out and the enormous challenges particularized.
S 39.1
13:00
S 39.2
13:18
S 39.3
13:36
S 39.4
13:54
S 39.5
14:12
Tropical Dermatology-An experience in Ethiopia A. Morrone (Rome, Italy) Cutaneous Leishmaniasis: different clinical presentation, differential diagnosis and treatment A. H. El-Zurghany (Tripoli, Libya) Dermatology: What is new in Sub-Saharan Africa J. Masenga (Moshi, Tanzania) Pellagra Revisited S. Verma (Vadodara, India) Innovation and the future of Medicine, Inhibition that must be dealt with T. Ryan (Oxfort, United Kingdom)
S40 UPDATE ON THE MANAGEMENT OF MELANOMA 10.15 – 11.45 HALL 2 Chair: C. Garbe (Tübingen, Germany) Co-Chairs: J. L. Diaz-Perez (Bilbao, Spain) H. Pehamberger (Vienna, Austria) S 40.1
10:15
S 40.2
10:33
S 40.3
10:51
S 40.4
11:09
S 40.5
11:27
How to improve melanoma awareness in the public J. L. Diaz-Perez (Bilbao, Spain) Basics in melanoma diagnostics and staging. J. J. Grob (Marseille, France) New developments in the adjuvant melanoma treatment C. Garbe (Tübingen, Germany) Options of targeted systemic melanoma treatment H. Pehamberger (Vienna, Austria) Update on immunotherapy in melanoma B. Dreno (Nantes, France)
S41 VITILIGO AND HYPOPIGMENTATION 10.15 – 11.45 HALL4/5 Chair: Co-Chairs:
M. Picardo (Rome, Italy) K. Schallreuter (Bradford, United Kingdom) M. B. Abdel Naser (Cairo, Egypt)
Learning objectives: 1. Understand the mechanism of vitiligo 2. Define vitiligo and related disorders 3. Identify the most appropriate therapeutical approaches Description: This symposium will provide an overview on the different therapies applicable to vitiligo starting from the laboratory experience. Presenters will give you the headline for an efficient therapeutical approach to the disease with a specific focus on the latest methods. They will also indicate how to choose the most appropriate solution and when a therapy is not convenient for the patient. At the end of each session there will be the time for questions and answers where participants will be invited to join and stimulate the discussion. S 41.1
10:15
S 41.2
10:28
S 41.3
10:40
Introduction to the symposium and brief overview on therapies M. Picardo (Rome, Italy Pathogenetic mechanisms as basis for the therapies M. B. Abdel Naser (Cairo, Egypt) Target phototherapies G. Leone (Rome, Italy)
S 41.4
10:53
S 41.5
11:05
S 41.6
11:18
S 41.7
11:20
Combined phototherapies K. Schallreuter (Bradford, United Kingdom) Topical immunomodulators N. Van Geel (Ghent, Belgium) Graft T. Jouary (Bordeaux, France) Therapies for segmental vitiligo A. Taieb (Bordeaux, France)
S43 PHOTOTHERAPY AND PDT 13.00 – 14.30 HALL 4/5 Chair: Co-Chairs:
J. Hawk (London, United Kingdom) M. Szeimies (Regensburg, Germany) K. Ettler (Hradec Kralove, Czech Republic)
Learning Objectives: 1. Understand how phototherapy works in skin disease 2. Decide when phototherapy is the optimal treatment 3. Broadly know how to use phototherapy for skin disease Description: This symposium will teach the attendee what phototherapy is, the different forms which exist, including newer forms (except lasers), which diseases respond to it, how well they respond and to which form in particular, along with any useful adjunctive therapies, and the short- and long-term side effects of each modality. Finally, the current place of phototherapy in the overall therapeutic spectrum of skin disease will be considered and also its likely role in the future. S 43.1
13:00
S 43.2
13:12
S 43.3
13:24
S 43.4
13:36
S 43.5
13:48
S 43.6
14:00
S 43.7
14:13
How Phototherapy Works in Skin Disease J. Hawk (London, United Kingdom) Skin Diseases Responsive to Phototherapy K. Ettler (Hradec Kralove, Czech Republic) Whether to Use Narrowband UVB or PUVA, and How To Optimise This Further J. Ferguson Dundee, United Kingdom) The Efficacy and Adverse Effects of UVA1 Phototherapy - Does It Really Work? H. Stege (Düsseldorf, Germany) The Efficacy and Adverse Effects of Photodynamic Therapy M. Szeimies (Regensburg, Germany) The Acute and Chronic Adverse Effects of Phototherapy and How To Minimize Them A. Young (London, United Kingdom) The Future of Phototherapy H. Hönigsmann (Vienna, Austria)
S45 PHOTOPROTECTION: INNOVATIVE STRATEGIES Chair: V. del Marmol (Brussels, Belgium) Co-Chair:
P. Ortonne (Nice, France) N. Neumann (Dusseldorf, Germany)
Learning Objectives: 1. the cellular mechanisms induced by MSH or Melanocyte stimulating hormones to protect the cell against UV aggression and its anti-inflammatory effect ; 2. the potential therapeutic effect of MSH analog , N-Leu-D phe7 in different pathologies such as polymorphic light eruption , erythropoietic porphyria and skin cancer ; 3. the melanocortins which are commercialized on the internet. Description: αMSH is a melanocortin described as issued from the pituitary gland (and POMC clivage) but it is also synthetized in the keratinocyte after UV radiation. The MSH release induces, by activating the melanocyte melanocortin receptor 1 (MC1R) and through the elevated cAMP, the eumelanin synthesis which acts as a scavenger and thus protects secondarily the skin against UV induced damage. However, more than the protoprotective effect induced by the acquired pigmentation, MSH induces a different molecular pathway that improves this photo-protection. MSH has an antiinflammatory effect. This session will review the cellular photoprotection induced by MSH, the anti-inflammatory effect and some of the potential therapeutic uses in pathology, such as erythropoeitic porphyria, polymorphic light eruption and carcinogenesis. There will be a commentary on the non-licensed melanocortins which are sold currently on the internet and their potential dangers. S 45.1
08:30
S 45.2
08:48
S 45.3
09:06
S 45.4
09:24
S 45.5
09:42
Melanocortins:cellular photoproection V. del Marmol (Brussels, Belgium) Melanocortins: an antiinflammatory potential ? T. A: Luger (Münster, Germany) Melanocortins and erytropoietic porphyria E. Minder (Zurich, Switzerland) Melanocotins and polymorphic light eruption TBA Non licensed melanotropic peptides :right or wrong J. P. Ortonne (Nice, France)
DERMATOLOGY FORUM DF1 HOT TOPICS FROM THE POSTER HALL 13.00 – 14.30 ICC LOUNGE J.-P. Claudel (Tours, France) R. Wolf (Rechovot, Israel) DF2. HOW TO MANAGE MELANOCYTIC NEVI 8.30 – 10.00 HALL 3 J. J. Grob (Marseille, France) H. Tsao (Boston, USA) DF3. CRYOSURGERY UPDATE 10.15 – 11.45 HALL 15.2 P. Pasquali (Ioannina, Spain) I. Bassukas (Cambris, Greece) DF 3.1
10:15
DF 3.2
10:30
DF 3.3
10:45
Introductory and Historical Remarks I. Bassukas (Cambris, Greece) Limits of "Classic" Single-Modality Cryosurgery P. Pasquali (Ioannina, Spain) Molecular Aspects of Cryosurgery/Perspectives of Combination Cryosurgery-
DF 3.4
11:00
DF 3.5
11:15
DF 3.6
11:30
Chemotheraphy M. Hundeiker (Münster, Germany) Immunological Consequences of Cryosurgery V. Forest (France) Clinical Perspectives of Cryosurgery in Combination Modalities for Treating Skin Cancer G. J. Adema (Nijmegen, Netherlands) Non-Invasive Diagnosis and Follow-up in the Dermatological Oncology R. Hofmann-Wellenhof (Graz, Austria)
TEST YOURSELF TY3 WHAT’S YOUR VENEREOLOGICAL DIAGNOSIS? 14.30 – 16.30 HALL 7 M. Janier (France) J. Hercogova (Czech Republic)
WHAT’S NEW 14.30-16.30 Chairs:
HALL2 A. Katsambas (Athens, Greece) T. A. Luger (Münster, Germany) O. Larkö (Gothenburg, Sweden)
WN1. WHAT’S NEW IN DERMATOLOGICAL RESEARCH? J. Frank (Maastricht, Netherlands) WN2. WHAT’S NEW IN SKIN ALLERGY? T. Zuberbier (Berlin, Germany) WN3. WHAT’S NEW IN CUTANEOUS ONCOLOGY? M. Herlyn (Philadelphia, USA) WN4 WHAT’S NEW IN DERMATOSURGERY R. Kaufmann (Frankfurt, Germany)
PLENARY 12.00-13.00 Chairs:
HALL2 J. Ring (Munich, Germany) J-H Saurat (Geneva, Switzerland) C. Orfanos (Berlin, Germany)
P4. NANOTECHNOLOGY A NEW CHALLENGE FOR DERMATOLOGY S. Schneider (Münster, Germany) P5. ROLE OF STEM CELLS IN SKIN DISEASES AND THERAPIES D. Roop (Denver, USA) P6. THE PANDEMIC NEXT DOOR- HIV IN AFRICA P. N. Naidu (Durban, South Africa)
FREE COMMUNICATIONS FC 9 ECZEMA AND PRURITUS 08:30-10:00 HALL8 FC 10 ACNE AND RELATED DISORDERS 08:30-10:00 Room 42 FC 11 PSYCHODERMATOLOGY AND EPIDEMIOLOGY 10:15 – 11:45 HALL8 FC 12 MISCELLANEOUS I 10:15 – 11:45 Room 42 FC 13 MISCELLANEOUS II 13:00 – 14:30 HALL8 FC 14 MISCELLANEOUS III 13:00 – 14:30 Room 42
SSP31 Euromelanoma European Society (EES) 11.00 -14.00
Room 42
Chair: Co-Chairs:
A. Katsambas (Athens, Greece) Prof. Stratigos TBA
CLOSING CEREMONY 16.30 – 17.00 HALL 2
